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ABSTRACT 
Protein kinase C (PKC) isoforms, p53 tumour suppressor protein, and caspase family 
members are major regulators of cell proliferation and death. These proteins represent 
therefore key therapeutic targets in human diseases where these processes are 
dysregulated, such as cancer and neurodegeneration. A better understanding of their 
biology and pharmacology will certainly provide new therapeutic strategies against these 
pathologies. However, the high complexity of mammalian signalling pathways, particularly 
of those involving PKC isoforms, p53 and caspases, has highly hampered such a goal.  
In the last years, yeast has emerged as a powerful model organism to unravel the 
molecular basis of complex human diseases. Besides its technical advantages, it presents 
a high level conservation between its cellular processes and those of mammalian cells. 
Additionally, the heterologous expression of human disease-related proteins in yeast has 
been successfully used to gain understanding of their functions and provide clues to the 
mechanisms of disease progression. Moreover, yeast expressing a disease-related target 
protein has widely contributed to the discovery of promising therapeutic agents. Based on 
this, in the present thesis we used the yeast model system to uncover major functional, 
molecular and pharmacological aspects of mammalian PKC isoforms, p53, caspase-3 and 
-7.  
Though several works have already reported the phosphorylation and activation of p53 by 
PKCδ, the role of other PKC isoforms in the regulation of p53 activity was still elusive. 
Therefore, in order to discriminate the specific roles of PKCα, δ, ε and ζ, major PKC 
isoforms in carcinogenesis, in the regulation of p53 activity in cell proliferation and death, 
we reconstituted a mammalian PKC isoform-p53 network in yeast. With this work, we 
firstly confirmed the reported human wild-type (wt) p53-induced yeast growth inhibition, 
which was associated with a S-phase cell cycle arrest, and was regulated by a p53 
transcription-dependent mechanism. This allowed the development of a yeast p53 
phenotypic assay to be used in functional and pharmacological studies of p53. Using 
yeast cells co-expressing a PKC isoform and p53, it is shown a differential regulation of 
p53 activity in cell proliferation and death by PKC isoforms, with the identification of 
negative and positive regulators of p53 among the kinases tested. In fact, though PKCα 
does not interfere with the p53-mediated apoptosis, evidences are provided for a negative 
regulation of p53 activity in cell proliferation by this isoform. Most importantly, it is shown 
that PKCδ and ε phosphorylate and stimulate p53 activity in cell proliferation and apoptotic 
cell death. On the other hand, PKCζ has no effect on p53 activity. Another important 
outcome of this work is the reconstitution in yeast of the reported mammalian 
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transcription-dependent and -independent p53 apoptotic mechanisms, activated by PKCδ 
and ε, and which co-perate to ultimately cause an apoptotic cell death. Moreover, relevant 
insights about an unclear issue concerning the regulation of transcription-independent p53 
apoptosis are provided. Together, this work represents an additional contribution to 
advance our knowledge about the role of PKC isoforms in apoptosis. Additionally, it 
reveals a new strategy of p53 regulation through modulation by PKCδ and ε, and provides 
the identification of these kinases as key therapeutic targets in tumours with a wt p53. 
The elucidation of the molecular mechanism of action of coleon U, a diterpene compound 
isolated from Plectranthus grandidentatus reported to induce apoptosis in human cells, 
was another issue addressed in the present thesis. Using yeast cells individually 
expressing PKCα, βI, δ, ε or ζ, we reveal a potent and selective activator of PKCδ and ε 
with promising pharmacological applications as a probe in the PKC research field and as 
an anticancer agent. Moreover, with the comparison of the mechanism of action of coleon 
U with that of the standard PKC activator phorbol 12-myristate 13-acetate, we confirm in 
yeast that different stimuli can induce the translocation of a same PKC isoform to distinct 
cellular compartments, which is subsequently associated with different cellular responses.  
An additional goal of this thesis was the development of yeast phenotypic assays for the 
screening of small molecule modulators of caspase-3 and -7. In fact, similarly to wt p53, 
the expression of active forms of human caspase-3 or -7 in yeast caused a marked growth 
inhibition that was proportional to the degree of activation of human caspases. With the 
established assays promising caspase-3 inhibitors were identified by testing a library of 
vinyl sulfones. Additionally, potent caspase-7 activators were identified by testing several 
prenylated flavonoids with antiproliferative effects on distinct human tumour cells. Besides 
the potential applications as pharmacological probes and therapeutic agents in cancer 
(caspase-7 activators) and neurodegeneration (caspase-3 inhibitors), the identified small 
molecules can also be used as lead compounds in the synthesis of new small molecules 
with improved potency and selectivity. 
As a whole, in this thesis valuable data about the biology of major protein regulators of cell 
proliferation and death are provided using the yeast model system. Additionally, the 
exploitation of the yeast assays in the screening of small molecule modulators of these 
disease-related proteins led to the discovery of promising therapeutic agents against 
devastating diseases, such as cancer and neurodegeneration. 
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RESUMO 
As isoformas da família da cínase C de proteínas (PKC), a proteína supressora tumoral 
p53 e os membros da família das caspases desempenham um papel crucial na regulação 
da proliferação e morte celular. Desta forma, estas proteínas representam alvos 
terapêuticos importantes em doenças onde estes processos celulares estão 
desregulados, como o cancro e as doenças neurodegenerativas. Um conhecimento mais 
aprofundado sobre a biologia e a farmacologia destas proteínas irá certamente permitir o 
desenvolvimento de novas abordagens terapêuticas no tratamento destas doenças. No 
entanto, a elevada complexidade das suas vias de sinalização nas células de mamífero 
tem dificultado o alcance de tal objetivo.  
Nos últimos anos, a levedura tem-se revelado um organismo modelo na elucidação da 
base molecular de doenças humanas complexas. Para além das vantagens técnicas da 
sua utilização, os processos celulares básicos encontram-se conservados entre a 
levedura e as células humanas. Adicionalmente, a expressão heteróloga de proteínas 
envolvidas em doenças humanas tem permitido o estudo das suas funções e dos 
processos celulares em que estão envolvidas, assim como a pesquisa de novos agentes 
terapêuticos. Com base no referido, nesta tese utilizou-se a levedura como modelo 
celular no estudo de aspetos funcionais, moleculares e farmacológicos cruciais das 
proteínas de mamífero, isoformas da PKC, p53, caspase-3 e -7. 
Apesar de a fosforilação e ativação da p53 pela PKCδ ter sido demonstrada 
anteriormente, o papel de outras isoformas da PKC na regulação da atividade da p53 
continua por esclarecer. Desta forma, com o objetivo de discriminar as funções 
especificas das PKCα, δ, ε e ζ, isoformas principais na carcinogénese, na regulação da 
atividade da p53, utilizaram-se leveduras a co-expressar cada uma das isoformas da 
PKC e a proteína p53 na forma nativa. Inicialmente confirmou-se a inibição do 
crescimento das leveduras causada pela expressão da p53, um efeito atribuído a uma 
paragem do ciclo celular na fase S e que se mostrou dependente da atividade 
transcricional da p53. Tal facto permitiu o desenvolvimento de um ensaio fenotípico com 
leveduras para estudos funcionais e farmacológicos da p53. De seguida, demonstrou-se 
uma regulação diferencial da atividade da p53 na proliferação e morte celular pelas 
isoformas da PKC, com a identificação de reguladores positivos e negativos da p53 entre 
as cínases testadas. De facto, apesar da PKCα não interferir com a morte apoptótica 
mediada pela p53, esta isoforma inibe a atividade da p53 na proliferação celular. 
Adicionalmente, mostrou-se que as PKCδ e ε fosforilam e estimulam os efeitos da p53 na 
morte e proliferação celular, ao passo que a PKCζ não afeta a atividade da p53. 
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Reconstituíram-se ainda na levedura os mecanismos apoptóticos dependentes e 
independentes da atividade transcricional da p53, que sendo ativados pelas PKCδ e ε, 
cooperam na indução de uma morte apoptótica. Estes trabalhos contribuíram, assim, 
para a elucidação da regulação da atividade da p53 independente da transcrição ainda 
por esclarecer. Com a identificação das PKCδ e ε como ativadores da p53, foi ainda 
reforçado o papel relevante destas isoformas como alvos terapêuticos, concretamente em 
cancros que expressam a forma nativa da p53.  
Foi ainda objetivo desta tese elucidar o mecanismo molecular de ação do composto 
coleona U, um diterpeno isolado de Plectranthus grandidentatus e descrito como um 
indutor apoptótico em células humanas. Para tal utilizaram-se leveduras a expressar 
individualmente as PKCα, βI, δ, ε ou ζ. Os resultados obtidos revelaram que a coleona U 
é um ativador potente e seletivo das PKCδ e ε, e portanto um composto com 
aplicabilidade promissora em estudos farmacológicos experimentais destas cínases e 
como anticancerígeno. Comparando o seu mecanismo de ação com o do ativador padrão 
da PKC, 12-miristato 13-acetato de forbol, confirmamos na levedura que estímulos 
diferentes podem induzir a translocação da mesma isoforma da PKC para 
compartimentos celulares diferentes e, desta forma, respostas celulares distintas. 
Nesta tese, implementaram-se ainda ensaios fenotípicos com leveduras para a pesquisa 
de pequenas moléculas moduladoras das caspases-3 e -7 humanas. Confirmou-se que a 
expressão de formas ativas destas caspases na levedura causava uma inibição do 
crescimento destas, proporcional ao grau de ativação das caspases humanas. Com estes 
ensaios identificamos inibidores da caspase-3, pesquisando uma biblioteca de vinil 
sulfonas, e ativadores da caspase-7, pesquisando vários flavonóides prenilados com 
atividade antiproliferativa em várias linhas celulares de tumores humanos. Para além do 
potencial terapêutico no tratamento do cancro (ativadores da caspase-7) ou de doenças 
neurodegenerativas (inibidores da caspase-3), os compostos identificados podem ser 
usados como precursores na síntese de novos compostos mais potentes e seletivos.  
Em resumo, utilizando a levedura como modelo celular foi possível esclarecer vários 
aspetos da biologia de proteínas de mamífero com um papel central na regulação da 
proliferação e morte celular. Adicionalmente, a utilização deste modelo celular permitiu a 
identificação de pequenas moléculas moduladoras da atividade destas proteínas, com 
aplicações terapêuticas promissoras no tratamento de doenças humanas, como o cancro 
e as doenças neurodegenerativas.  
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1.1. INTRODUCTION 
 
Most of our knowledge about basic cellular processes has come from model 
organisms like yeast, which has given a major contribution to fields as diverse as cell 
metabolism, DNA replication, recombination, cell cycle, cell death, protein folding, 
trafficking, and organelle biogenesis (1, 2). Unpredictably, in the last years this knowledge 
has been applied and expanded to the understanding of human diseases. In fact, as a cell 
model of human diseases, yeast has given us insights into basic processes underlying 
pathogenesis. However, as a unicellular organism, the obvious limitation of this cell 
system for the study of human diseases is in the analysis of disease aspects that rely on 
multicellularity and cell-cell interactions. Additionally, as a less complex system, some 
relevant genes involved in the pathology may not be present in the yeast genome. While 
important aspects of human diseases lie beyond the reach of Saccharomyces cerevisiae, 
this cell system has already proven to be a valuable first-line tool in the discovery of 
mechanistic processes involved in the disease. This has been possible because many 
molecular processes are conserved from yeast to humans (1, 3). A remarkable example is 
the direct application of the fundamental knowledge of cell cycle regulation uncovered in 
yeast towards studies in human cancer biology (4). More recently, with the finding that 
yeast can undergo an apoptotic cell death exhibiting phenotypic features and basic 
molecular machinery similar to those found in higher eukaryotes, the mechanisms of 
apoptosis could also be intensively addressed in yeast and the knowledge obtained 
transposed to human cells, providing clues towards the understanding of apoptosis-
related diseases (5).  
Yeast shows other undeniable advantages as a model organism as far as 
molecular studies are concerned. The genome of the budding yeast Saccharomyces 
cerevisiae was the first eukaryotic genome to be sequenced (6) and over the years this 
knowledge fuelled whole-genome scale screening methods including DNA and protein 
microarrays (7-9), two-hybrid analysis (10, 11) and the use of deletion and overexpression 
libraries (12, 13). Another advantage of the yeast model is the broad selection of easily 
accessible online dataset on genetic interactions, transcriptional changes, protein 
interactions and localization, further facilitating its widespread use by the scientific 
community [reviewed in (2)]. In addition, yeast presents many technical advantages over 
other systems, as a short generation time, ease of manipulation and a highly amenability 
to genetic modifications by gene deletion/replacement or by using recombinant DNA 
techniques. The ability to be maintained in a haploid or diploid state allows the study of 
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lethal mutations in heterozygous diploids and recessive mutations in haploids (14). Yeast 
is also one of the rare eukaryotes with a good fermenting capacity allowing the analysis of 
mitochondrial defects that would be lethal in other systems. This is of particular interest 
since mitochondrial dysfunction and oxidative stress have been linked to many human 
diseases (15). 
All the advantages presented above contributed to the emergence of yeast models 
for a broad spectrum of human diseases. Different approaches are adopted when 
establishing these models, usually depending on the degree of conservation of the gene 
under study. If the gene implicated in the disease is conserved in yeast, it is possible to 
study directly its function. In fact, it became clear that yeast and human share many 
orthologues and pathways, what has allowed transposing the knowledge obtained in yeast 
to mammalian cells and vice-versa. On the other hand, even when the gene underlying 
the disease has no orthologue in yeast, the heterologous expression of the human gene in 
this organism (the so-called humanized yeast) has been also crucial to solve fundamental 
questions about the role of proteins and the molecular mechanisms of complex human 
disorders, such as cancer and neurodegenerative diseases (16). Yeast expressing the 
Parkinson´s disease associated protein α-synuclein (17) or the tumour suppressor p53 
(18) protein are examples of this strategy. The absence of orthologues of a protein or of 
an entire pathway can be sometimes highly advantageous, since the protein can be 
studied in a simpler eukaryotic environment without the interference of other proteins with 
similar or overlapping functions and of its endogenous regulators. For instance, yeast has 
been widely used in the analysis of individual protein kinase C (PKC) isoforms (19, 20) or 
members of the caspase family (21, 22). 
The unquestionable advantages exposed above also justify the extensive use of 
the yeast cell system in the drug discovery field (23-25). In fact, despite the presence of a 
cell wall, it is now well-known that it does not significantly interfere with the permeability of 
small molecules in yeast cells (23). Moreover, yeast cell-based assays have clear 
advantages over the in vitro biochemical drug screening assays. Particularly, the 
possibility to immediately select compounds having into account some relevant drug-like 
properties, such as permeability and stability in the intracellular environment; the ability to 
select against compounds that are cytotoxic; and the chance to examine a specific cellular 
process triggered by a define target are some of the relevant advantages. On the other 
hand, though mammalian cells provide a more physiological model system, yeast 
represents a more economical, rapid and simpler alternative for a first analysis of drug 
targets in a cellular environment. Additionally, in opposition to mammalian cells, where 
redundant processes often interfere with unambiguous measurement of a specific effect 
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on a given target, yeast allows a clean read-out in a null background environment for the 
expression of the human target protein. Yeast presents therefore potential benefits as a 
high-throughput first-line screening tool, accelerating the drug discovery process with 
concomitant economic advantages.  
Commonly used experimental approaches to study mammalian proteins in yeast 
are summarized in Fig. 1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1. Schematic illustration of commonly used experimental approaches for functional, molecular and 
pharmacological analysis of mammalian proteins in yeast. Firstly, the gene of interest is cloned into a yeast 
vector with a constitutive or more often regulatable promoter, since many mammalian disease-related proteins 
are cytotoxic in yeast. Secondly, the cytotoxicity of a mammalian protein is determined with growth assays by 
measuring the optical density (OD) or by counting the number of colony-forming units (cfu) in solid plates. The 
OD is a simple and fast method that can be used in high-throughput genomic or pharmacological screenings. 
The cfu counts allow distinguishing between decreased growth rates and increased cell death rates. Thirdly, it 
can be assessed whether the mammalian protein-induced yeast growth inhibition is due to a cell cycle arrest 
or cell death. Several techniques are available in yeast to distinguish between different types of cell death 
(apoptotic, necrotic or autophagic). Apoptosis can be identified for instance by the terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL) assay that visualizes DNA fragmentation, by morphological 
analysis of chromatin condensation upon staining with 4',6-diamidino-2-phenylindole (DAPI), and by 
externalization of phosphatidylserine (PS) in the absence of membrane rupture. Propidium iodide, which only 
enters dead cells with ruptured cellular membranes, is used as a marker of necrosis. Autophagy can be 
assessed by monitoring the autophagy-associated increase of mature Atg8p or by monitoring the uptake of 
material by the vacuole. Since many proteins associated mainly to degeneration affect the vesicular trafficking, 
this can be also monitored by following the delivery of the lipophilic dye FM4-64 to the vacuole. As a first-line 
 
Analysis of cellular effects
Growth (optical density   or 
cfu counts) 
Control   Expression
Cell cycle profile
Determination of oxidative
stress levels
Determination of cell death: 
• apoptosis (PS externalization; 
DNA fragmentation; chromatin  
condensation) 
• necrosis (plasma membrane integrity) 
• autophagy (autophagosome formation)
Analysis of vesicular traficking
Study of mammalian proteins in yeast
Validation in higher organisms
Cloning mammalian 
gene into a yeast vector
Overnight culture
(no expression)
Shift to
expression 
media
Protein expression
Transformation
Functional, molecular and pharmacological studies 
CHAPTER 1 
 
6 
 
model system all the discoveries made in yeast must be validated in more physiological model organisms 
(adapted from Pereira et al., 2011; manuscript submitted for publication).  
The present chapter is an overview of the contribution of yeast to unravel 
structural, functional and molecular aspects of crucial mammalian regulators of cell 
proliferation and death. Moreover, the use of this cell system in the discovery of 
pharmacological modulators of these cancer and neurodegeneration-target proteins is 
also discussed. 
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1.2. YEAST AS A CELL MODEL TO STUDY PROTEIN KINASE C ISOFORMS 
 
The protein kinase C (PKC) family consists of at least 10 serine/threonine protein 
kinases grouped into the classical (cPKC; α, βΙ, βΙΙ and γ), novel (nPKC; δ, ε, η and θ) and 
atypical (aPKC; ζ and λ\ι) sub-families, according to their primary structure and activating 
co-factors requirements (Fig. 1.2) (26).  
 
 
 
 
 
 
 
 
 
Fig. 1.2. Structural domains of PKC isoforms. PKC isoforms are composed by a regulatory domain at the N-
terminus and a catalytic domain at the C-terminus, separated by a hinge region (V3) which is the site of 
caspase proteolytic cleavages, protein-protein interactions and tyrosine phosphorylations. The regulatory 
domain of cPKCs contains a C1 domain with two cysteine motifs, essential for binding diacylglycerol (DAG) 
and its analogs (e.g. phorbol esters), and a C2 domain that binds phosphatidylserine (PS) in a calcium-
dependent manner. C2 domain is also responsible for the binding of receptors for activated C kinases 
(RACKS), a family of anchoring proteins that confers specificity to PKC isoforms by regulating the activation 
and subcellular localization and, consequently, the cellular functions of PKC isoforms. nPKCs contain a C1 
domain and a C2-like domain that binds PS in a calcium-independent manner. aPKCs contain a C1 domain 
with only one cysteine motif, and therefore unable to bind DAG, and a Phox and Bem 1 (PB1) domain, 
responsible for protein-protein interactions. The auto-inhibitory pseudosubstrate (PSE) domain in the 
regulatory domain interacts with the substrate binding site/kinase catalytic centre (C4) in the catalytic domain, 
maintaining the enzyme in a catalytically inactive form. The catalytic domain of PKC isoforms contains an 
adenosine triphosphate (ATP) binding domain (C3) and a V5 C-terminal domain that is a site of protein-protein 
interactions and phosphorylation events determinant for PKC isoform-specific targeting and function [adapted 
from (26)]. 
 
PKC is responsible for regulating major cellular processes, such as cell 
proliferation and death, in an isoform-specific manner [reviewed in (27-29)]. The PKC 
isoform-specificity is basically a result of isoform-specific patterns of subcellular 
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compartmentalization, protein-protein interactions and post-translational modifications. 
The specificity of each PKC isoform is therefore highly dependent on its primary structure, 
which determines the requirement for activating co-factors, regulatory phosphorylations, 
and intra- and inter-molecular interactions (Fig. 1.2) (26, 30). The activity of a PKC isoform 
is also highly dependent on the cellular background (27-29). This explains why distinct 
and even opposing functions are frequently ascribed to a same PKC isoform. For 
instance, PKCα and ε are frequently described as promoters of cell proliferation and 
survival (29, 31-34). However, these PKC isoforms have been also described as apoptotic 
promoters. For instance, PKCα meditates cisplatin-induced apoptosis in renal cells (35). 
Also, ethanol induces apoptosis in hepatocytes via activation of nPKC isoforms, including 
PKCε (36). Additionally, it was reported that, in a same cellular environment, the function 
of a given PKC isoform is dependent on the stimulus applied. Indeed, it was shown that 
distinct stimuli can induce the translocation of a specific PKC isoform to distinct 
subcellular compartments and the subsequent phosphorylation of distinct substrates 
involved in distinct cellular responses (37-39).  
Not surprisingly, the activity and expression of some of these kinases are altered in 
human diseases where the cellular proliferation and death processes are dysregulated, 
such as in cancer and neurodegeneration [reviewed in (40, 41)]. PKC isoforms are 
therefore key pharmacological targets in these pathologies and their isoform-selective 
modulators promising therapeutic agents. However, the high complexity of the mammalian 
PKC family, namely the coexistence of several PKC isoforms in a same cell, has 
hampered the study of individual PKC isoforms, and particularly the discovery of isoform-
selective PKC modulators [reviewed in (40-43)]. In this context, yeast arose as a 
promising cell system for an independent analysis of individual mammalian PKC isoforms 
in a simpler eukaryotic environment. In fact, in 1993, several works performed by Riedel 
and collaborators demonstrated that yeast, which endogenous PKC (Pkc1p in S. 
cerevisiae; Pkc1p and Pkc2p in Schizosaccharomyces pombe) is a structural but not a 
functional homologue of mammalian PKC isoforms (44-46), was a promising cell system 
to study individual mammalian PKC isoforms (47-49). These works showed that 
mammalian cPKCα and βI are functionally expressed in yeast leading to biological 
responses similar to those observed in mammalian cells. In fact, the activation of PKCα 
and βI by phorbol 12-myristate-13-acetate (PMA) caused PKC down-regulation, uptake of 
extracellular Ca2+, Ca2+-dependence of cell viability, changes in cell morphology, and a 
growth inhibition. Together, these findings indicated the conservation in yeast of a 
mammalian PKC signalling pathway. Several studies were performed to further explore 
the mechanisms behind PKC-induced yeast growth inhibition. Particularly, it was observed 
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that expression of PKCε in respiring yeast inhibited cell growth by delaying cell cycle 
progression through multiple mechanisms (e.g. delaying bud formation, altering cell 
morphology and impairing chromosome segregation and septum formation) (50). 
Additionally, activation of PKCα by PMA induced a G2/M cell cycle arrest through 
impairment of chromosome segregation, cytokinesis and septum formation, which was 
related to altered expression profile of genes regulating cell wall dynamics. The altered 
gene expression profile and phenotypic alterations observed were attributed to the 
phosphorylation and activation of the yeast cell division cycle 55 (Cdc55) by PKCα, which 
may therefore represent a PKCα substrate in yeast (51).  
The observation that the degree of mammalian PKC-induced growth inhibition was 
proportional to the degree of its enzymatic activity led to the establishment of a yeast 
phenotypic assay for the assessment of PKC activity. Such method, based on yeast cell 
growth, revealed to be sensitive and fast to quantitatively measure PKC activity. 
Therefore, it was successfully explored by several groups in functional, molecular and 
pharmacological studies of several mammalian PKC isoforms, namely cPKCα, βI and γ, 
nPKCδ, η and ε and aPKCζ.   
Indeed, the yeast PKC phenotypic assay was extensively used by several authors 
to establish PKC structure-function relationships. For instance, based on the phenotypic 
response of various PKCα mutants lacking amino acid sequences within the regulatory 
(V1, C1, V2 and C2) and catalytic (V5 and C4) domains, it was possible to analyse the 
function of these domains in the regulation of PKC catalytic activity and interaction with 
activating co-factors. These studies revealed that most of the C2 domain was not 
essential for phorbol ester stimulation and most of the regulatory domain was dispensable 
for Ca2+ regulation of PKC activity (52). These results were confirmed in mammalian cells 
and presently the structural basis for co-factor requirements of PKC isoforms is a well-
established issue [reviewed in (26, 30)]. Additionally, carboxyl terminus truncated mutants 
of PKCα (49) and PKCβI (47) were expressed in yeast in order to map the carboxyl 
terminus sequence essential for their activity. The function of the carboxyl terminus was 
further analysed using a chimeric PKCα in which its carboxyl terminus had been replaced 
by the corresponding PKCβI sequence, PKCαβI. The PKCαβI chimera exhibited the same 
phenotypic characteristics observed with PKCα, confirming that the carboxyl terminus of 
distinct isoforms can complement each other (53). Later, it was observed that co-
expression of PKCα regulatory domain with full-length PKCβI protein in yeast abolished 
the PKCβI-induced phenotype (54, 55). These results sustained the cross-talk observed in 
mammalian cells between some PKC isoforms (26). In a continuous effort to establish the 
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function of the PKC regulatory domain, another study suggested that, in addition to the 
PSE region, an amino acid segment in the C2 domain of PKCα, essential for the 
maintenance of the PKC inactive conformation, also regulates the PKC catalytic activity 
(56). The observation that PKCα activity was not strictly regulated by the PSE sequence 
led other authors to study the regions within the regulatory domain essential for the auto-
inhibition of PKCα catalytic activity (57). The authors found multiple sequences in the 
regulatory domain of PKCα, outside the PSE sequence, with a direct role in the inhibition 
of PKCα activity. Together, in accordance with studies in mammalian cells (30), these 
works performed in yeast provided evidence to the existence of intra-molecular 
interactions between the regulatory and catalytic regions of PKCα responsible for the 
maintenance of its inactive conformation form.  
Several works demonstrated the suitability of the yeast PKC phenotypic assay in 
pharmacological studies of individual mammalian PKC isoforms. In fact, it was shown that 
standard PKC activators (e.g. PMA, mezerein) induced growth inhibition in yeast cells 
expressing a mammalian PKC isoform that was proportional to the degree of PKC 
activation (58-60), while PKC inhibitors (e.g. chelerythrine and calphostin C) reverted the 
effects of PKC activators (58, 61). This was used for an in vivo characterization of the 
PKC regions required for the activity of small molecule modulators of mammalian PKC 
isoforms. Particularly, it was observed that distinct PKC activators displayed a differential 
ability to bind the C1 domain and activate cPKCα (62-64), βΙ and γ (63). In fact, while PMA 
and 12-deoxyphorbol 13-phenylacetate 20-acetate (dPPA) activated PKC via any of the 
cysteine motifs in the C1 domain, indolactam V, ingenol-3 and 20-dibenzoate required 
both cysteine motifs. Additionally, whereas mezerein displayed a strong preference for the 
first cys-repeat of the C1 region, bryostatin 5 preferentially binds to the second cys-repeat. 
Guo and colleagues (65) further assessed additional sites within the PKCα regulatory 
domain necessary for phorbol esters activity. Curiously, they found that only some of the 
PKCα amino acid sequences necessary for phorbol ester activation were directly involved 
in phorbol ester binding. It was proposed that the other sequences functioned by providing 
the appropriate three-dimensional PKCα conformation for activation by phorbol esters. 
This approach was also used to characterize the potency and selectivity of small molecule 
modulators of PKC isoforms. For instance, the isoform-selectivity of several PMA 
analogues on cPKCα and βΙ, nPKCδ and ε and aPKCζ, was analysed using this assay 
(59). Surprisingly, two of the PMA analogues tested, namely PMA-4-O-methyl-ether 
(MPMA) and 4α−PMA displayed an effect similar to that exhibited by the PKC inhibitors 
NPC 15437 and chelerythrine, being therefore characterized as PKC inhibitors. 
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Subsequent studies performed with this yeast assay allowed the identification of new 
potent and selective small molecule modulators of individual mammalian PKC isoforms. 
Particularly, it was used to analyse the potency and isoform-selectivity of mezerein and its 
derivative daphnetoxin (60). Mezerein is a standard PKC activator with antiproliferative 
and antileukemic activities, while daphnetoxin is devoid of these effects. In this study, it 
was shown that mezerein was much more potent on PKCδ than on PKCα. Contrarily to 
mezerein, daphnetoxin showed to be much more potent on PKCα than on PKCδ. These 
results therefore suggested that the lack of antileukemic activity of daphnetoxin may be 
due to its higher activity on an anti-apoptotic isoform, PKCα, being its effect on the pro-
apoptotic PKCδ almost negligenciable when compared to mezerein (60). Additionally, 
using yeast cells expressing PKCα, βΙ, δ, η or ζ, it was possible to ascertain the molecular 
mechanism of action of euxanthone, a natural compound that caused neuroblastoma cells 
differentiation(66). This work showed that euxanthone was a PKC activator with a 
remarkable selectivity for PKCζ, a PKC isoform reported to be involved in the 
differentiation of neuroblastoma cells. In a continuous effort to discover new PKC 
modulators more potent and selective towards individual PKC isoforms, the activity of 
several synthetic xanthones (67, 68) and xanthonolignoids (69) on PKCα, βΙ, δ, η and ζ 
was also evaluated using the yeast assay. Some of the tested xanthones showed to be 
more effective than the standard PKC activators (namely PMA for cPKCs and nPKCs, and 
arachidonic for aPKCζ). Most importantly, some of them showed to be highly selective for 
an individual PKC isoform as PKCδ, η and ζ (68). Additionally, two of the tested 
xanthones behaved as PKC inhibitors and presented differences on their potency towards 
the distinct PKC isoforms tested (67). A potent and selective inhibitor of PKCζ was also 
identified using the yeast PKC assay by testing a library of xanthonolignoid derivatives 
(69). Together, these works allowed the identification of several isoform-selective PKC 
modulators with promising applications as pharmacological probes in PKC-signalling 
pathway research field and/or as therapeutic agents. Additionally, they can be used as 
lead compounds for the synthesis of new compounds with improved potency and 
selectivity.  
The finding that yeast can undergo apoptosis with similar characteristics of 
mammalian cells [reviewed in (5)] uncovered the possibility to exploit this model organism 
to unravel the role of PKC isoforms in the regulation of this cellular process. In fact, our 
group used the yeast model to study the ability of distinct PKC isoforms to modulate the 
activity of major apoptotic proteins of the Bcl-2 family, namely Bcl-xL (20) and Bax (70). 
Using yeast cells co-expressing an individual mammalian PKC isoform and the anti-
apoptotic human Bcl-xL protein, it was shown that PKC isoforms differently interfered with 
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the cytoprotective effect of Bcl-xL in acetic acid-induced yeast cell death, by affecting the 
Bcl-xL phosphorylation state. Whereas PKCα phosphorylated Bcl-xL abolishing its anti-
apoptotic activity, PKCε and ζ markedly inhibited Bcl-xL phosphorylation and stimulated 
its anti-apoptotic activity. Meanwhile, PKCδ had no effect on Bcl-xL phosphorylated state 
and anti-apoptotic activity (20). Du and colleagues (71) have proposed the existence in 
mammalian cells of a kinase and phosphatase system that may be operating in tandem, 
leading to a coordinated phosphorylation-dephosphorylation cycle that modulates Bcl-xL 
activity. However, the precise mechanisms for this modulation remain undetermined. 
Therefore, the study performed in yeast offered new insights into the role of 
phosphorylation on the modulation of the Bcl-xL function and identified individual PKC 
isoforms as key regulators of the phosphorylation-dephosphorylation state of Bcl-xL. In a 
later study, it was also demonstrated that PKCα was able to regulate the activity of Bax in 
yeast (70). The pro-apoptotic function of this Bcl-2 family protein depends on its ability to 
translocate, oligomerize and insert into the mitochondrial membrane following stress 
[reviewed in (72)]. Using yeast cells co-expressing an active form of Bax and PKCα, it was 
shown that PKCα increases the translocation and insertion of Bax into the outer 
mitochondrial membrane. This was associated with an increase in cytochrome c (cyt c) 
release, reactive oxygen species (ROS) production, mitochondrial network fragmentation 
and autophagic cell death. Curiously, this PKCα effect revealed to be independent of its 
kinase activity (70). This observation obtained with yeast supported the notion that PKCα 
can promote apoptosis by a kinase-independent way. In fact, non-traditional PKC 
activation mechanisms, such as kinase-independent actions of freed regulatory, are 
frequently reported for PKCs (26). Together, in agreement with several reports in 
mammalian cells (34), the studies performed in yeast identified the members of the Bcl-2 
family as major apoptotic targets of PKC isoforms. Moreover, they represent an important 
contribution to the design of new strategies for apoptosis regulation through modulation of 
PKC isoforms activity. 
Overall, valuable insights about the genetic, molecular and functional profile of 
individual PKC isoforms have been provided by the yeast PKC assay. Additionally, potent 
and selective pharmacological modulators of these kinases have been identified using this 
cell system. The suitability of this cell system to uncover many other aspects in the PKC 
research field is therefore undeniable.  
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1.3. YEAST AS A CELL MODEL TO STUDY P53 
 
The p53 tumour suppressor protein acts as a major defence against cancer, and 
altered p53 activity is often observed in human cancers. In fact, about 50% of all reported 
cancers have a mutation in the TP53 gene. Among the remaining cancers that retain a 
wild-type (wt) p53, the p53 pathway is often inactivated leading to multiple defects in p53 
responses. Hence, restoring p53 function has been considered a promising strategy in 
anticancer therapy (73, 74). In this context, a better elucidation of the mechanisms of p53 
regulation may contribute to the development of new approaches and therapies to restore 
the p53 function in human cancers. This has been therefore the focus of an intensive 
research.  
The best-understood function of p53 is its transcriptional activity. In unstressed 
cells, the activity of p53 is normally held in check by its negative regulator MDM2, (Murine 
Double Minute 2), an E3 ubiquitin ligase, which binds to p53 and targets it for proteasomal 
degradation. In response to several stimuli, however, this inhibition is relieved, and p53, 
as a sequence-specific transcription factor, regulates the expression of several target 
genes to cause multiple cellular outcomes such as cell cycle arrest (e.g. p21 gene, growth 
arrest and DNA damage inducible gene 45 (GADD45), apoptosis (p53-inducible gene 
(PIG), BAX, p53 upregulated modulator of apoptosis (PUMA), and apoptotic protease 
activating factor 1 (APAF1) genes) and numerous other processes (75, 76). However, not 
all target genes are equally and coordinately responsive to p53. Instead, p53 
transcriptional activity is regulated by several factors that contribute to this variable p53 
response [reviewed in (75-77)]. After various types of genotoxic insults, p53 is stabilized, 
translocates to the nucleus, and binds to its response element (RE) most commonly found 
in the promoter at varying distances upstream from the transcription start site (TSS) of the 
target gene. It was shown that p53 binds with higher affinity to REs found in cell cycle 
arrest-related genes than to REs found in apoptosis-related genes (78). Hence, low levels 
of active p53 normally result in growth arrest, whereas high levels usually result in 
apoptosis (75-77). Moreover, multiple interactions with p53 binding proteins allow p53 to 
either promote or inhibit the transcription of different target genes. For instance, members 
of apoptotic specific regulator of p53 (ASPP) 1 and 2 (79) stimulate the p53 binding to 
REs from apoptotic genes, while the inhibitory ASPP (iASPP) (80) or the p53 family 
proteins, p63 and p73 (81) were described as inhibitors of the transactivation of pro-
apoptotic genes. Finally, many covalent p53 post-translational modifications have shown 
to predispose p53 to selectively activate or repress certain target genes. In fact, p53 
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contains numerous conserved sites that can be regulated by a multitude of post-
translational modifications including phosphorylation, acetylation, methylation, 
ubiquitination, sumoylation and neddylation. Among these, post-translational modification 
by phosphorylation, which can be brought about by several kinases, such as ataxia-
telangiectasia mutated (ATM), AT and Rad3-related (ATR), DNA-dependent protein 
kinase (DNA-PK), checkpoint kinase (Ckh) 1 and Chk2, c-Jun N-terminal kinases (JNK) 
and PKC (Fig. 1.3), has been shown to play critical roles in the stabilization and activation 
of p53 (82, 83). In particular, several works underscored a major role of PKC in p53 
phosphorylation and activation. In fact, it was demonstrated that PKCδ activated a p53-
dependent apoptosis in mammalian cells through p53 phosphorylation (84-87). However, 
the role of other PKC isoforms in the regulation of p53 function is still elusive.  
 
 
 
 
 
Fig. 1.3. Schematic representation of p53 domains and p53 phosphorylation sites. Human p53 
protein consists of five well-defined functional domains: at the N-terminus, the transactivation domain (TAD), 
required for transcriptional activation, and the proline-rich domain (PRD) that enables protein–protein 
interactions; the central sequence-specific DNA-binding domain (DBD), required for DNA binding and where 
the vast majority of p53 cancer related-mutations occurs; and at the C-terminus, the tetramerization domain 
(TD), and the basic C-terminal regulatory domain (CTD), a non-specific DNA binding domain that binds to 
damaged DNA and is involved in the down-regulation of the DNA binding capability of the central domain. 
Major sites for p53 phosphorylation are indicated (red arrow). Major kinases involved in p53 phosphorylation 
are also listed, and include the ATM, ATR, DNA-PK, Chk1, Chk2, JNK and PKC kinases [adapted from (82)]. 
 
The high complexity of the mammalian p53-signalling pathway, associated with the 
absence of p53 orthologues in yeast (88, 89), led several researchers to explore yeast as 
a simpler eukaryotic cell system to study p53. In fact, it was earlier demonstrated that 
mammalian wt p53 was also a sequence-dependent transcription factor in yeast (18, 90). 
It was also found that p53 was predominantly localized in the nucleus of both S. 
cerevisiae (91) and S. pombe (92), a hallmark for p53 transcriptional activity in 
mammalian cells. Several yeast proteins affecting the p53 transcriptional activity were 
also identified. For instance, it was shown that the yeast p53 activating kinase (PAK1) 
regulated the p53 transcriptional activity in yeast, although this study did not evaluate a 
possible phosphorylation of p53 by PAK1 (93). The ability of p53 to be phosphorylated by 
PRDTAD DBD CTDTD CNp53 ATM, ATR, DNA-PK, Chk1, Chk2, JNK, PKC, etc
Potential modifying 
kinases
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endogenous yeast kinases was confirmed in another study, although the kinases 
responsible for this effect were not revealed (94). Moreover, it was shown that the p53 
transcriptional activity in yeast was strongly reduced in the absence of the gene encoding 
thioredoxin reductase, a redox enzyme (95, 96). Evidences that the p53 transcriptional 
activity in yeast was subjected to redox regulation and required thioredoxin reductase 
were thereafter provided in mammalian cells (97). A recent study also revealed 
remarkable similarities between co-activator requirements for p53 transcriptional activity in 
yeast and mammalian cells (89). Yeast has been also extensively used to study how p53 
mutations affect its transcriptional activity and therefore the p53 response, an issue with a 
high clinical value. The functional analysis of separated alleles in yeast (FASAY), 
developed by Ishioka and colleagues (98), allows a rapid detection of p53 mutations in 
cancer cells (98). In this technique, the p53 status can be easily measured based on the 
ability of p53 to express a reporter gene. An enhanced version of this assay used ADE2, 
instead of HIS3, as a reporter gene and located it downstream of a p53 RE (99). This 
assay was based on the observation of the colour of the colonies, where white or red 
colonies indicated the presence of a wt p53 or a total loss-of-function mutant, respectively, 
and intermediate phenotypes (colonies exhibiting pink colour) indicated the presence of a 
partial inactivating p53 mutation. This assay was used in the analysis of the factors that 
regulate the differential p53 transcriptional activity. For instance, a study using 26 different 
p53 RE evaluated the effect on the p53 transcriptional activity of p53 levels and 
recognition and binding affinity of p53 to specific p53 REs (100). The results obtained 
showed a distinct ability of p53 to bind REs derived from genes involved in cell cycle, DNA 
repair and apoptosis. In fact, p53 had a weaker affinity to most of the apoptotic genes 
tested, requiring higher levels of p53 for their transactivation. This suggests that p53 
levels, as well as p53 binding affinity to a RE, are important determinants of the p53 
differential transcriptional activity (100). An extended study, to analyse all known p53 REs, 
revealed similar results in yeast and mammalian cells (101). Recently, an adaptation of 
the yeast transcriptional assay was performed for the high-throughput screening of factors 
that can influence the p53 activity, including mutations, co-factor proteins and small 
molecules (102). Using this assay it was shown for instance that MDM2 also led to a 
reduction in the p53-dependent transactivation in yeast. In fact, a study performed by Di 
Ventura and colleagues (91) showed that, as in mammalian cells, MDM2 can interact with 
endogenous yeast pathways to ubiquitinate and sumoylate p53. Ubiquitination led to p53 
degradation, while sumoylation was essential for the localization of p53-MDM2 complexes 
to yeast nuclear bodies. Together, these studies established the yeast assay as an 
appropriate model system to elucidate the complex regulatory interplay between p53 and 
MDM2, and possibly other p53 regulatory proteins. 
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Despite the prominence of the p53 transcriptional activity in the induction of 
apoptosis, a transcription-independent p53 apoptotic activity, triggered by the p53 
exported from the nucleus to the cytoplasm and/or mitochondria, has also been reported 
[reviewed in (103, 104)]. In fact, several evidences provide encouragement to further 
explore the potential of cancer therapeutics based on the activation of the p53 
transcription-independent pathway, specially in those cancers carrying p53 mutants with 
no transcriptional activity. Moreover, unlike the transcriptional activity, transcription-
independent p53 responses lead necessarily to apoptosis, therefore eliminating the cell 
cycle or other outcomes in tumour cell targets (103, 105). A better understanding of the 
mechanisms involved in the regulation of this p53 apoptotic pathway may therefore 
underscore new therapeutic strategies. 
Although p53 transcription-dependent and -independent activities are independent 
pathways, several data indicate that they co-exist and complement each other for full 
apoptotic responses of p53. Apoptosis can be initiated by two convergent signalling 
pathways, extrinsic and intrinsic, both regulated by p53 (Fig. 1.4). The extrinsic pathway is 
initiated by the activation of death receptors at the cell surface, while the intrinsic 
mitochondria-mediated pathway is initiated by stress signals originated within the cell. In 
the intrinsic pathway mitochondria and, specifically, mitochondrial outer membrane 
permeabilization (MOMP), which is controlled by Bcl-2 family members, play a central 
role. These two pathways trigger a cascade of events that results in caspase activation 
and death (Fig. 1.4) [reviewed in (103, 104)]. Through its transcription-dependent activity, 
p53 regulates the expression of several proteins involved in both intrinsic and extrinsic 
pathways, including pro-apoptotic proteins, such as Bax, Bid, PUMA, Apaf1, the death 
receptor Fas, the adaptor protein p53-induced protein with a death domain (PIDD), and 
anti-apoptotic proteins, such as Bcl-2, Bcl-xL and the inhibitor of apoptosis protein (IAP) 
survivin (75, 76, 106) (Fig. 1.4). Outside the nucleus, p53 induces apoptosis in a 
transcription-independent manner through its interaction with several cellular proteins, 
such as Bcl-2 family members (Fig. 1.4). In fact, p53 has a dual action of neutralizing anti-
apoptotic members (namely Bcl-xL and Bcl-2) and activating pro-apoptotic members 
(namely Bax and Bak) of the Bcl-2 family [reviewed in (103, 104)]. For instance, p53 can 
interact with Bak in the mitochondria, releasing it from an inhibitory complex formed with 
the anti-apoptotic protein myeloid cell leukemia sequence 1 (Mcl-1). This leads to the 
oligomerization and activation of Bak. At the cytosol, p53 can activate Bax by activating its 
translocation to mitochondria and oligomerization.  
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Fig. 1.4. Signalling pathways leading to caspase activation and apoptosis that are influenced by p53. In the 
extrinsic pathway, extracellular signals induce caspase-8/-10 recruitment to the death-inducing signalling 
complex (DISC), a typical transmembrane signalling receptor which includes a death receptor (e.g. Fas) and 
an adaptor protein (e.g. Fas-Associated protein with DD, FADD). Once activated, caspase-8 directly cleaves 
and activates procaspase-3/-7 and/or Bid, activating the intrinsic apoptotic pathway. Activated Bid (tBid) 
triggers oligomerization and activation of the pro-apoptotic proteins Bax/Bak, which lead to MOMP and to the 
release of mitochondrial signalling proteins into the cytosol, the most well-known being cyt c. Activation of 
Bax/Bak is also achieved indirectly when Bcl-2 anti-apoptotic members (namely Bcl-2 and Bcl-xL) are 
neutralized. At the cytoplasm, cyt c associates with Apaf-1 and procaspase-9 to form the apoptosome, which 
results in an activated caspase-9 and consequent procaspase-3/-7 proteolytic activation. Activation of the 
intrinsic pathway is also achieved independently of the extrinsic pathway, by other signals originated within the 
cell, such as DNA damage. In the figure, transcriptional targets of p53 are underlined (activation is indicated 
by a green arrow and repression by a red arrow), whereas proteins affected by transcription-independent 
activity of p53 are highlighted in red [adapted from (103)].  
 
Apoptosis can be also promoted by interaction of p53 with Bcl-xL and Bcl-2, which 
releases Bax and Bak from the inhibitory complexes formed with pro- and anti-apoptotic 
Bcl-2 family members. In a second step, PUMA, a p53 transcriptional product, releases 
p53 from the inactivating complex formed with BcL-xL, freeing p53 to activate pro-
apoptotic proteins. These observations clearly evidence the co-operation between the p53 
transcription-dependent and -independent pathways. In addition to its direct interaction 
with Bcl-2 family members, p53 was also found to regulate the activity of other proteins 
involved in the intrinsic pathway in a transcription-independent manner. For instance, p53 
was found to interact with Ku70, a protein that binds to Bax preventing its translocation to 
mitochondria. Upon post-translational modification by acetylation, Ku70-Bax complex is 
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disrupted and Bax is activated resulting in apoptosis (107). In fact, besides their important 
role in the regulation of p53 transcriptional activity, post-translational modifications also 
appear to play a major role in the regulation of p53 transcription-independent apoptotic 
activity [reviewed in (103, 104)]. For instance, the export of p53 from the nucleus to the 
cytosol has been attributed to its post-translational mono-ubiquitination by MDM2. In 
addition, MDM2-mediated mono-ubiquitination of p53 greatly promotes its mitochondrial 
translocation. Once in the mitochondria, p53 is deubiquinated and free to induce 
apoptosis (108, 109). Although p53 phosphorylation has also been proposed as an 
obvious mechanism of regulation of p53 activities, this remains unconfirmed (103, 110).  
The recognised involvement of p53 in the regulation of cell cycle and apoptosis 
(76, 77) along with the feasibility of the yeast cell model to study these cellular processes 
(4, 5) have prompted several researchers to use the yeast model to further explore the 
p53 functions in these cellular processes. In fact, similarly to that reported in mammalian 
cells, it was found that expression of wt p53 in S. cerevisiae caused growth inhibition 
associated with a G1/S cell cycle arrest, which was markedly increased by co-expression 
of human cell cycle-regulated protein kinase CDC2Hs (111). Curiously, it was shown that 
p53-induced growth arrest in S. pombe was abrogated by co-expression of the human cell 
cycle regulator protein phosphatase CDC25, indicating a functional interaction of both 
proteins (112). In a later study in mammalian cells, it was confirmed that p53 regulated 
cell cycle progression by interacting with CDC25 (113). Instead, Hadj Amor and 
colleagues (114) showed that expression of wt p53 in S. cerevisiae resulted in an 
apoptotic cell death. This work also revealed that p53 affected the yeast gene expression 
since a decrease of the expression of the gene that encodes the anti-apoptotic and anti-
oxidant protein thioredoxin, was detected. Since this protein has a crucial function in the 
protection of yeast cells against ROS, these results suggested that p53 may induce 
apoptosis in part by down-regulation of anti-apoptotic proteins. The aforementioned 
distinct phenotypes achieved in yeast upon expression of p53 were attributed to different 
p53 expression levels due to the use of different yeast expression vectors (114). 
Altogether, these results revealed that yeast is a suitable model system to further 
elucidate p53-dependent activities in cell cycle and apoptosis. 
In summary, the works referred above provided several evidences that highlight 
yeast as a powerful cell model system, which can be further explored for functional, 
molecular and pharmacological studies of p53. 
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1.4. YEAST AS A CELL MODEL TO STUDY CASPASE FAMILY MEMBERS 
 
 Caspases are a conserved family of cysteine-dependent aspartate-specific 
proteases composed by at least 15 members that are grouped into the inflammatory and 
apoptotic sub-families according to their major cellular functions. Apoptotic caspases can 
be further divided into two functional groups based on their position in the apoptotic 
cascade, the apical or initiator caspases (caspase-2, -8, -9 and -10) and the executioner 
or downstream caspases (caspase-3, -6 and -7) (115, 116). Besides its widely established 
roles in apoptosis, apoptotic caspases are also involved in other non-apoptotic processes, 
including cell survival, proliferation and differentiation. In fact, it has been assumed that 
high levels of caspase activity lead to a caspase-dependent apoptosis, while transient or 
low levels may lead to the induction of its non-apoptotic activities (117-119). Caspases are 
synthesized as catalytically inactive enzymes called procaspases, and possess distinct 
mechanisms of activation. Basically, initiator procaspases become active by proximity-
induced dimerization at caspase activation complexes, which favours autoproteolytic 
processing, resulting in a mature caspase. Instead, downstream procaspases occur as 
inactive dimers in the cytosol, requiring proteolytic cleavage by upstream effectors (e.g. 
initiator caspases) to become active (see Fig. 1.4 for a schematic representation of the 
cascade of caspase activation during apoptosis) (115, 116). The final outcome of this 
activating cascade is the specific and irreversible cleavage of a wide variety of substrates 
that determine the cell fate (115, 120). Caspases activity can be suppressed by caspase 
inhibitor proteins, such as cowpox virus cytokine response modifier A (crmA), baculoviral 
p35/p49 and inhibitors of apoptosis proteins (IAPs), a family of cellular proteins including 
neuronal apoptosis inhibitory protein (NAIP), cellular IAP1 (cIAP1) and 2 (cIAP2), X-linked 
IAP (XIAP), survivin, bruce, melanoma IAP (ML-IAP) and IAP-like protein 2 (ILP2) (121, 
122). Due to their key roles in coordinating major cellular processes, it is not surprising 
that dysregulation of caspase expression or activity has been associated with many 
human diseases, including cancer and neurodegeneration (123, 124). Caspases, 
especially caspase-3 and -7 due to their well-established contribution for executing the 
final processes of apoptosis (115, 116, 120, 125), therefore represent promising 
therapeutic targets in these human diseases. In fact, the identification of selective small 
molecule modulators of caspase family members, particularly of caspase-3 and -7, has 
been the focus of an intensive research (121, 126-128). Besides its potential as 
therapeutic agents, these compounds are highly required for the study of caspase-
signalling pathways.  
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The high complexity of mammalian caspase-signalling pathways, particularly the 
co-existence of several caspase members and endogenous caspase regulators in 
mammalian cells, led several research groups to explore yeast for an independent 
analysis of caspase family members in a simpler eukaryotic cell system. Although yeast 
encodes a metacaspase (Yca1p) that shares structural homology and mechanistic 
features with mammalian caspases, major differences in the primary cleavage specificity 
have questioned its classification as a “true” caspase. This has been the subject of an 
intensive discussion (129, 130). In fact, Yca1p has been implicated in the same cellular 
processes as mammalian caspases, namely in apoptosis (131). However, while 
mammalian caspases specifically cleave their substrates after aspartic acid residues 
(132), metacaspases specifically cleave substrates after arginine or lysine (basic 
residues) (133). Though it is still being a controversial issue, recent reports have 
demonstrated that the activity of mammalian caspases in yeast (namely of caspase-2, -3, 
-4, -7, -8 and -10) is independent of Yca1p (22, 134). Based on this, yeast has been 
widely exploited to study several aspects of mammalian caspase family members, 
particularly to identify their regulators and substrates. However, while the majority of 
mammalian caspases are auto-activated in yeast when expressed at high levels, 
downstream caspases, namely caspase-3, -6 and -7, and the initiator caspase-9 cannot 
undergo auto-activation. In fact, these caspases require for their activation mammalian 
upstream proteins, such as initiator caspases or the caspase-9 adaptor protein Apaf-1, 
which are absent in yeast (115, 116). This has been surpassed using engineered auto-
activated variants that allow auto-activation of these caspases even in the absence of 
their upstream activators. A commonly used strategy to induce caspase auto-activation in 
yeast is the generation of reverse caspases by rearrangement of their subunits (Fig. 1.5) 
(135-137). In fact, reverse caspases fold spontaneously into an active conformation 
inducing apoptosis in mammalian cells (138). Moreover, they exhibit similar intrinsic 
enzymatic activity to wt constructs, both in mammalian (138) and yeast (135) cells. Auto-
activation in yeast has also been achieved using caspase variants lacking the N-terminal 
prodomain from the caspase coding sequence (139). This form of caspase was shown to 
induce apoptosis in mammalian cells due to the spontaneous interdomain cleavage, while 
the intrinsic enzymatic activity is not affected (140). Other strategies involved co-
expressing the large and small subunits separately, for an intracellular assembling of the 
active caspase (141), and joining in-frame the caspase cDNA to the coding regions for 
bacterial β-galactosidase (lacZ), a fusion protein able to auto-activate probably due to 
multimer formation mediated by the β-galactosidase moiety (142, 143).  
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Fig. 1.5. Schematic representation of the structure, processing and folding of procaspase-3 and reverse 
caspase-3. (A) Similarly to other procaspases, procaspase-3 is composed by an N-terminal prodomain (PD) 
that is followed by a large subunit (LS or p20), containing the catalytic cysteine conserved site (QACR(X)G, 
where X varies according to the caspase members) and a small subunit (SS or p10). After proteolytic 
processing at specific aspartic acid residues (Asp; black arrow), the free SS and LS can fold properly into an 
active conformation. In this conformation, the N-terminus of the SS and the C-terminus of the LS are set apart, 
whereas the N-terminus of the LS and the C-terminus of the SS are close to each other. (B) Reverse caspase-
3, with the SS before the prodomain and LS, folds spontaneously into an active conformation that simulates 
the three-dimensional structure of the processed procaspase. The linker region between SS and LS includes 
the prodomain [adapted from (138)]. 
 
An approach developed to monitor the activity of mammalian caspases in yeast 
used a modified yeast two-hybrid system, in which the bait vector contains the sequences 
for the two caspase-3 subunits and the LexA DNA-binding domain, and the prey vector 
contains a cDNA expression library fused to Gal4 activation domain. In this system, the 
interaction of caspase-3 with its substrates was detected through the activation of a 
reporter gene (e.g. the bacterial lacZ) (141). Using this approach, gelsolin, an actin-
regulatory protein cleaved during apoptosis in human cells, was identified as a substrate 
of caspase-3. This result was also confirmed in vitro using recombinant gelsolin and 
caspase-3, and in human cell lines (141). These experiments validated this yeast assay to 
identify caspase substrates. Later, a similar approach was developed to identify new 
caspase family members and their regulators. In this case, it was used a fusion protein in 
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which a transcription factor was linked to the intracellular domain of a transmembrane 
protein by caspase cleavage sites. The caspase activation resulted in the release of the 
transcription factor from the membrane, which drove the transcriptional activation of the 
reporter gene (139, 144). This assay was validated using the caspase-9 activating adaptor 
protein Apaf-1 that induced reporter gene expression, and mammalian caspase inhibitors 
(namely XIAP and baculoviral p35) that suppressed caspase-dependent reporter gene 
expression (139). Later, Hayashi and colleagues (144) adapted this yeast system to the 
high-throughput screening of caspase modulators. However, despite the advantages of 
this cell system as a first-line screening tool, so far no small molecule modulators of 
caspase family members have been identified using yeast.  
 The most commonly used strategy to study mammalian caspases in yeast relied on 
the fact that, in most cases, high expression levels of an active caspase induce yeast 
growth inhibition, which can be reverted or stimulated by caspase inhibitors or activators, 
respectively. For instance, it was shown that natural caspase-3 activators, such as initiator 
caspase-2 (145), -8 and -10 (137), stimulated caspase-3-induced yeast growth inhibition. 
Also, natural caspase-3 inhibitors, such as p35, p49 (146) and several members of IAPs 
(136, 143, 147), and the chemical caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-
[O-methyl]- fluoromethylketone (z-VAD-FMK) (148) reverted the observed phenotype. 
These observations led to the establishment of a yeast phenotypic assay suitable to study 
the mechanisms of mammalian caspase activation and to identify new regulators and 
substrates. In fact, this yeast phenotypic assay was used to reconstitute in yeast the 
mammalian cascade of caspase activation, namely the roles of caspase-8 and -10 in the 
activation of caspase-3 and -6. In this study, it was shown that activation of caspase-3 in 
yeast was successfully achieved by co-expression of caspase-8β or -10, whereas these 
caspases were insufficient to activate caspase-6. These results distinguished sequential 
modes of action for different caspases in vivo (149). Other authors used this yeast assay 
to reconstitute the Apaf-1-activated apoptotic mechanisms. In fact, as reported in 
mammalian cells (150), it was shown that Apaf-1 activated caspase-9, which in turn 
activated caspase-3 (136, 151). Also, in accordance with previous reports in mammalian 
cells [reviewed in (121)], XIAP was able to prevent this caspase activation cascade by 
inhibiting caspase-3 and/or caspase-9 activation (136, 151). Additionally, this effect was 
reverted by the IAP-binding antagonist Diablo (direct IAP-binding protein with low 
isoelectric point, also known as Smac, second mitochondria-derived activator of 
caspases), which disrupted the interaction between XIAP and caspase-9 (151). This yeast 
assay was also used to study the potency of some natural caspase activators and 
inhibitors on individual caspase members. For instance, it was shown that caspase-2 
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activated caspase-7 more effectively than caspase-3 (145). Furthermore, similarly to that 
described in mammalian cells (121), p35 and p49 exhibited a broad-spectrum inhibitory 
activity, inhibiting caspase-1, -2, -3, -4, -5, -7 and -8 in yeast, although with some different 
efficiencies (146). Also, a similar order of IAP activities found in mammalian cells 
expressing an auto-activating caspase-3, namely XIAP>cIAP2>cIAP1>survivin, was 
observed in yeast (152).  
 Distinct causes have been attributed to this caspase-induced yeast growth inhibition. 
In most studies, it has been associated with the induction of a cell death (22, 134). 
However, it was detected that this could vary depending on the yeast strain, possibly due 
to differences in the expression levels of endogenous caspase substrates and/or other 
proteases with similar functions (22, 151). Moreover, the strategy used to produce auto-
activating forms of caspases was also referred as having some impact on the final 
outcome of caspase activation. For instance, while co-expression of the subunits of 
caspase-3 as separate proteins inhibited yeast growth without causing cell death (147, 
148), expression of reverse caspase-3 induced yeast cell death (22). It was proposed that 
this can be related to different efficiencies on generating an active caspase by the two 
approaches, where the first strategy led to comparatively lower caspase activation 
sufficient to impair yeast growth but not to induce cell death. These results revealed that, 
as in mammalian cells where distinct levels of caspase activation lead to distinct cellular 
responses (117-119), different phenotypes can be obtained in yeast by manipulation of 
caspase activation levels. This cell system can therefore be further explored to 
reconstitute distinct phenotypes for functional, molecular and pharmacological studies of 
mammalian caspases.  
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1.5. SCOPE OF THIS THESIS 
 
 As addressed in previous section, the heterologous expression of disease-related 
proteins in yeast has been successfully used to gain understanding of the functions of 
these proteins, providing clues about the potential causes underpinning the associated 
disorders. Moreover, yeast expressing a disease-related target protein has widely 
contributed to the discovery of promising therapeutic agents.  
 The scope of this thesis was to use yeast for functional, molecular and 
pharmacological studies of major neurodegenerative and cancer-related proteins, 
particularly PKC isoforms, p53 and caspase family members. In fact, the high complexity 
of the signalling pathways associated to these proteins in mammalian cells has hampered 
the study of their biology, and especially the discovery of selective pharmacological 
modulators. Based on this, a mammalian PKC-p53 network was reconstituted in yeast 
and relevant insights about the regulation of p53 activity in cell proliferation (chapter 2) 
and death (chapter 3) by distinct PKC isoforms are provided. Also, a yeast PKC assay 
was used to elucidate the molecular mechanism of action of coleon U, a natural 
compound with an antiproliferative activity on several human tumour cell lines (chapter 4). 
With this assay, it was possible to identify a potent and selective activator of nPKCδ and ε 
with promising applications as a probe in the PKC research field and as an anticancer 
agent. Another goal of this thesis was the development of yeast phenotypic assays for the 
screening of small molecule modulators of caspase-3, caspase-7 and p53. With the 
established assays promising caspase-3 inhibitors (chapter 5) and caspase-7 activators 
(chapter 6) were identified.  
 The chapter 7 of this thesis is dedicated to a general discussion focusing on the 
major contributions of this work to advance our knowledge about the functional, molecular 
and pharmacological regulation of the studied proteins. 
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DIFFERENTIAL REGULATION OF P53 FUNCTION BY PROTEIN 
KINASE C ISOFORMS REVEALED BY A YEAST CELL SYSTEM 
 
 
2.1. ABSTRACT 
 The complexity of the mammalian p53 pathway and protein kinase C (PKC) 
family has hampered the discrimination of the effect of PKC isoforms on p53 activity. 
Using yeast co-expressing the human wild-type p53 and a mammalian PKC−α, −δ, −ε or 
−ζ, we showed a differential regulation of p53 activity and phosphorylation state by PKC 
isoforms. Whereas PKC-α reduced the p53-induced yeast growth inhibition and cell cycle 
arrest, PKC−δ, −ε enhanced the p53 activity through p53 phosphorylation, and PKC−ζ had 
no effect on p53. This work identified positive and negative p53 regulators which 
represent promising pharmacological targets in anti-cancer therapy.  
Keywords: p53, PKC isoforms, Cell growth, Cell cycle, p53 phosphorylation, Yeast  
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2.2. INTRODUCTION 
 
 The p53 tumour suppressor protein is mutated in about half of all human tumours 
and in many others that retain a wild-type (WT) p53, p53-dependent pathways leading to 
cell cycle arrest or cell death are often deficient. Restoring p53 function represents 
therefore a promising approach for cancer therapeutics. Among the different mechanisms 
of p53 regulation, post-translational modification by phosphorylation has been shown to 
play a critical role in the stabilization and activation of WT p53 (1).  
 One of the key enzymes involved in p53 phosphorylation is protein kinase C 
(PKC) (2,3). PKC is a family of serine/threonine kinases with at least 10 isoforms grouped 
into three subfamilies based on their primary structure and cofactors required for 
activation: classical (α, βI, βII and γ), novel (δ, ε, η and θ) and atypical (ζ and λ/ι). PKC 
isoforms are important regulators of several cellular processes, such as cell proliferation 
and death, and a striking feature is that individual isoforms can exert either similar or 
opposite effects in these processes (4,5).  
 Due to the high complexity of the mammalian p53 pathway and PKC family, 
particularly the coexistence of several PKC isoforms in the same cell, discrimination of the 
role of each PKC isoform in the regulation of p53 activity has been hampered. To 
circumvent this limitation, in this work, we exploited yeast cells co-expressing the human 
WT p53 and an individual mammalian PKC isoform.  
 The remarkably high degree of conservation of many pathways and cellular 
processes among yeast and human has allowed transposing the knowledge obtained in 
yeast to mammalian cells and vice versa. Additionally, the data obtained with the 
expression of human proteins that lack a yeast orthologue have been crucial to elucidate 
the role of proteins and the molecular mechanisms of complex human disorders, such as 
cancer and neurodegenerative diseases (6). Since the yeast PKC (Pkc1p in 
Saccharomyces cerevisiae) is a structural but not a functional homologue of mammalian 
PKC isoforms, yeast was considered a well-suited organism to study individual 
mammalian PKC isoforms (7). Indeed, the yeast PKC assay has been used by us to 
search for isoform-selective PKC modulators (8) and to study the regulation of human 
apoptotic proteins by PKC isoforms (9). Similarly, though no orthologues of human p53 
have been identified in yeast, S. cerevisiae has been extensively used to score several 
functional properties of human p53 (10).  
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 The yeast expression systems established in this study allowed investigating the 
existence in yeast of a molecular mechanism underlying the regulation of cell proliferation 
through specific PKC isoforms and WT p53. The results obtained underscore a differential 
regulation of p53 activity by PKC isoforms with the identification of kinases responsible for 
both a positive and negative regulation of p53. 
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2.3. MATERIAL AND METHODS 
 
2.3.1. Plasmids 
 Constructed yeast expression plasmids YEplac181-LEU2 encoding bovine 
PKC−α, rat PKC−δ, mouse PKC−ε or PKC−ζ and the empty vector, and pLS89-TRP1 
encoding human WT p53 and the empty vector, were kindly provided by Dr. Nigel Goode 
(The Royal Veterinary College, UK) and Dr. Richard Iggo (Swiss Institute for Experimental 
Cancer Research, Switzerland), respectively. Plasmids used have a galactose-inducible 
GAL1-10 promoter.  
 
2.3.2. Yeast strain, transformation and growth conditions 
 S. cerevisiae CG379 was co-transformed by the lithium acetate method, as 
reported (9). For selection of co-transformed yeast, cells were routinely grown in a 
minimal selective medium, with 2% glucose, 0.67% yeast nitrogen base without amino 
acids and all the amino acids required for yeast growth (50 µg/ml) except leucine and 
tryptophan, to approximately 1 optical density (OD)600. To induce expression of 
mammalian proteins, yeast were diluted to 0.05 OD600 in selective medium with 2% 
galactose and raffinose instead of glucose and incubated at 30 ºC with shake (200 r.p.m.) 
for up to 60 hours in growth curves experiments, or for approximately 45 hours (time 
required by control yeast, co-transformed with the empty vectors pLS89 and YEplac181, 
to achieve 0.5 OD600) in all other experiments. Yeast growth was analysed by counting the 
number of colony-forming units per ml (CFU/ml) after 2 days incubation at 30 ºC on 
Sabouraud Dextrose Agar plates.  
 
2.3.3. Effect of the selective PKC inhibitor Ro 32-0432 on yeast growth 
 To analyse the effect of Bisindolylmaleimide XI hydrochloride (Ro 32-0432; ALX-
270-058, Alexis Biochemicals) on yeast growth, co-transformed cells were incubated in 
galactose selective medium with 1 µM Ro 32-0432 or solvent only (0.1% DMSO) for 
approximately 45 h, at 30 ºC with shake (200 r.p.m.). Yeast growth was analysed as 
described above.  
 
CHAPTER 2 
 
37 
 
2.3.4. Cell death markers 
 Plasma membrane integrity and DNA fragmentation were analysed by 
fluorescence microscopy using propidium iodide (PI) and In Situ Cell Death Detection Kit, 
Fluorescein, respectively, whereas yeast metacaspase (Yca1p) activation and reactive 
oxygen species (ROS) accumulation were analysed by flow cytometry using FITC-VAD-
fmk and dihydroethidium (DHE), respectively, as described (8).  
 
2.3.5. Cell cycle 
 Flow cytometric analysis of DNA content was performed using Sytox Green 
Nucleic Acid, as described (8). Yeast cell cycle phases were identified and quantified 
using ModFit LT software (Verity Software House Inc., Topsham, USA).  
 
2.3.6. Western blot 
 For human WT p53 and mammalian PKC isoforms detection, anti-p53 (DO-1) 
and anti-PKC−α/PKC−δ/PKC−ε/PKC−ζ mouse monoclonal antibodies (Santa Cruz 
Biotechnology) were used. p53 phosphorylation was analysed using phospho-p53(Ser15) 
mouse monoclonal antibody, phospho-p53(Ser20) and phosphop53( Ser46) rabbit 
polyclonal antibodies (Cell Signalling Technology), and PAb421 mouse monoclonal 
antibody (Calbiochem). The etoposite-treated MCF7 cell lysate (sc-2281; Santa Cruz 
Biotechnology) was used as positive control. Immunoblots were developed by enhanced 
chemiluminescence, as described (9). Band intensities were quantified using Bio-Profil 
Bio-1D++ software.  
 
2.3.7. Statistical analysis 
 Data were analysed statistically using SigmaStat 3.5 programme. Differences 
between means were tested for significance using the unpaired Student’s t-test (P < 0.05). 
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2.4. RESULTS 
 
2.4.1 Differential regulation of WT p53-induced yeast growth inhibition by PKC isoforms 
 In accordance with other authors (11,12), we verified that expression of human 
WT p53 in S. cerevisiae inhibited cell growth (Fig. 2.1A,B). Instead, and as previously 
reported by us (8,9), in our experimental conditions expression of a mammalian PKC 
isoform did not significantly interfere with yeast growth (Fig. 2.1A,B). However, when 
PKC−α, −δ, −ε or −ζ was co-expressed with p53, a differential regulation of p53-induced 
growth inhibition by PKC isoforms was obtained (Fig. 2.1A,B). This was particularly 
evident for 45 hours incubation (Fig. 2.1B). For this time, whereas PKC−α significantly 
reduced the p53-induced growth inhibition, PKC−δ and −ε significantly increased the p53 
growth-inhibitory effect and PKC−ζ did not interfere with the p53 effect.  
 The direct effect of PKC isoforms on p53 was evidenced using the selective PKC 
inhibitor Ro 32-0432. Though 1 µM Ro 32-0432 did not significantly interfere with the 
growth of yeast expressing p53 or a PKC isoform only, it significantly reduced the effects 
exhibited by PKC−α, −δ and −ε on p53 activity (Fig. 2.1C).  
 As confirmed by Western blot analysis, this distinct influence of each PKC 
isoform on p53 effect was not a consequence of significant changes in the expression 
levels of p53 or a PKC isoform in yeast co-expressing both proteins (Fig. 2.2).  
 
2.4.2. WT p53 yeast growth-inhibitory effect and its stimulation by PKC−δ and −ε are not 
associated with cell death 
 A recent work associated the human WT p53 growth-inhibitory effect to the 
induction of an apoptotic cell death in S. cerevisiae (11). Hence, typical necrotic and 
apoptotic markers, as loss of plasma membrane integrity, DNA fragmentation, ROS 
accumulation and Yca1p activation, were investigated.  
 However, in our experimental conditions, expression of human WT p53 in yeast 
did not significantly increase the PI and TUNEL positive cells (Fig. 2.3A,B), Yca1p 
activation and ROS levels (Fig. 2.3C,D). Even in the presence of a PKC isoform, 
particularly PKC−δ or −ε, characteristic features of cell death were not detected (Fig. 
2.3B–D). Indeed, though yeast co-expressing p53 and PKC−ε presented a significant 
increase in ROS levels, this was not accompanied by an increase of PI and TUNEL 
positive cells and Yca1p activation (Fig. 2.3B–D).  
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Fig. 2.1. WT p53-induced yeast growth inhibition is differently regulated by PKC isoforms. (A) Growth curves 
were obtained by CFU counts. (B) Percentage of growth obtained for 45 hours incubation; value of yeast co-
expressing p53 and a PKC isoform significantly different from that of yeast expressing p53 only: *P<0.05. (C) 
Effect of 1 µM RO 32-0432 on the growth of co-transformed cells for 45 hours incubation; value obtained with 
RO 32-0432 significantly different from that obtained with DMSO only: *P<0.05. In B and C, values were 
obtained considering the growth achieved with control yeast (YEplac181+pLS89) as 100%. Data represent 
mean ± S.E.M. (n=4). 
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 According to Amor et al. (11), a complete abolishment of yeast growth associated 
with cell death can be achieved using a multicopy vector for p53 expression and minimal 
medium culture conditions that rendered yeast more responsive to target gene regulation 
by p53. In fact, similarly to that obtained by us, Nigro et al. (12) only observed a modest 
yeast growth inhibition using a centromeric low-copy-number vector for p53 expression. 
However, considerable levels of p53 expression were also achieved in our work using a 
pLS89 centromeric vector (Fig. 2.2A,B). Additionally, a minimal medium similar to that 
described by Amor et al. (11) was used in our study. In order to understand the different 
results obtained, co-transformed yeast expressing WT p53 only (YEplac181 + p53) were 
treated with different concentrations of hydrogen peroxide (a known yeast apoptotic 
inducer, see (13)). In accordance with the high-level resistance to cell death detected in a 
previous work performed by us with co-transformed yeast (9), a significant percentage of 
TUNEL positive cells (21.3 ± 5.4%; n = 3), with a low percentage of IP positive cells (9.2 ± 
4.1%; n = 3), was only achieved at high concentrations of hydrogen peroxide (10 mM 
H2O2, 1 hour treatment). Thus, the use of co-transformed yeast strains with high-level 
resistance to cell death may be a possible explanation for the results obtained by us. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2. Expression of human WT p53 or a mammalian PKC isoform is not affected by co-expression of both 
proteins in yeast. Western blot analysis of (A, B) p53, (C) PKC-α (D) PKC-δ (E) PKC-ε and (F) PKC-ζ 
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represent 1 of duplicate experiments; β-actin was used as loading control. (G, H) Quantification of band 
intensities of Western blots obtained for (G) p53 and (H) PKC isoforms; data represent mean ± S.E.M. (n=2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.3. Effects of WT p53 and/or a PKC isoform on yeast growth are not associated with cell death. (A) Cells 
with DNA fragmentation (TUNEL +) and necrotic cells (PI +) obtained from yeast expressing WT p53 for 35, 
45 and 60 hours incubation; (B) TUNEL and PI positive cells, (C) Yca1p activation and (D) ROS accumulation 
obtained from yeast expressing WT p53 and/or a PKC isoforms for 45 hours incubation. In B, C and D, yeast 
expressing PKC-ε treated with 1 µM coleon U (see (8)) were used as positive control (C+). Data represent 
mean ± S.E.M. (n=2); values significantly different from control yeast (YEplac181+pLS89): * P<0.05. 
 
2.4.3. WT p53 yeast growth-inhibitory effect is associated with S-phase cell cycle arrest 
that is differently regulated by PKC isoforms 
 As in mammalian cells, where p53 controls cell cycle mainly through the G1/S 
checkpoint (2), we detected that p53-induced yeast growth inhibition was associated with 
S-phase cell cycle arrest (Fig. 2.4). Instead, and in agreement with the absence of effect 
on yeast growth, PKC isoforms only slightly interfered with the yeast cell cycle progression 
(Fig. 2.4). However, when PKC−α, −δ, −ε or −ζ was co-expressed with p53, a specific 
PKC isoform-dependent modulation of cell cycle through p53 was obtained (Fig. 2.4). 
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Whereas PKC−α decreased the percentage of cells in S-phase and increased the 
percentage of cells in G2/M, PKC−δ and −ε markedly increased the percentage of cells 
arrested in S-phase. Consistently, PKC−ζ that did not affect the p53-induced growth 
inhibition also did not interfere with the p53-induced S-phase arrest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.4. WT p53-induced S-phase cell cycle arrest is differently regulated by PKC isoforms. (A) Histograms 
represent 1 of triplicate experiments. (B) Quantification of yeast cell cycle phases; data represent mean values 
(n=3). 
 
2.4.4. Differential regulation of p53 effects by PKC isoforms is associated with distinct patterns of 
p53 phosphorylation in yeast 
 Phosphorylation of WT p53 at commonly reported p53 phosphorylation sites, 
Ser15, Ser20, Ser46 and Ser376-378 (2,3,14), was checked by Western blot analysis. 
p53 phosphorylation at Ser15, Ser20 and Ser46, analysed using a phospho-p53 antibody 
specific for each serine, was not detected neither in yeast expressing p53 only nor in 
yeast co-expressing p53 and a PKC isoform (Fig. 2.5A–C). 
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Fig. 2.5. PKC isoforms cause distinct patterns of p53 phosphorylation in yeast. p53 phosphorylation was 
analysed using (A) phospo-p53(Ser15), (B) phospo-p53(Ser20), (C) phospo-p53(Ser46) and (D) PAb421 
(Ser376-378) antibodies. Detection of p53 with DO-1 antibody was used as a loading control. In A, B and C, 
the etoposite-treated MCF7 cell lysate was used as positive control (C+); in D, the positive control 
corresponds to p53 from yeast cells expressing p53 only (YEplac181+p53), which expression was confirmed 
using the anti-p53 DO-1 antibody. Immunoblots represent 1 of duplicate experiments. In D, YEplac181/p53 
lane was located in a different part of the same gel. (E) Quantification of band intensities of D; data represent 
mean ± S.E.M. (n=2); values significantly different from control band (YEplac181+p53): *P<0.05. 
p53 phosphorylation at Ser376-378 was analysed using the PAb421 antibody which 
preferentially recognises unphosphorylated p53 residues at Ser376-378. Indeed, it was 
demonstrated that when p53 was phosphorylated at Ser376-378 by PKC the PAb421 
band almost disappeared (3). In our case, a high intensity PAb421 band was obtained for 
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yeast expressing p53 only (Fig. 2.5D,E), indicating the absence of p53 phosphorylation at 
Ser376–378 by endogenous yeast kinases. This band was therefore used as control. 
Interesting, when compared to control band, whereas PKC−α slightly decreased and 
PKC−ζ did not interfere with the PAb421 band intensity, PKC−δ and −ε markedly 
decreased the intensity of this band (Fig. 2.5D,E). This indicated that, while PKC−α and 
−ζ did not significantly interfere with the degree of p53 phosphorylation, PKC−δ and −ε 
markedly increased p53 phosphorylation.  
 Overall, despite phosphorylation of human WT p53 by endogenous kinases was 
already reported for S. cerevisiae (12), to our knowledge the sites of p53 phosphorylation 
were still unclear. The results obtained indicated that p53 is not phosphorylated at Ser15, 
Ser20, Ser46 and Ser376-378 by yeast kinases. Importantly, though p53 phosphorylation 
by PKC has been described at distinct serine residues (2,3,14), in yeast we only detected 
phosphorylation at Ser376–378, which is the most commonly reported PKC 
phosphorylation site in mammalian cells (2,3). For this p53 residue, a PKC isoform-
dependent phosphorylation pattern was identified. 
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2.5. DISCUSSION 
 
 The involvement of PKC family in the regulation of cell proliferation was early 
recognised. While PKC−α and −ζ are frequently associated to the proliferation of human 
cancers and PKC−δ is often linked to an anti-proliferative effect (4,5), PKC−ε has been 
associated both to proliferative (4,5) and anti-proliferative (15) effects. In spite of this, the 
molecular mechanism of induction or suppression of cell proliferation by PKC isoforms 
remains unclear. Another open issue is the role of PKC isoforms in the regulation of p53, 
a key player in cell proliferation and death. The PKC-mediated effects are in fact largely 
tissue and cell-type-specific, thus it has been difficult and controversial to extrapolate 
conclusions from one mammalian cell type to another. This study represents the first 
attempt to reconstitute in yeast key parts of the intricate mammalian p53-PKC network. 
With this yeast approach, it was possible to ascertain the effect of individual PKC 
isoforms, representative of the classical (PKC−α), novel (PKC−δ and −ε) and atypical 
(PKC−ζ) PKC subfamilies and considered major isoforms in carcinogenesis, cell 
proliferation and human WT p53 activity. The results obtained revealed that even though 
the PKC isoforms per se had no effect on yeast growth and cell cycle, they differentially 
interfered with the p53-induced yeast growth inhibition and cell cycle arrest and p53 
phosphorylation. They underscored an anti-proliferative effect of PKC−δ and −ε through 
phosphorylation and consequent activation of p53. In opposition, they evidenced a 
proliferative effect of PKC−α through inhibition of p53 function. Further studies are 
underway to better elucidate the molecular mechanism of this PKC−α-inhibitory effect. 
Finally, the absence of effect of PKC−ζ on the activity and phosphorylation state of p53 
indicated that p53 was not a target of this kinase. As a whole, this study established a 
unifying mechanism between the modulation of cell proliferation by PKC−α, −δ and −ε and 
the regulation of p53. For PKC−ζ, a p53-independent effect on cell proliferation was 
suggested. Additionally, it underscored a differential regulation of p53 activity and 
phosphorylation state by PKC isoforms, with the identification of kinases responsible for 
both a positive and negative regulation of p53. These kinases represent therefore 
promising molecular and pharmacological targets in anti-cancer therapy. As reported by 
others, the distinct roles of individual PKC isoforms in cancer progression suggests that 
either PKC activators or inhibitors may serve as anti-tumour agents if target specific 
members of the PKC family (5). Accordingly, our data support that selective PKC−α 
inhibitors as well as selective PKC−δ and −ε activators may be beneficial in the therapy of 
several cancers by inhibiting the proliferation particularly of those tumours where PKC−α 
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is up-regulated and PKC−δ or −ε are down-regulated. This study will certainly contribute to 
the elucidation of the effect of PKC activators and inhibitors on tumour cells proliferation, 
providing new perspectives for PKC modulators as anti-cancer agents. 
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DISTINCT REGULATION OF P53-MEDIATED APOPTOSIS BY PROTEIN 
KINASE Cα, δ, ε AND ζ: EVIDENCE IN YEAST FOR TRANSCRIPTION-
DEPENDENT AND -INDEPENDENT P53 APOPTOTIC MECHANISMS 
 
 
3.1. ABSTRACT 
 The role of individual protein kinase C (PKC) isoforms in the regulation of p53-
mediated apoptosis is still uncertain. Using yeast cells co-expressing the human wild-type 
p53 and a single mammalian PKCα, δ, ε or ζ, we showed a differential regulation of p53-
mediated apoptosis by these PKC isoforms. Whereas PKCα and ζ had no effect on p53 
activity, PKCδ and ε stimulated a p53-mediated mitochondria-dependent apoptosis. 
Moreover, using pifithrin-α and -µ, selective inhibitors of p53 transcriptional activity and 
mitochondrial p53 translocation, respectively, we showed the activation of a transcription-
dependent and -independent p53-mediated apoptosis by PKCδ and ε. The activation of 
mitochondrial p53 translocation by PKCδ and ε was further confirmed by 
immunofluorescence and Western blot analysis. 
 Together, this work reveals the conservation in yeast of functional transcription-
dependent and -independent p53 apoptotic mechanisms. Furthermore, it gives 
mechanistic insights about the regulation of p53-mediated apoptosis by PKCδ and ε 
through modulation of p53 transcriptional activity and of its translocation to mitochondria. 
Finally, it underscores a major role of PKCδ and ε as positive regulators of p53-mediated 
apoptosis, and therefore as promising therapeutic targets in cancer. 
Keywords: p53; PKC isoforms; Apoptosis; Transcription; Mitochondria; Yeast 
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3.2. INTRODUCTION 
 
 The major tumour suppressor protein, p53, is a sequence-specific transcription 
factor that determines the fate of a cell. p53 regulates the expression of an assortment of 
genes involved in cell cycle regulation, apoptosis and numerous other processes. In large 
part, the potent tumour suppressing function of p53 has been attributed to its ability to 
induce apoptosis. Despite the prominence of p53 nuclear transcriptional activity in the 
induction of apoptosis, a transcription-independent mechanism involving mitochondrial 
p53 translocation, is receiving increasing attention. Indeed, recent findings provide 
encouragement to further explore the potential of mitochondrial p53-based cancer 
therapeutics (1-3).  
 Inactivating mutations of the p53 gene are found in approximately half of all 
human cancers. In most of the remaining cancers that retain a wild-type (WT) p53, the 
p53 pathway is deactivated by an increase in its inhibitors, a reduction in its activators or 
by inactivation of downstream targets (1). In these cases, restoring WT p53 apoptotic 
function has been recognised as a promising strategy for cancer therapy. Hence, a 
detailed understanding of the mechanisms of regulation of p53-mediated apoptosis has 
been an important research objective with significant clinical impact (3).  
 One of the key enzymes involved in the regulation of WT p53 function is the 
protein kinase C (PKC). PKC is a family of serine/threonine kinases with at least 10 
isoforms grouped into three major subfamilies according to their primary structure and 
cofactors required for activation: classical (α, βI, βII and γ), novel (δ, ε, η and θ) and 
atypical (ζ and λ\ι). PKC isoforms are important regulators of several cellular processes, 
such as cell proliferation and death, and a striking feature is that individual isoforms can 
exert either similar or opposite effects in these processes (4). In fact, several studies 
underscore a major role of PKC, particularly of PKCδ, in the regulation of p53 apoptotic 
activity. It was demonstrated that PKCδ leads to p53 accumulation and phosphorylation 
with consequent activation of a p53-mediated apoptosis (5-10).  
 However, due to the high complexity of the mammalian p53 pathway and PKC 
family, namely the coexistence of several PKC isoforms in the same cell, the 
discrimination of the role of PKC isoforms in the regulation of p53 apoptotic mechanisms, 
particularly of its transcription-dependent and -independent activity, is still uncertain. To 
address this issue, yeast cells co-expressing the human WT p53 and an individual 
mammalian PKC isoform of the classical (PKCα), novel (PKCδ and ε) and atypical (PKCζ) 
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PKC subfamilies, and considered the isoforms most commonly involved in 
carcinogenesis, were used. In fact, using this yeast co-expression system, a differential 
modulation of p53-induced yeast growth inhibition and cell cycle arrest by distinct PKC 
isoforms was shown in our previous work (11). Moreover, other authors have confirmed 
the versatility of the yeast cell model to study different aspects of p53 function (12). For 
instance, a recent work showed that p53 could also function as a sequence-specific 
transcription factor in yeast. This study revealed several remarkable similarities between 
the transcription-dependent p53 activity in yeast and mammalian cells (13).  
 With the yeast approach used, it was possible to ascertain the role of PKCα, δ, ε 
and ζ in the regulation of p53-mediated apoptosis. In contrast to PKCα and ζ, PKCδ and ε 
activated transcription-dependent and -independent p53 mechanisms that cooperated to 
ultimately cause an apoptotic cell death. This study therefore identified PKCδ and ε as 
major positive regulators of p53-mediated apoptosis, and consequently as promising 
therapeutic targets for cancer treatment. Another relevant point arising from this study was 
to provide the first evidence for the conservation in yeast of a transcription-dependent and 
-independent p53-mediated apoptosis, with the validation of the yeast cell model to further 
understand the regulation of these p53 apoptotic mechanisms.  
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3.3. MATERIAL AND METHODS 
 
3.3.1. Plasmids 
 The following yeast expression plasmids were used: pLS89-TRP1 encoding 
human WT p53 and the respective empty vector (kindly provided by Dr. Richard Iggo, 
Swiss Institute for Experimental Cancer Research, Switzerland); YEplac181-LEU2 
encoding bovine PKCα, rat PKCδ, mouse PKCε or PKCζ and the respective empty vector 
(kindly provided by Dr. Nigel Goode, The Royal Veterinary College, Hawkshead Lane, 
Hertfordshire, UK). All plasmids have a galactose-inducible GAL1-10 promoter.  
 
3.3.2. Yeast strain, transformation and growth conditions 
 Co-transformants of Saccharomyces cerevisiae strain CG379 were prepared in 
previous work (11). To ensure selection of co-transformed yeast, cells were routinely 
grown in a minimal selective medium with 2% (w/v) glucose, 0.67% (w/v) yeast nitrogen 
base without amino acids, and all the amino acids required for yeast growth (50 µg/ml) 
except leucine and tryptophan, at 30ºC with mechanical shaking (200 r.p.m.) to 
approximately 1 optical density measured at 600 nm (OD600; Jenway 6310 
Spectrophotometer, Jenway). To induce expression of mammalian proteins, yeast 
cultures were diluted to 0.05 OD600 in selective medium with 2% (w/v) galactose and 1% 
(w/v) raffinose, instead of glucose, and incubated at 30ºC with mechanical shaking (200 
r.p.m.) to 0.45 OD600. Expression of human WT p53 and/or a mammalian PKC isoform (α, 
δ, ε or ζ in S. cerevisiae was confirmed by Western blot analysis in previous work (11). 
 
3.3.3. Cell death assays 
 Co-transformed yeast cells, previously grown in galactose selective medium to 
0.45 OD600, were treated with 5 mM H2O2 for 1 hour at 30ºC with mechanical shaking (200 
r.p.m.). Cell death was assessed by counting the number of colony-forming units (CFU) 
after 2 days incubation at 30ºC on Sabouraud Dextrose Agar plates. For each co-
transformant, the percentage of dead cells was estimated considering 100% survival (0% 
death) as the number of CFU obtained with cells incubated in the same conditions but 
without H2O2. 
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3.3.4. Propidium iodide (PI) and terminal deoxynucleotidyl transferase-mediated dUTP 
nick-end labelling (TUNEL) staining 
 PI and TUNEL staining, to monitor plasma membrane integrity and DNA 
fragmentation, respectively, were analysed by fluorescence microscopy, as described 
(14,15). For PI staining, cells were incubated with 5 µg/ml PI (Molecular Probes) for 10 
minutes at room temperature. TUNEL assay was performed using the In Situ Cell Death 
Detection Kit, Fluorescein (Roche Applied Science). 
 
3.3.5. Reactive oxygen species (ROS) accumulation and modification of mitochondrial 
transmembrane potential (∆ψm) 
 Mitochondrial ROS accumulation and modification of ∆ψm were monitored by 
flow cytometry, as described (15). For analysis of ROS accumulation and modification of 
∆ψm, about 106 untreated and 5 mM H2O2-treated cells were incubated with 5 µg/ml 
dihydroethidium (DHE; Sigma-Aldrich) and 1 nM 3,3'-dihexyloxacarbocyanine iodide 
(DiOC6(3); Molecular Probes), respectively, for 30 minutes at 30ºC. For analysis of 
modification of ∆ψm, 2 µg/ml PI was added to exclude necrotic cells; yeast cells treated 
with 0.4 µM carbonyl cyanide 3-chlorophenylhydrazone (CCCP; Sigma-Aldrich) for 15 
minutes at 30ºC, instead of H2O2, were used as positive control of depolarised cells. 
 
3.3.6. Mitochondrial network fragmentation 
 Fragmentation of mitochondrial network was analysed using cells transformed 
with the pCLbGFP-URA3 plasmid encoding green fluorescent protein (GFP) fused to the 
mitochondrial presequence of citrate synthase (mt-GFP) under the control of the GAL1/10 
promoter, as described (15). In this set of experiments, uracil was also omitted from the 
selective medium. Untreated and 5 mM H2O2-treated cells were observed under a 
fluorescence microscopy. 
 
3.3.7. Generation of rho0 mutants from WT co-transformed yeast cells, growth conditions 
and cell death assays 
 For abrogation of mtDNA (rho0), WT co-transformed yeast cells were treated 
basically as described (16). Briefly, cells were grown in minimal selective medium 
containing 10 µg/ml ethidium bromide (Bio-rad) for 3 days. Treatment with ethidium 
bromide was repeated twice. The resulting respiratory deficiency was confirmed by 
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complete lack of growth on obligatory respiratory selective medium, containing 3% (v/v) 
glycerol instead of glucose. Depletion of mtDNA was also confirmed by fluorescence 
microscopy using 4 µg/ml 4`,6-diamidino-2-phenylindole (DAPI; Molecular Probes). To 
induce expression of mammalian proteins, rho0 co-transformed yeast cells were grown in 
the galactose selective medium described in 2.2., supplemented with 0.2% (w/v) glucose, 
as reported (16). Effect of 5 mM H2O2 on cell death of WT and rho0 co-transformed yeast 
cells was assessed by CFU counts as described in 3.3.3. 
 
3.3.8. Ro 32-0432, pifithrin-α and pifithrin-µ assays 
 To analyse the effect of bisindolylmaleimide XI hydrochloride (Ro 32-0432; Alexis 
Biochemicals) and pifithrin-α (PFT-α; Sigma-Aldrich) on cell death, co-transformed yeast 
cells were grown in galactose selective medium with 1 µM Ro 32-0432, 10 µM PFT-α or 
solvent (0.1% DMSO) only at 30ºC with mechanical shaking (200 r.p.m.) to 0.45 OD600 
before treatment with 5 mM H2O2. For pifithrin-µ (PFT-µ, Calbiochem), co-transformed 
yeast cells were grown in galactose selective medium at 30ºC with mechanical shaking to 
0.4 OD600, and then incubated with 75 µM PFT-µ or 0.1% DMSO only for 4 hours before 
treatment with 5 mM H2O2; effect of PFT-µ on ∆ψm was monitored by flow cytometry as 
described in 3.3.5. Effects of Ro 32-0432, PFT-α and PFT-µ on yeast cell death were 
assessed by CFU counts as described in 3.3.3. To analyse the effect of PFT-α on yeast 
cell growth, co-transformed yeast cells were incubated in galactose selective medium with 
10 µM PFT-α or 0.1% DMSO only at 30ºC with mechanical shaking for approximately 45 
hours (time required by control yeast, co-transformed with the empty vectors YEplac181 
and pLS89, to achieve 0.5 OD600); yeast cell growth was assessed by CFU counts 
considering 100% growth (0% growth inhibition) as the number of CFU obtained with 
control yeast.  
 
3.3.9. Immunofluorescence assays 
 Immunofluorecence assays were performed basically as described (15). About 
107 untreated and 5 mM H2O2-treated yeast cells were incubated with 0.4 µg/ml 
MitoTrackerRed CM-H2XROS (Molecular Probes) for 20 minutes at room temperature for 
mitochondrial labelling. After fixation, spheroplasts formation and permeabilization, 
spheroplasts were incubated with the anti-mouse p53 monoclonal antibody DO-1 (1:500; 
Santa Cruz Biotechnology) for 2 hours at room temperature, followed by the anti-mouse 
Alexa Fluor 488 secondary antibody (1:200; Molecular Probes) for 2 hours at room 
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temperature. Mounting medium containing 1.5 µg/ml DAPI (Vector Laboratories) was used 
to visualize nuclear DNA. Samples were observed under a fluorescence microscope. 
 
3.3.10. Preparation of whole cell extracts and mitochondrial fractions 
 Whole cell extracts (WCE) and mitochondrial fraction were prepared basically as 
described (17). Briefly, for spheroplasts formation, untreated and 5 mM H2O2-treated 
yeast cells were incubated in dithiothreitol (DTT) buffer (100 mM Tris–H2SO4, pH 9.4, 10 
mM DTT) for 30 minutes at 30°C with mechanical shak ing (80 r.p.m.), and then in 
zymolyase buffer (1.2 M sorbitol, 1 mM EDTA, 60 mM K2PO4, pH 7.5) containing 2.5 
mg/g of cells (wet weight) of zymolyase-20T (MP Biomedicals Solon) for approximately 45 
minutes at 30°C with mechanical shaking (80 r.p.m.) . For cell homogenization, 
spheroplasts were resuspended in ice-cold homogenization buffer (0.5 M sorbitol, 20 mM 
Tris-base, 1 mM EDTA, 100 mM phenylmethylsulfonyl fluoride). The resulting 
homogenate (WCE) was centrifuged twice (at 1500 g and 3000 g) for 5 minutes at 4°C to 
pellet cell debris and nuclei. Mitochondrial fraction was pellet by centrifugation at 12,000 g 
for 15 minutes at 4°C. Proteins were precipitated w ith 3 M trichloroacetic acid. 
 
3.3.11. Western blot analysis 
 Western blot was performed basically as described (11). Protein content was 
determined using Coomassie Protein Assay Reagent Kit (Pierce). p53 phosphorylation in 
5 mM H2O2-treated yeast cells was analysed as described (11) and using the primary 
rabbit polyclonal antibodies phospho-p53(Ser15) (1:4000; Calbiochem), phospho-
p53(Ser20) (1:500; Calbiochem) and phospho-p53(Ser46) (1:500; Calbiochem) and the 
mouse monoclonal antibody PAb421 (1:100; Calbiochem), followed by incubation with the 
respective horseradish peroxidise (HRP)-conjugated secondary antibodies (1:5000; Santa 
Cruz Biotechnology). The etoposide-treated MCF7 cell lysate (Santa Cruz Biotechnology) 
was used as positive control. For p53 subcellular localization, 10 µg of WCE and 
mitochondrial fraction were analysed using the primary mouse monoclonal antibodies 
against p53 (DO-1) (1:500; Santa Cruz Biotechnology), yeast porin (Por1p) (1:5000; 
Molecular Probes) and yeast phosphoglycerate kinase (Pgk1p) (1:6000; Molecular 
Probes), followed by the anti-mouse HRP-conjugated secondary antibody (1:5000; Santa 
Cruz Biotechnology). Immunoblots were developed by chemiluminescence. Band 
intensities were quantified using Bio-Profil Bio-1D++ software (Vilber-Lourmat).  
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3.3.12. Flow cytometric data acquisition and analysis 
 Flow cytometric analysis was performed using a FACSCalibur flow cytometer (BD 
Biosciences) and the CellQuest software (BD Biosciences).  
 
3.3.13. Fluorescence microscopy 
 For fluorescent microscopic examination, samples were observed under an 
Eclipse E400 fluorescence microscope (Nikon) equipped with a 100 W mercury lamp and 
appropriate filter setting. Yeast cells were observed with an oil immersion lens (Plan Fluor 
100/1.30) and images were captured by a Digital Sight Camera System (Nikon DS-5Mc) 
carrying built-in software for image acquisition (Nikon ACT-2U). 
 
3.3.14. Statistical analysis  
 Data were analysed statistically using the SigmaStat 3.5 software. Differences 
between means were tested for significance using the unpaired Student´s t test (P < 0.05). 
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3.4. RESULTS 
 
3.4.1 Differential regulation of p53 effects by PKCα, δ, ε and ζ in H2O2-treated yeast cells 
 To ascertain the role of individual mammalian PKC isoforms in the regulation of 
human WT p53-mediated apoptosis, co-transformed yeast cells were treated with H2O2. 
The H2O2 is an inducer of yeast apoptosis (18) and of a p53-mediated apoptotic pathway 
in mammalian cells (5,19). Moreover, the involvement of PKCδ in the activation of a p53-
mediated apoptosis was previously demonstrated in H2O2-treated mammalian cells (5,7). 
To estimate the percentage of dead cells, for each co-transformant the number of CFU 
obtained with yeast cells incubated for 1 hour without H2O2 was considered as 100% 
survival (0% death). With this procedure, the previously reported growth inhibition induced 
by expression of human WT p53 in yeast (11) was not taken into account.  
 In accordance with the previously reported high-level resistance of co-
transformed yeast cells to cell death (11,14), a pronounced resistance to H2O2-induced 
yeast apoptosis was also observed with the experimental conditions and co-transformed 
yeast cells used in this study. Indeed, upon 1 hour treatment with 5 mM H2O2, control 
yeast (co-transformed with the empty vectors, YEplac181 and pLS89) exhibited no more 
than 37% of dead cells (Fig. 3.1A) and a non-significant percentage of TUNEL-positive 
(DNA fragmentation; Fig. 3.1B) and PI-positive (loss of plasma membrane integrity; Fig. 
3.1C) cells.  
 We firstly analysed the effect of single expression of human WT p53 and a 
mammalian PKCα, δ, ε or ζ on 5 mM H2O2-induced yeast cell death. Surprisingly, with the 
exception of PKCε, expression of these proteins did not significantly increase the 
percentage of dead cells, TUNEL- and PI-positive cells, when compared to control yeast 
(Fig. 3.1A-C).  
 However, when PKCα, δ, ε and ζ were individually co-expressed with p53, a 
differential regulation of p53 effects was obtained in H2O2-treated yeast cells. In fact, when 
compared to yeast cells expressing only p53, contrarily to PKCα and ζ, co-expression of 
PKCδ\ε with p53 significantly increased the p53 effects. Indeed, co-expression of PKCδ/ε 
with p53 significantly increased the percentage of dead cells and cells with DNA 
fragmentation obtained with the single expression of p53, without interfering with the 
plasma membrane integrity (Fig. 3.1A-C). Although expression of PKCε significantly 
increased per se H2O2-induced cell death, when co-expressed with p53 a 1.3-fold 
increase in the percentage of dead cells was obtained. The stimulation of p53-mediated 
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cell death by PKCδ and ε was further supported using the selective PKC inhibitor Ro 32-
0432. Indeed, though 1 µM Ro 32-0432 did not interfere with the percentage of H2O2-
induced dead cells obtained with control yeast and yeast expressing only p53 or PKC 
isoform, it reduced the increase in the percentage of H2O2-induced dead cells obtained 
when PKCδ/ε were co-expressed with p53 (Fig. 3.1D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1. PKCδ and ε increase p53 effects on cell death and DNA fragmentation without interfering with the 
plasma membrane integrity of 5 mM H2O2-treated yeast cells. Control yeast (YEplac/pLS89) and yeast 
expressing p53 and/or a PKC isoform (α, δ, ε or ζ) were incubated in galactose selective medium to 0.45 
OD600 before treatment with 5 mM H2O2 for 1 hour at 30ºC. Cell death, DNA fragmentation and plasma 
membrane integrity were analysed by CFU counts (for each co-transformant 100% survival, 0% death, was 
considered the number of CFU obtained with H2O2-untreated cells), TUNEL and PI staining, respectively. 
Percentage of (A) dead cells, (B) cells with DNA fragmentation and (C) cells with loss of plasma membrane 
integrity obtained with control yeast and yeast expressing p53 and/or a PKC isoform after treatment with 5 mM 
H2O2. Data represent means ± s.e.m. of 4 independent experiments; values significantly different from control 
yeast (*P < 0.05) and yeast expressing only p53 (#P < 0.05). (D) Effect of the selective PKC inhibitor Ro 32-
0432 on the percentage of dead cells obtained with 5 mM H2O2-treated control yeast and yeast expressing 
p53 and/or PKCδ/ε. Before treatment with 5 mM H2O2, yeast cells were incubated in galactose selective 
medium with 1 µM Ro 32-0432 or DMSO only to 0.45 OD600. Data represent means ± s.e.m. of 4 - 5 
independent experiments; values significantly different from DMSO only, *P < 0.05. 
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Additionally, co-expression of PKCδ/ε with p53 significantly increased the percentage of 
cells with mitochondrial ROS accumulation (Fig. 3.2A,B) and ∆ψm loss (Fig. 3.3A,B) 
obtained with H2O2-treated yeast cells expressing only p53. Curiously, as previously 
reported, even in the absence of a stress stimulus, a marked mitochondrial ROS 
accumulation was observed in yeast cells co-expressing p53 and PKCε (11). Moreover, 
though the single expression of p53 or PKC isoform did not increase the percentage of 
H2O2-induced mitochondrial network fragmentation obtained with the control yeast (56.2 ± 
8.3%, n=4), this percentage was significantly increased when PKCδ/ε were co-expressed 
with p53 (Fig. 3.3C). In ROS accumulation, ∆ψm modification and mitochondrial network 
fragmentation experiments, to estimate the increase of p53 effects by a PKC isoform, the 
effect obtained with yeast expressing only p53 was subtracted to that obtained with yeast 
co-expressing p53 and PKC isoform. The requirement of respiring mitochondria for the 
PKCδ and ε stimulatory effect was confirmed using co-transformed yeast cells devoid of 
mtDNA (rho0). Surprisingly, although respiratory deficient yeast cells have been reported 
as more sensitive to H2O2 (20), this was not detected with our rho0 co-transformed yeast 
cells (Fig. 3.3D, control yeast) In spite of this, and even though similar expression levels of 
p53 and PKCδ/ε were detected in WT and rho0 co-transformed yeast cells (data not 
shown), PKCδ and ε failed to stimulate p53-mediated cell death in H2O2-treated rho0 cells 
(Fig. 3.3D).  
 Together, these results indicated that PKCδ and ε, contrarily to PKCα and ζ were 
activators of a p53-mediated mitochondria-dependent apoptosis.  
 
3.4.2. Phosphorylation of p53 at Ser376-378 was detected in H2O2-treated yeast cells co-
expressing p53 and PKCδ/ε 
 As previously performed for untreated yeast cells (11), phosphorylation of p53 by 
PKCδ and ε at commonly reported PKC phosphorylation sites, namely Ser15 (5,9), Ser20 
(5), Ser46 (7,10) and Ser376-378 (6,8), was also checked in H2O2-treated yeast cells by 
Western blot analysis.  
 In 5 mM H2O2-treated yeast cells, phosphorylation of p53 at Ser15, Ser20 and 
Ser46 was not detected neither in yeast cells expressing only p53 nor in yeast cells co-
expressing p53 and PKCδ/ε (Fig. 3.4A-C). However, phosphorylation of p53 at Ser376-
378 was detected in yeast cells co-expressing p53 and PKCδ/ε. In fact, using the PAb421 
antibody, which preferentially recognises unphosphorylated p53 residues at Ser376-378 
(6), a high intensity PAb421 band was obtained with yeast cells expressing only p53.  
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Fig. 3.2. PKCδ and ε increase the p53 effect on mitochondrial ROS accumulation. Control yeast 
(YEplac/pLS89) and yeast expressing p53 and/or a PKC isoform (α, δ, ε or ζ) were incubated in galactose 
selective medium to 0.45 OD600 before treatment with 5 mM H2O2 for 1 hour at 30ºC. ROS accumulation was 
analysed by flow cytometry using DHE. (A) Overlays of red fluorescence histograms were obtained with 
untreated (0 mM) and 5 mM H2O2-treated cells; histograms represent 1 of 2 independent experiments. M2 
cursor indicates the sub-populations analysed; ∆ values correspond to the increase in the percentage of DHE 
positive cells obtained when cells were treated with 5 mM H2O2, and represent means ± s.e.m. of 2 
independent experiments. (B) Increase in the percentage of DHE positive cells obtained when PKCα, δ, ε or ζ 
were co-expressed with p53; values correspond to differences between the effect obtained with yeast co-
expressing p53 and PKC isoform and that obtained with yeast expressing only p53. Data represent means ± 
s.e.m. of 2 independent experiments; value of yeast co-expressing p53 and PKC isoform significantly higher 
than that obtained with yeast expressing only p53, *P < 0.05.  
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Fig. 3.3. PKCδ and ε increase the p53 effect on ∆ψm loss and mitochondrial network fragmentation, and fail to 
stimulate p53-mediated cell death in rho0 co-transformed yeast cells. Control yeast (YEplac/pLS89) and yeast 
expressing p53 and/or a PKC isoform (α, δ, ε or ζ) were incubated in galactose selective medium to 0.45 
OD600 before treatment with 5 mM H2O2 for 1 hour at 30ºC. (A, B) ∆ψm was monitored by flow cytometry using 
DiOC6(3). (A) Overlays of green fluorescence histograms were obtained with untreated (0 mM) and 5 mM 
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H2O2-treated cells (or CCCP for positive control; C+); histograms represent 1 of 2 - 4 independent 
experiments. M2 cursor indicates the sub-populations analysed; ∆ values correspond to the increase in the 
percentage of cells with ∆ψm loss obtained when cells were treated with 5 mM H2O2 (CCCP for C+), and 
represent means ± s.e.m. of 2 - 4 independent experiments. Increase in the percentage of cells with (B) ∆ψm 
loss and (C) mitochondrial network fragmentation obtained when PKCα, δ, ε or ζ were co-expressed with p53; 
values correspond to differences between the effect obtained with yeast co-expressing p53 and PKC isoform 
and that obtained with yeast expressing only p53. In C, normal tubular mitochondria observed in untreated 
cells (0 mM) and fragmentation of the mitochondrial network observed in 5 mM H2O2-treated cells (5 mM) 
were evaluated using cells expressing mt-GFP, p53 and PKC isoform. Data represent means ± s.e.m. of 2 - 4 
independent experiments; value of yeast co-expressing p53 and PKC isoform significantly higher than that 
obtained with yeast expressing only p53, *P < 0.05. (D) Effect of mtDNA deletion on the stimulation of p53-
mediated cell death by PKCδ and ε. The percentage of dead cells obtained with 5 mM H2O2-treated yeast cells 
with (WT) and without (Rho0) mtDNA was assessed by CFU counts, considering 100% survival (0% death) as 
the number of CFU obtained with H2O2-untreated cells. Data represent means ± s.e.m. of 4 independent 
experiments; values of yeast co-expressing p53 and PKCδ/ε significantly higher than that obtained with yeast 
expressing only p53, *P < 0.05.  
 
This indicated a low level of p53 phosphorylation at Ser376-378 by endogenous yeast 
kinases. On the other hand, a pronounced decrease in the intensity of PAb421 band, 
indicative of a high level of p53 phosphorylation at Ser376-378, was obtained with yeast 
cells co-expressing p53 and PKCδ/ε (Fig. 3.4D,E).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4. PKCδ and ε phosphorylate p53 at Ser376-378 in H2O2-treated yeast cells. Yeast cells expressing 
only p53 and co-expressing p53 and PKCδ/ε were incubated in galactose selective medium to 0.45 OD600 
before treatment with 5 mM H2O2 for 1 hour at 30ºC. p53 phosphorylation was analysed using (A) phospho-
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p53(Ser15), (B) phospho-p53(Ser20), (C) phospho-p53(Ser46) and (D) PAb421 (Ser376-378) antibodies. 
Detection of p53 with DO-1 antibody was used as loading control. In A - C, the etoposite-treated MCF7 cell 
lysate was used as positive control (C+); in D, p53 from yeast expressing only p53 (YEplac/p53), which 
expression was previously confirmed with the anti-p53 DO-1 antibody, was used as positive control. (E) 
Quantification of band intensities obtained in D. 
 
 In fact, similar results were obtained with untreated yeast cells co-expressing p53 
and PKCδ/ε (11). This indicated that stimulation of p53-mediated apoptosis, likewise 
stimulation of p53-induced growth inhibition (11), by PKCδ and ε was accompanied by p53 
phosphorylation at Ser376-378.  
 
3.4.3. Stimulation of p53 translocation to mitochondria by PKCδ and ε in H2O2-treated 
yeast cells 
 As previously reported (21), immunofluorescence studies performed with 
untreated yeast cells expressing only p53 confirmed that human WT p53 was 
predominantly localized in the nucleus of yeast cells (Fig. 3.5A,B). Additionally, we verified 
that p53 nuclear localization was not significantly modified in yeast by co-expression with 
PKCα, δ, ε or ζ (Fig. 3.5B).  
 Under stress conditions, an increase in the percentage of cells exhibiting p53 
nuclear staining with partial mitochondrial co-localization was observed in all co-
transformed yeast cells tested (Fig. 3.5A,C). However, a significant increase in the 
percentage of these cells was only achieved with yeast cells co-expressing p53 and 
PKCδ/ε. Indeed, when compared to yeast expressing only p53, about a 3-fold increase in 
the percentage of cells exhibiting nuclear and mitochondrial p53 co-localization was 
obtained with yeast co-expressing p53 and PKCδ/ε (Fig. 3.5C). Additionally, Western blot 
analysis of mitochondrial fractions of untreated and H2O2-treated yeast cells expressing 
only p53 and co-expressing p53 and PKCδ/ε revealed a marked increase in the level of 
mitochondrial p53 in H2O2-treated yeast cells co-expressing p53 and PKCδ/ε. In fact, 
when compared to yeast expressing only p53, a 13- and 9-fold increase in the amount of 
mitochondrial p53 were obtained in the presence of PKCδ and ε, respectively (Fig. 3.5D-
F). Together, these results showed that, under stress conditions, PKCδ and ε stimulated 
mitochondrial p53 translocation. A correlation between stimulation of p53-mediated 
apoptosis and enhancement of mitochondrial p53 localization by PKCδ and ε was 
therefore established.  
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Fig. 3.5. PKCδ and ε activate mitochondrial p53 translocation in H2O2-treated yeast cells. Control yeast 
(YEplac/pLS89) and yeast expressing p53 and/or a PKC isoform (α, δ, ε or ζ) were incubated in galactose 
selective medium to 0.45 OD600 before treatment with 5 mM H2O2 for 1 hour at 30ºC. (A - C) Subcellular 
localization of p53 in yeast assessed by immunofluorescence microscopy using the anti-p53 DO-1 antibody 
followed by Alexa Fluor 488 secondary antibody; nuclear and mitochondrial DNA were visualized using DAPI; 
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mitochondrial labelling was also performed using MitoTrackerRed. (A) Nuclear p53 localization observed in 
H2O2-untreated cells (0 mM); nuclear and mitochondrial p53 localization observed in 5 mM H2O2-treated yeast 
cells co-expressing p53 and PKCδ (as representative of the two nPKCs) (5 mM). (B, C) Quantification of p53 
subcellular localization in (B) untreated and (C) 5 mM H2O2-treated yeast cells; data represent means ± s.e.m. 
of 4 independent experiments; values significantly different from that obtained with yeast expressing only p53, 
*P < 0.05; values obtained in C significantly different from those obtained with the same co-transformed yeast 
in B, #P < 0.05. (D - F) Mitochondrial localization of p53 in yeast assessed by Western blot analysis of whole 
cell extract (WCE) and mitochondrial fraction (M) of untreated (0 mM) and 5 mM H2O2-treated yeast cells 
expressing only p53 and co-expressing p53 and PKCδ/ε. Pgk1p and por1p were used as loading controls for 
WCE and mitochondrial fraction, respectively. Quantification of p53 levels in (E) whole cell extract and (F) 
mitochondrial fraction. Data represent 1 of 2 independent experiments. 
 
3.4.4. Stimulation of transcription-dependent and -independent p53 activities by PKCδ and 
ε in yeast 
 Our previous work showed that expression of human WT p53 in yeast induced a 
marked growth inhibition (11). Yeast cell growth was assessed by CFU counts, but 
considering 100% growth (0% growth inhibition) the number of CFU obtained with control 
yeast. In the present study, we verified that the treatment of yeast cells expressing only 
p53 with 10 µM PFT-α, a selective inhibitor of p53 transcriptional activity (22,23), 
practically abolished the p53-induced yeast growth inhibition (Fig. 3.6A). These results 
corroborated the preservation in yeast of a p53 transcriptional activity previously reported 
by others (13). Additionally, they established a correlation between p53 transcriptional 
activity and p53 growth-inhibitory effect in yeast.  
 The effect of 10 µM PFT-α on p53-mediated cell death was also analysed. 
Unexpectedly, a significant reduction in the percentage of dead cells was achieved when 
5 mM H2O2-treated yeast cells expressing only p53 were pretreated with 10 µM PFT-α 
(Fig. 3.6B). In fact, the single expression of p53 in yeast only slightly increased 5 mM 
H2O2-induced cell death. This seemed therefore to indicate the activation of a 
transcription-dependent p53 apoptotic activity, which was not strong enough to 
significantly stimulate H2O2-induced cell death in yeast expressing only p53. However, a 
pronounced reduction in the percentage of dead (Fig. 3.6B) and TUNEL-positive (Fig. 
3.6C) cells was achieved when yeast cells co-expressing p53 and PKCδ/ε were pretreated 
with 10 µM PFT-α. Together, these results identified PKCδ and ε as activators of a 
transcription-dependent p53 apoptotic activity.  
 Accumulating evidence for a transcription-independent p53 apoptosis in 
mammalian cells, characterized by translocation of a fraction of p53 to mitochondria in 
response to stress stimuli (1-3), together with the observation of mitochondrial p53 
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translocation in H2O2-treated yeast cells co-expressing p53 and PKCδ/ε, led us to also 
investigate the existence in yeast of a transcription-independent p53 apoptotic 
mechanism. With this goal, before treatment with H2O2, yeast cells were treated with 75 
µM PFT-µ, an inhibitor of the transcription-independent p53 apoptosis that selectively 
inhibits p53 translocation to mitochondria without interfering with its transcriptional activity 
(2,3,24). Although PFT-µ did not interfere with the percentage of dead cells of yeast 
expressing only p53 or PKCδ/ε, it significantly reduced the percentage of dead cells (Fig. 
3.6D), TUNEL-positive cells (Fig. 3.6E) and cells exhibiting ∆ψm loss (Fig. 3.6F) of yeast 
co-expressing p53 and PKCδ/ε. Together, these results showed, for the first time, the 
preservation in yeast of a transcription-independent p53 apoptotic mechanism, which was 
activated by PKCδ and ε. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6. PKCδ and ε activate transcription-dependent and -independent p53 mechanisms in yeast. (A) Effect 
of PFT-α, a selective inhibitor of p53 transcriptional activity, on the growth of yeast cells expressing only p53 
Yeast cells were incubated in galactose selective medium with 10 µM PFT-α or DMSO only at 30ºC for 
approximately 45 hours (time required by control yeast to achieve 0.5 OD600). Effect of PFT-α on yeast cell 
D
ea
d 
ce
lls
 
(%
)
0
20
40
60
80
100
YEplac
pLS89
YEplac
 p53
PKCδ
pLS89
PKCε
pLS89
PKCδ
p53
PKCε
p53
*
*
 
0
10
20
30
YEplac
pLS89
TU
N
EL
 
+
 
ce
lls
 
(%
)
YEplac
p53
PKCδ
pLS89
PKCε
pLS89
PKCδ
p53
PKCε
p53
*
*
 
D 
DMSO PFT-µ 
F E 
0
10
20
30
*
*
PKCδ
p53
PKCε
p53  
 
Ce
lls
 
w
ith
 
∆∆ ∆∆ ΨΨ ΨΨ
m
 
lo
ss
 
(%
) 
 
0
20
40
60
80
100
YEplac
p53
*G
ro
w
th
 
in
hi
bi
tio
n
 
(%
)
 
D
ea
d 
ce
lls
 (%
)
0
20
40
60
80
100
YEplac
pLS89
*
YEplac
 p53
PKCδ
pLS89
PKCε
pLS89
PKCδ
p53
PKCε
p53
*
*
 
0
10
20
30
YEplac
pLS89
TU
NE
L 
+
 
ce
lls
 
(%
)
YEplac
p53
PKCδ
pLS89
PKCε
pLS89
PKCδ
p53
PKCε
p53
**
 
DMSO PFT-α 
B A C 
CHAPTER 3 
 
69 
 
growth was assessed by CFU counts, considering 100% growth (0% growth inhibition) as the number of CFU 
obtained with control yeast. Effect of PFT-α on (B) cell death and (C) DNA fragmentation of 5 mM H2O2-
treated yeast cells. Co-transformed cells were incubated in galactose selective medium with 10 µM PFT-α or 
DMSO only to 0.45 OD600 before treatment with 5 mM H2O2 for 1 hour at 30ºC. Effect of PFT-α on yeast cell 
death was assessed by CFU counts, considering for each co-transformant 100% survival (0% death) as the 
number of CFU obtained with H2O2-untreated cells. Effects of PFT-µ, a selective inhibitor of p53 translocation 
to mitochondria, on (D) cell death, (E) DNA fragmentation, and (F) ∆ψm loss of 5 mM H2O2-treated yeast cells. 
Co-transformed cells were incubated in galactose selective medium to 0.4 OD600, and then pretreated with 75 
µM PFT-µ or DMSO only for 4 hours before treatment with 5 mM H2O2 for 1 hour at 30ºC. Effect of PFT-µ on 
cell death was assessed by CFU counts as in B. Effect of PFT-µ on ∆ψm was monitored by flow cytometry 
using DiOC6(3); values correspond to the increase in the percentage of cells with ∆ψm loss obtained upon 
treatment with 5 mM H2O2. In A - F, data represent means ± s.e.m. of 4 - 5 independent experiments; values 
significantly different from DMSO only, *P < 0.05.  
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3.5. DISCUSSION 
 
 Contrarily to what was reported in mammalian cells (5,19), in the present work we 
observed that human WT p53 is unable to stimulate per se H2O2-induced yeast cell death. 
The absence in yeast of orthologues of mammalian positive regulators of p53 activity 
might explain this result. Since PKC family isoforms, particularly PKCδ, have been 
described as regulators of p53-mediated apoptosis (5-10), we addressed the question 
whether PKC isoforms could regulate the p53 apoptotic activity in yeast. Additionally, 
though several works have already reported the p53 phosphorylation and the activation of 
a p53-mediated apoptosis by PKCδ, the involvement of this PKC isoform in crucial 
aspects of the p53 apoptotic activity, namely in its transcription-dependent and -
independent mechanisms, is still unknown. Besides, the discrimination of the role of other 
PKC isoforms commonly involved in carcinogenesis in the regulation of p53-mediated 
apoptosis is also unclear. To address these issues, yeast cells co-expressing the human 
WT p53 and an individual mammalian PKCα, δ, ε or ζ were used.  
 The present study reveals a distinct regulation of p53-mediated apoptosis by 
PKCα, δ, ε and ζ and identifies PKCδ and ε as positive regulators of p53 activity. Whereas 
the classical PKCα and the atypical PKCζ had no effect on p53 activity, the novel PKCδ 
and ε stimulated a p53-mediated mitochondria-dependent apoptosis in H2O2-treated yeast 
cells. In fact, PKCδ and ε increased the p53 effects on cell death, DNA fragmentation, 
mitochondrial ROS accumulation, ∆ψm loss and mitochondrial network fragmentation, 
without interfering with the plasma membrane integrity. The strict requirement of respiring 
mitochondria in the stimulation of p53-mediated apoptosis by PKCδ and ε was confirmed 
using rho0 co-transformed yeast cells, where PKCδ and ε failed to stimulate p53-mediated 
cell death. The enhancement of p53-mediated apoptosis by PKCδ and ε was further 
supported using the selective PKC inhibitor, Ro 32-0432, which markedly reduced the 
stimulatory effect of these two kinases. The absence of effect of Ro 32-0432 on the 
isolated PKCε-mediated cell death may be probably due to the mechanism of action of 
this PKC inhibitor. Ro 32-0432 interacts with the PKC catalytic region (specifically with the 
ATP binding site), inhibiting the protein kinase activity, and therefore the PKC capability to 
phosphorylate its substrates (25,26). Based on this, the effect of this inhibitor on yeast 
cells co-expressing PKCε and p53 supports the regulation of p53 activity by PKCε through 
a mechanism that involves the PKCε kinase activity. The absence of effect of Ro 32-0432 
on the isolated PKCε-mediated cell death may suggest that, in this case, a kinase-
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independent mechanism is involved in the PKCε activity. In fact, nontraditional PKC 
activation mechanisms, such as kinase-independent actions of freed regulatory domains, 
are frequently reported for PKCε (27). For example, PKCε, via its regulatory domain and 
independently of its catalytic domain, induces neurite-like processes in neuroblastoma 
cells (28). 
 In the present work, phosphorylation of p53 by PKCδ and ε at commonly reported 
PKC phosphorylation sites, namely Ser15, Ser20, Ser46 and Ser376-378, was also 
analysed. The results obtained showed that under stress conditions p53 is not 
phosphorylated by PKCδ and ε at Ser15, Ser20 and Ser46. Although it was shown that 
stimulation of p53-mediated apoptosis by PKCδ and ε was accompanied by p53 
phosphorylation at Ser376-378, similar results were also obtained with stimulation of p53-
induced growth inhibition by PKCδ and ε in unstressed yeast cells (11). Therefore, it is still 
unclear whether phosphorylation of p53 by PKCδ and ε in yeast is a relevant factor for the 
stimulation of p53-mediated apoptosis by PKCδ and ε. Further work must be carried out in 
order to clarify this issue.  
 This work confirms the already reported nuclear localization of human WT p53 
expressed in yeast (21). Though the conservation in yeast of a transcription-dependent 
p53 function was already demonstrated (13), as well as the p53-induced yeast growth 
inhibition (29), the regulation of yeast cell growth by p53 through a transcription-
dependent mechanism was pointed out in the present work. Additionally, it reveals that 
the transcription-dependent p53 apoptotic mechanism in yeast is activated by PKCδ and 
ε. 
 Moreover, we demonstrate that the stimulation of p53-mediated apoptosis by 
PKCδ and ε entailed translocation of a fraction of p53 to mitochondria and was reduced by 
PFT-µ, a selective inhibitor of mitochondrial p53 translocation (2,3,24). Hence, another 
interesting outcome of the present work is to provide the first evidence for the 
conservation in yeast of a functional transcription-independent p53-mediated apoptosis, 
which is activated under cell death conditions and in the presence of PKCδ or ε. These 
data therefore support the possibility raised by others that mitochondrial localization of 
p53 is a subtle deciding factor that dictates whether cells die or arrest growth (2,3). 
Additionally, they provide new insights about an unclear issue concerning the regulation of 
p53 translocation to mitochondria.  
 As a whole, this study underscores a major role of PKCδ and ε as key positive 
regulators of transcription-dependent and -independent p53 activities that cooperate to 
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ultimately cause an apoptotic cell death. In fact, supporting our data, previous works 
reported that the treatment of mouse skin epidermal JB6 cells and skin tissues with 
phorbol 12-myristate 13-acetate, a potent selective activator of classical and novel PKC 
isoforms, increased not only the p53 transcriptional activity, but also the translocation of a 
fraction of p53 to mitochondria (30,31).  
 However, why only nPKCδ and ε can affect p53-mediated apoptosis? It is well 
known that individual PKC isoforms can exert either similar or opposite effects in distinct 
cellular processes, such as cell proliferation and death (4). One of the major regulatory 
mechanisms implicated in these PKC isoform-specific activities is the phosphorylation of 
distinct target substrates. For example, it was reported that PKCα is a potent kinase for 
histones, myelin basic protein and protamine, whereas PKCδ and ε do not exhibit this 
activity (32). Crucial for substrate recognition is the relief of the inhibitory pseudosubstrate 
region within the regulatory domain. However, other mechanisms must exist to direct 
these PKC isoforms to distinct signalling pathways. These include isoforms-specific 
subcellular compartmentalization patterns, protein-protein interactions, and 
posttranslational modifications that influence catalytic function (27,32). The present work 
gives an additional information regarding the specific actions (and cellular substrate) of 
individual PKC isoforms in the apoptotic cell death. The identification of p53 as a cellular 
target for some PKC isoforms may represent a challenge and opportunity for future 
research in the p53 field. 
 It has been proposed that direct participation of p53 in the intrinsic mitochondria-
mediated apoptotic pathway involves the interaction with the multidomain members of the 
Bcl-2 family, and particularly the activation of one of its pro-apoptotic members Bax or 
Bak, to induce MOMP. However, considering the large number of proteins that control 
MOMP, it has also been suggested that the regulation of p53 transcription-independent 
apoptosis might involve many more factors than the original concept of a direct interaction 
with Bcl-2 proteins implies (3). Since there are no orthologues of the Bcl-2 family 
members in yeast (12), the present work corroborates this hypothesis. Further studies are 
underway to ascertain whether p53 interacts with the already identified yeast orthologues 
involved in MOMP (33). 
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3.6. CONCLUSION 
 
 The present work represents the first attempt to reconstitute in yeast a 
mammalian p53-PKC isoform apoptotic network. Additionally, it provides the first evidence 
for the conservation in yeast of a transcription-dependent and -independent p53-mediated 
apoptosis and further validates the yeast cell model to elucidate the mechanisms 
underlying the regulation of p53-mediated apoptosis. Moreover, it gives a mechanistic 
insight on apoptosis regulation by PKCδ and ε through regulation of p53 transcriptional 
activity and p53 translocation to mitochondria. Since compelling evidence indicates that 
the transcription-independent pathway driven by p53 contributes significantly to the effect 
and outcome of cancer therapy, this work underscores that PKCδ and ε are promising 
therapeutic targets in cancer and that selective activators of these isoforms are potential 
anti-cancer agents. 
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SELECTIVE ACTIVATION OF PROTEIN KINASE C-δ AND -ε BY 
6,11,12,14-TETRAHYDROXYABIETA-5,8,11,13-TETRAENE-7-ONE 
(COLEON U) 
 
 
4.1. ABSTRACT 
 6,11,12,14-tetrahydroxy-abieta-5,8,11,13-tetraene-7-one (coleon U) is a 
diterpene compound isolated from Plectranthus grandidentatus with an antiproliferative 
effect on several human cancer cell lines. Herein, we studied the modulatory activity of 
coleon U on individual isoforms of the three protein kinase C (PKC) subfamilies, 
conventional (cPKC-α and -βΙ), novel (nPKC-δ and -ε) and atypical (aPKC-ζ), using a 
yeast PKC expression system. The results obtained showed that, whereas the PKC 
activator phorbol 12-myristate 13-acetate (PMA) activated every PKC tested except 
aPKC, coleon U not only had no effect on aPKC but also on cPKCs. Besides, the coleon 
U effect on nPKCs was higher than that exhibited by PMA. These data revealed that 
coleon U was a potent and selective activator of nPKCs. The isoform-selectivity of coleon 
U for nPKC-δ and -ε was further confirmed using an in vitro PKC assay. Most importantly, 
in opposition to PMA, which activated nPKCs inducing an isoform translocation from the 
cytosol to the plasma membrane and a G2/M cell cycle arrest, coleon U induced nPKCs 
translocation to the nucleus and a metacaspase- and mitochondrial-dependent apoptosis. 
This work therefore reconstitutes in yeast distinct subcellular translocations of a specific 
PKC isoform and the subsequent distinct cellular responses reported for mammalian cells. 
Together, our study identifies a new isoform-selective PKC activator with promising 
pharmacological applications. Indeed, since coleon U has no effect on cPKCs and aPKC, 
recognised as anti-apoptotic proteins, and selectively induces an apoptotic pathway 
dependent on nPKC-δ and -ε activation, it represents a promising compound for 
evaluation as an anti-cancer drug. 
Keywords: Coleon U; Selective PKC activator; PKC-δ; PKC-ε; Apoptosis; Yeast 
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4.2. INTRODUCTION 
 
 6,11,12,14-tetrahydroxy-abieta-5,8,11,13-tetraene-7-one (coleon U) is an 
abietane diterpene compound isolated from P. grandidentatus, shown to inhibit the growth 
of several human cancer cell lines such as MCF-7 (breast), NCI-H460 (lung), SF-268 
(CNS), TK-10 (renal) and UACC-62 (melanoma) in a dose-dependent manner (1). 
However, the mechanisms of action responsible for this coleon U-induced growth 
inhibition have not been elucidated. In a later study, a dose-dependent antiproliferative 
effect of coleon U on T- and B-lymphocyte cells was also reported (2). Although this study 
established a relationship between the antiproliferative effect of coleon U and its capacity 
to induce apoptosis in lymphocyte cells, the molecular mechanisms associated with its 
antiproliferative effect remained unclear. However, the interference of this small-molecule 
with some cell signalling transduction kinases, such as protein kinase C (PKC) and/or 
protein tyrosine kinases, was hypothesized as a possible mechanism responsible for 
coleon U-induced growth inhibition (2). Since several diterpene compounds, such as 
phorbol esters, represent potent PKC activators (3,4), we questioned whether coleon U 
could indeed modulate PKC activity. 
 PKC is considered an important family of signalling serine/threonine kinases with 
at least 10 isoforms grouped into three subfamilies based on their primary structure and 
cofactors required for activation: the classical PKCs (cPKCs: α, βΙ, βΙI and γ), activated by 
the second messengers Ca2+ and diacylglycerol (DAG), the novel PKCs (nPKCs: δ, ε, η 
and θ) which respond only to DAG and the atypical PKCs (aPKCs: ζ and λ\ι) not 
responsive to either of the second messengers (4). The PKC family is responsible for 
regulating a variety of physiological processes such as differentiation, proliferation, cell 
cycle and apoptosis, in an isoform specific manner. Hence, PKC isoforms represent key 
pharmacological targets for the treatment of numerous pathologies. For instance, some 
PKC isoforms have been recognised as important players in carcinogenesis, rendering 
them potentially suitable targets for anti-cancer therapy (3,5-7). While PKC-α, -β and -ζ 
are frequently associated with proliferative effects being involved in the tumorigenesis of 
various cancers, PKC-δ is often linked to anti-proliferative/pro-apoptotic effects in 
mammals (3,5-7). Consequently, selective activators of PKC-α, -β and -ζ are considered 
tumour promoters, while selective activators of PKC-δ represent promising anti-cancer 
drugs (3,5-7). Although PKC-δ and -ε display a high degree of homology and similar 
substrate specificity, suggesting similar targets in signal transduction pathways for both 
nPKCs, they are frequently described as mediating quite contrasting physiological effects 
CHAPTER 4 
 
81 
 
(3,5,6). However, although several studies suggest that PKC-ε favors life over death (3,5-
7), recent research works also showed that PKC-ε activation can contribute to apoptosis. 
For example, it was demonstrated that ethanol induces apoptosis in hepatocytes via 
activation of the nPKC isoforms, PKC-δ and -ε (8).  
 In order to achieve the regulation of a particular PKC isoform, without affecting 
the activity of other isoforms also present in the cell, PKC isoform-selective activators are 
required. However, the complexity of the PKC family and the difficulty in carrying out 
independent analysis of an individual PKC isoform in mammalian cells may justify the low 
number of PKC isoform-selective modulators identified until now (3,7,9).  
 Based on these data, we exploited a yeast PKC expression system to study the 
modulatory activity of coleon U on individual PKC isoforms of the three PKC subfamilies, 
cPKCs (α and βΙ), nPKCs (δ and ε) and aPKCs (ζ), considered as major isoforms in 
carcinogenesis. The conservation of many pathways and cellular processes in yeast, such 
as apoptosis (10), has allowed transposing the knowledge obtained in yeast to 
mammalian cells and vice-versa. Additionally, yeast expressing human proteins has been 
used as a valuable tool to elucidate the role of these proteins in complex cellular 
processes, and to screen for their pharmacological modulators (11,12). Furthermore, 
since the yeast PKC (Pkc1p in Saccharomyces cerevisiae) is a structural but not a 
functional homologue of mammalian PKC isoforms (13), yeast has been considered a 
well-suited organism to study individual mammalian PKC isoforms. In fact, it was 
demonstrated that mammalian PKCs expressed in yeast have functional characteristics 
similar to those found in mammalian cells (14,15). It was also shown that the yeast PKC 
expression system was a potential in vivo assay for the screening of PKC modulators 
(14,16). Based on these data, this yeast PKC assay has been used by our group not only 
to study the role of PKC isoforms on apoptosis regulation (17), but also to search for 
isoform-selective PKC activators (18,19) and inhibitors (20,21). This simpler eukaryotic 
cell model, established and validated in such studies, allows the effect of small-molecules 
on each PKC isoform to be analysed without the genetic complexity of the PKC family, 
specifically the coexistence of multiple PKC isoforms in the same mammalian cells and 
the extensive cross-talk amongst numerous mammalian signalling pathways.  
 In the present study, we found that coleon U is a potent and selective activator of 
nPKC-δ and -ε. Besides, several experiments were carried out in order to elucidate the 
molecular mechanisms of action behind the observed coleon U-induced growth inhibition 
in yeast expressing the nPKC-δ or -ε. Another relevant point arising from this work was 
the validation of the yeast assay to reconstitute the distinct subcellular translocations of a 
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specific mammalian PKC isoform and the subsequent different cellular responses 
described in higher eukaryotes. 
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4.3. MATERIAL AND METHODS 
 
4.3.1. Plant material, isolation and identification of coleon U 
 Details concerning the extraction, isolation and structure elucidation of the 
abietane diterpene coleon U from P. grandidentatus Gürke (Fig. 4.1) have previously been 
described (1,22). 
 
4.3.2. Plasmids 
 Constructed yeast expression plasmids YEplac181-LEU2 with the cDNA encoding 
for bovine PKC-α, rat PKC-βΙ, or PKC-δ, mouse PKC-ε or PKC-ζ, under control of a 
galactose-inducible GAL1 promote, were kindly provided by Dr. Nigel Goode (The Royal 
Veterinary College, Hawkshead Lane, Hertfordshire, UK). Constructed yeast expression 
plasmid pOW4-URA3 with the cDNA encoding for human Bcl-xL, under control of an 
ADH1 promoter, was kindly provided by Dr. Charles Rudin (Cancer Research Building, 
Baltimore, USA). Constructed yeast expression plasmid pCLbGFP-TRP3 with the cDNA 
encoding for mitochondria-localized green fluorescent protein (mt-GFP), under control of a 
GAL1-10 promoter, was kindly provided by Dr. Stéphen Manon (Université de Bordeaux, 
Bordeaux, France). All the plasmids used were amplified in Escherichia coli DH5α and 
confirmed by restriction analysis. 
 
4.3.3. Yeast strain, growth conditions and yeast expression of a mammalian protein 
 For yeast expression studies Saccharomyces cerevisiae strain CG379 (α ade5 
his7-2 leu2-112 trp1-289α ura3-52 [Kil-O]); Yeast Genetic Stock Center, University of 
California, Berkeley, USA) was transformed as reported (17). To ensure selection of 
transformed yeast, cells were routinely grown in a minimal selective medium. To induce 
yeast expression of a mammalian protein, cells were diluted to 0.05 measured at 600 nm 
(OD600; Jenway 6310 Spectrophotometer, Jenway, Felsted, Dunmow, Essex, UK) in a 2% 
(w/v) galactose and raffinose (Sigma-Aldrich, Sintra, Portugal) selective medium and 
grown, at 30 ºC under continuous shaking, to 0.5 OD600 (mid-log phase; about 42 h 
incubation), as described (17). Yeast expression of a mammalian PKC isoform and/or 
human Bcl-xL was previously confirmed by Western blot analysis (17,19). 
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4.3.4. Effect of compounds on yeast cell growth 
 All compounds tested were prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich, 
Sintra, Portugal). To analyse the effect of compounds on yeast growth, transformed cells 
were incubated in galactose selective medium with 0.1 – 10 µM coleon U, 1 µM phorbol 
12-myristate 13-acetate (PMA; Sigma-Aldrich, Sintra, Portugal) or 0.1% DMSO only to 0.5 
OD600. Cell growth was determined by colony forming unit (c.f.u.) counts, as described 
(17). The percentage of growth inhibition was estimated considering 100% growth as the 
number of c.f.u. obtained with yeasts incubated with DMSO only. 
 
4.3.5. In vitro PKC assay 
 The in vitro PKC assay was performed using the non-radioactive kit MESACUP 
Protein Kinase Assay System and purified PKC enzymes from Upstate (Grupotaper, 
Sintra, Portugal): cPKCs (mixture of classical PKC isoforms, α, β and γ, obtained from rat 
brain; 5 ng per assay); nPKC-δ (50 ng/assay); nPKC-ε (12.5 ng/assay); aPKC-ζ (12.5 
ng/assay), basically according to the kit procedure. Briefly, this ELISA-based detection 
method uses a peptide pseudosubstrate, pre-coated on a 96-well plate that can be 
phosphorylated by PKC. Samples containing the active PKC enzyme were transferred to 
the pseudosubstrate-coated wells. A biotinylated monoclonal antibody that recognises the 
phosphorylated form of the pseudosubstrate was added to the wells and detected using 
HRP-conjugated streptavidin. Colour intensity of reaction mixtures containing the 
endogenous PKC activator phosphatidylserine (PS), with or without 0.3 µM coleon U, was 
determined photometrically at 490 nm using a microplate spectrofluorometer 
(PowerWave™ S Microplate Spectrophotometer, Bio-TEK instruments, Inc., Highland 
Park, Winooski VT, USA). PKC activity is directly proportional to color intensity. OD490 
obtained with the reaction mixture containing PS only (control) was considered as 100% 
PKC activation.  
 
4.3.6. Cell cycle analysis 
 Flow cytometric analysis of DNA content was obtained using Sytox Green Nucleic 
Acid from Molecular Probes (Alfagene, Carcavelos, Portugal), basically as reported (23). 
Briefly, about 107 cells incubated in galactose selective medium with 1 µM PMA, 1 µM 
coleon U or DMSO only were fixed in 70% (v/v) ethanol overnight at 4 ºC, treated with 250 
µg/ml RNase A (DNase-free; Sigma-Aldrich, Sintra, Portugal) for 3 h at 50 ºC and 
thereafter with 1 mg/ml Proteinase K (Sigma-Aldrich, Sintra, Portugal) for 3 h at 37 ºC. 
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Subsequently, cells were incubated with 10 µM Sytox Green overnight at 4 ºC. 
Fluorescence from at least 30,000 cells was analysed using the FL1 detector in linear 
amplification from a flow cytometer. Yeast cell cycle phases were quantified using ModFit 
LTTM software (Verity Software House, Inc., Topsham, USA).  
 
4.3.7. Analysis of plasma membrane integrity, DNA fragmentation and chromatin 
condensation 
 Propidium iodide (PI) and TUNEL staining to monitor plasma membrane integrity 
and DNA fragmentation respectively were carried out as described (17). Briefly, about 107 
cells incubated in galactose selective medium with 1 µM coleon U or DMSO only were 
collected and incubated with 5 µg/ml PI (Sigma-Aldrich, Sintra, Portugal) for 10 min at 
room temperature. TUNEL was performed using the In Situ Cell Death Detection Kit, 
Fluorescein (Roche Diagnostics, Amadora, Portugal). For chromatin condensation 
analysis, cells were incubated with 4 µg/ml DAPI (4,6-diamido-2-phenyl-indole; Sigma-
Aldrich, Sintra, Portugal) for 15 min at room temperature, as described (24). At least 600 
cells per sample were analysed under a fluorescence microscope. 
 
4.3.8. Assessment of yeast metacaspase activity 
 Yeast metacaspase (Yca1p) activation was analysed basically as described (17). 
Flow cytometric analysis: about 106 cells incubated in galactose selective medium with 1 
µM coleon U or DMSO only were collected and incubated with 12.5 µM of FITC-VAD-fmk 
from Promega (VWR International Material de Laboratório, Lda., Lisboa, Portugal) for 1 h 
at 30 ºC; fluorescence from at least 10,000 cells was analysed using the FL1-H detector 
from a flow cytometer. Cell death assay: cells were incubated in galactose selective 
medium with 1 µM coleon U and 20 µM of the caspase inhibitor z-VAD-fmk from Promega 
(VWR International Material de Laboratório, Lda., Lisboa, Portugal). Cell death was 
assessed by c.f.u. counts, considering 100% survival as the number of c.f.u. obtained with 
cells incubated with DMSO only. 
 
4.3.9. Assessment of reactive oxygen species (ROS) production 
 ROS production was monitored by flow cytometry using dihydroethidium (DHE) 
from Molecular Probes (Alfagene, Carcavelos, Portugal) as described (25). About 106 
cells, incubated in galactose selective medium with 1 µM coleon U or DMSO only, were 
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collected and incubated with 5 µg/ml DHE for 30 min at 30 ºC. Fluorescence from at least 
10,000 cells was analysed using the FL2-H detector from a flow cytometer.  
 
4.3.10. Assessment of mitochondrial membrane potential (∆ψm) 
 Modification of ∆ψm in transformed yeast was monitored by flow cytometry using 
3,3'-dihexyloxacarbocyanine iodide (DiOC6(3)) from Molecular Probes (Alfagene, 
Carcavelos, Portugal). About 106 cells, incubated in galactose selective medium with 1 µM 
coleon U or DMSO only were incubated with 1 nM DiOC6(3) for 30 min at 30 ºC. 
Thereafter, 2 µg/ml PI was added to exclude necrotic cells. Carbonyl cyanide 3-
chlorophenylhydrazone (CCCP; Sigma-Aldrich, Sintra, Portugal) was used as positive 
control; after treatment with DiOC6(3), cells incubated with DMSO only were treated with 
0.4 nM CCCP for 15 min at 30 ºC. Fluorescence from at least 10,000 cells was analysed 
using the FL1-H and FL2-H detectors from a flow cytometer.  
 
4.3.11. Assessment of mitochondrial fragmentation 
 Analysis of mitochondrial fragmentation of transformed yeast was carried out using 
the plasmid pCLbGFP encoding for mt-GFP, as described (26). Cells incubated in 
galactose selective medium with 1 µM coleon U or DMSO only were observed under a 
fluorescence microscope.  
 
4.3.12. Immunofluorescence assay 
 About 107 cells grown in galactose selective medium with 1 µM PMA, 1 µM coleon 
U or DMSO only were fixed with 3.7% formaldehyde (Sigma-Aldrich, Sintra, Portugal) for 
30 min at 30 ºC. For spheroplasts formation, cells were treated with zymolyase solution, 
containing 0.1M potassium phosphate pH 7.5, 2 µl/ml 2-mercaptoethanol (Sigma–Aldrich, 
Sintra, Portugal), 1 mg/ml zymolyase 20 T (MP Biomedicals Solon, Fountain Parkway 
Solon, USA), at 37 ºC for 25 min. Spheroplasts were transferred to polylysine-coated 
glass slides (Sigma-Aldrich, Sintra, Portugal) and permeabilised with 1% Triton X-100 
(Sigma-Aldrich, Sintra, Portugal) for 2 min at 4 ºC before incubation with the mouse 
monoclonal antibody anti-PKC-δ or anti-PKC-ε (1:50) from Santa Cruz Biotechnology 
(Frilabo, Porto, Portugal) for 2 h at room temperature. This was then followed by 
incubation with the anti-mouse Alexa Fluor 488 secondary antibody (1:200) from 
Molecular Probes (Alfagene, Carcavelos, Portugal) for 2 h at room temperature. Mounting 
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medium containing 1.5 µg/ml DAPI was used to visualize nuclear DNA. Samples were 
observed under a fluorescence microscope. 
 
4.3.13. Flow cytometric data acquisition and analysis 
 Flow cytometric analysis was performed using a FACSCaliburTM flow cytometer 
and the CellQuest software (BD Biosciences, San José, CA, USA).  
 
4.3.14. Fluorescence microscopy 
 For fluorescent microscopic examination, samples were observed under an 
Eclipse E400 fluorescence microscope (Nikon, Japan) equipped with a 100 W mercury 
lamp and appropriate filter setting. Yeast cells were observed with an oil immersion lens 
(Plan Fluor 100/1.30) and images were captured by a Digital Sight camera system (Nikon 
DS-5Mc, Japan) carrying built-in software for image acquisition (Nikon ACT-2U, Japan). 
 
4.3.15. Statistical analysis 
 Data were analysed statistically using the SigmaStat 3.1 programme (SYSTAT® 
Software, Inc., Mountain River, CA, USA). Differences between means were tested for 
significance using the unpaired Student´s t-test. P values of 0.05 or lower were 
considered statistically significant. Results are expressed as the mean ± s.e.m. of the 
indicated number of experiments. 
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4.4. RESULTS 
 
4.4.1. Coleon U is a potent and selective activator of nPKC-δ and -ε 
 In order to analyse a possible modulation of PKC isoforms by coleon U (Fig. 4.1), 
we used a yeast PKC expression system that consists of the use of yeast cells expressing 
an individual mammalian PKC-α, -βΙ, -δ, -ε or -ζ. In this assay, it was demonstrated that 
PKC activators inhibit the growth of yeast expressing a PKC isoform without interfering 
with the growth of yeast transformed with the empty vector (control yeast) (14,18,19). 
 
 
 
 
 
 
 
Fig. 4.1. Chemical structures of coleon U, an abietane diterpene isolated from P. grandidentatus, and phorbol 
12-myristate 13-acetate (PMA). 
 
 Hence, we began by analysing the effect of several concentrations of coleon U, 
0.1 – 10 µM, on the growth of yeast expressing PKC-α, -βΙ, -δ, -ε or -ζ and control yeast 
(Fig. 4.2A). Yeast cell growth was analysed by c.f.u. counts and the effects obtained with 
coleon U were compared to those obtained with the standard PKC activator, PMA (Fig. 
4.1; an activator of cPKCs and nPKCs). We detected that 0.1 and 1 µM coleon U 
significantly inhibited the growth of yeast expressing PKC-δ or -ε without affecting the 
growth of control yeast and yeast expressing PKC-α, -βΙ or -ζ (Fig. 4.2A). This selectivity 
of coleon U to inhibit the growth of yeast expressing PKC-δ or -ε was particularly evident 
for 1 µM (Fig. 4.2B). In fact, for this concentration, and in opposition to PMA that activated 
every PKC tested except aPKC-ζ, coleon U had no effect on cPKCs as well as on aPKC-ζ 
(Fig. 4.2B,C). In addition, the effect of coleon U on yeast expressing the nPKCs, PKC-δ or 
-ε, was shown to be higher than that obtained with PMA (Fig. 4.2B,C). These results 
therefore indicated that coleon U was a potent and selective activator of the two nPKCs, 
PKC-δ and -ε. 
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Fig. 4.2. Effect of PMA and coleon U on the growth of control yeast and yeast expressing PKC-α, -βΙ, -δ, -ε or 
-ζ. Transformed yeast cells were diluted to 0.05 OD600 in galactose selective medium and grown with coleon 
U, PMA or DMSO only to 0.5 OD600 (about 42 h incubation). The percentage of growth inhibition was 
estimated by c.f.u. counts, considering 100% growth as the number of c.f.u. obtained with yeast incubated 
with DMSO only. (A) Concentration–response curves for the coleon U effect on the growth of transformed 
yeast. Effect of (B) 1 µM coleon U and (C) 1 µM PMA on the growth of transformed yeast. Data are the mean 
± s.e.m. of 4 - 8 independent experiments with 6 replicates each. Values significantly different from those 
obtained with (A) DMSO and (B, C) control yeast, *P <= 0.001. 
 
 Direct activation of PKC-δ and -ε by coleon U and the selectivity of this small-
molecule for these nPKCs was further confirmed using an in vitro protein kinase assay 
system and purified PKC enzymes: cPKCs (mixture of classical PKC isoforms, α, β and γ), 
nPKC-δ, nPKC-ε and aPKC-ζ. In the in vitro PKC assay, PKC activators increase the 
phosphatidylserine (PS; an endogenous PKC activator) effect. In fact, in this assay, it was 
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observed that 0.3 µM coleon U significantly increased the PS effect on nPKC-δ and -ε. In 
opposition, 0.3 µM coleon U did not interfere with the PS effect on cPKCs and aPKC-ζ 
(Fig. 4.3).  
 
 
 
 
 
 
 
Fig. 4.3. In vitro PKC assay. Direct activation of nPKC-δ and -ε by coleon U and its selectivity for these nPKCs 
was confirmed in vitro using a protein kinase assay system and purified PKC enzymes: cPKCs (mixture of 
classical PKC isoforms, α, β and γ); nPKC-δ; nPKC-ε and aPKC-ζ. Coleon U was tested at the final 
concentration of 0.3 µM. Colour intensity of reaction mixtures containing the endogenous PKC activator 
phosphatidylserine (PS) with and without coleon U was determined photometrically at 490 nm using a 
microplate spectrofluorometer. Data represent the increase in the percentage of PKC activation obtained 
when coleon U was added to PS, considering 100% PKC activation the OD490 obtained with the reaction 
mixture containing PS only (control), and correspond to the mean ± s.e.m. of 2 independent experiments. 
Values significantly higher than those obtained with the control, *P < 0.05.  
 
4.4.2. Coleon U-induced growth inhibition in yeast expressing nPKC-δ or -ε is associated 
with the occurrence of a metacaspase- and mitochondrial-dependent apoptotic cell death 
 It was showed that the expression of bovine PKC-α in S. cerevisiae causes 
growth inhibition associated with the occurrence of a G2/M arrest, which is markedly 
increased by treatment of these cells with PMA (15). However, as previously reported by 
us (17), under our experimental conditions and with the yeast strain used, single 
expression of a mammalian PKC-α, -δ, -ε or -ζ in yeast did not significantly interfere with 
cell growth and survival. Even so, in agreement with that reported for PKC-α (15), 
treatment of yeast expressing nPKC-δ or -ε with PMA caused significant growth inhibition 
related to a G2/M cell cycle arrest (Fig. 4.4A, B). This blockage in cell cycle progression 
by PMA was not accompanied by the occurrence of cell death, as revealed by the 
preservation of plasma membrane integrity, the absence of DNA fragmentation and 
chromatin condensation in PMA-treated yeast cells (data not shown).  
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Fig. 4.4. Effect of PMA and coleon U on the cell cycle progression of control yeast and yeast expressing 
nPKC-δ or -ε. Transformed yeast cells were diluted to 0.05 OD600 in galactose selective medium and grown 
with 1 µM coleon U, 1 µM PMA or DMSO only to 0.5 OD600 (about 42 h incubation). Analysis of DNA content 
was carried out by flow cytometry using Sytox Green. (A) Histograms represent 1 of 3 independent 
experiments. (B) Quantification of yeast cell cycle phases; data are the mean of 3 independent experiments. 
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 With a view to elucidating the molecular mechanisms behind coleon U-induced 
growth inhibition in yeast cells expressing nPKC-δ or -ε, we began by analysing the effect 
of this small-molecule on the cell cycle progression of these transformed yeast. In contrast 
to PMA, coleon U only slightly interfered with the cell cycle progression of yeast 
expressing nPKC-δ or -ε (Fig. 4.4A,B). This small effect of coleon U on cell cycle could not 
explain per se the marked growth inhibition induced by this small-molecule on yeast 
expressing nPKC-δ or -ε. 
 Hence, we next addressed whether coleon U-induced growth inhibition could 
reflect cell death. With this goal, several apoptotic markers were investigated. We verified 
that 1 µM coleon U caused in yeast expressing nPKC-δ or -ε, but not in control yeast and 
yeast expressing PKC-α, -βΙ or -ζ, a marked increase in the percentage of cells with 
chromatin condensation and DNA fragmentation (TUNEL-positive cells), without loss of 
plasma membrane integrity as revealed by the low percentage of PI-positive cells 
(absence of necrosis) (Fig. 4.5A-C). These results indicated that coleon U-induced growth 
inhibition in yeast expressing PKC-δ or -ε was linked to the activation of an apoptotic cell 
death.  
 Additionally, flow cytometric analysis of FITC-VAD-fmk stained cells revealed the 
occurrence of yeast metacaspase (Yca1p) activation in coleon U-treated yeast cells 
expressing PKC-δ or -ε, but not in control yeast and yeast expressing PKC-α, -βΙ or -ζ 
(Fig. 4.6A,B). This was further confirmed by the marked decrease in the percentage of 
dead cells expressing nPKC-δ or -ε obtained when coleon U treatment was carried out in 
the presence of the caspase inhibitor z-VAD-fmk (Fig. 4.6C).  
 We further observed that 1 µM coleon U markedly increased mitochondrial ROS 
production (Fig. 4.7A,B), decreased ∆ψm (Fig. 4.8A,B) and increased mitochondrial 
fragmentation (Fig. 4.8C) in yeast expressing nPKC-δ or -ε, but not in control yeast and 
yeast expressing PKC-α, -βΙ or -ζ.  
 It was showed that human Bcl-xL is also a mitochondrial anti-apoptotic protein in 
yeast, inhibiting yeast apoptosis induced by stress stimuli such as hydrogen peroxide, 
menadione (27) and acetic acid (17). Moreover, a previous work performed by our group 
showed that co-expression of human Bcl-xL with a mammalian PKC isoform did not 
significantly interfere with yeast cell growth and survival (17). Based on these data, the 
interference of human Bcl-xL with coleon U-induced cell death in yeast expressing PKC-α, 
-βΙ, -δ, -ε or -ζ and control yeast was analysed. The results obtained showed that Bcl-xL 
completely abolished the coleon U-induced apoptosis in yeast expressing nPKC-δ or -ε, 
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without interfering with the coleon U effect in control yeast and yeast expressing PKC-α, -
βΙ, -δ, -ε or -ζ (Fig. 4.8D).  
 Together, the results obtained corroborate the activation by coleon U of a 
metacaspase- and mitochondrial-dependent apoptotic pathway dependent on nPKC-δ or -
ε expression in yeast.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.5. Effect of coleon U on chromatin condensation, DNA fragmentation and plasma membrane integrity of 
control yeast and yeast expressing PKC-α, -βΙ, -δ, -ε or -ζ. Transformed yeast cells were diluted to 0.05 OD600 
in galactose selective medium and grown with 1 µM coleon U to 0.5 OD600 (about 42 h incubation). (A) 
Chromatin condensation was analysed with DAPI. (B) Cells with DNA fragmentation are indicated as TUNEL 
+ cells. (C) Necrotic cells are indicated as PI + cells. Data are the mean ± s.e.m. of 3 – 4 independent 
experiments; means correspond to counts of at least 600 cells per sample analysed by fluorescence 
microscopy. Values significantly different from those obtained with the control yeast, *P<0.05. 
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Fig. 4.6. Effect of coleon U on metacaspase activation of control yeast and yeast expressing PKC-α, -βΙ, -δ, -ε 
or -ζ. Transformed yeast cells were diluted to 0.05 OD600 in galactose selective medium and grown with 1 µM 
coleon U or DMSO only to 0.5 OD600 (about 42 h incubation). (A, B) Yeast metacaspase activation was 
monitored by flow cytometry using FITC-VAD-fmk. (A) Overlays of green fluorescence histograms were 
obtained with cells incubated with coleon U and DMSO only. M2 values correspond to the increase in the 
percentage of FITC-VAD-fmk positive cells obtained when cells were incubated with coleon U. Data represent 
1 of 2 independent experiments. (B) Data are the mean ± s.e.m. of M2 values obtained from 2 independent 
experiments. Values significantly different from those obtained with the control yeast, *P<0.05. (C) Effect of 
the caspase inhibitor z-VAD-fmk on the survival of coleon U-treated yeast cells expressing nPKC-δ or -ε. Cells 
were incubated in galactose selective medium with 1 µM coleon U, 1 µM coleon U and 20 µM of z-VAD-fmk or 
DMSO only to 0.5 OD600. The percentage of dead cells was estimated by c.f.u. counts, considering 100% 
survival the number of c.f.u. obtained with cells incubated with DMSO only. Data are the mean ± s.e.m. of 4 
independent experiments with 6 replicates each. Values significantly different from those obtained with yeast 
incubated with coleon U only, *P < 0.05. 
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Fig. 4.7. Effect of coleon U on mitochondrial ROS production of control yeast and yeast expressing PKC-α, -
βΙ, -δ, -ε or -ζ. Transformed yeast cells were diluted to 0.05 OD600 in galactose selective medium and grown 
with 1 µM coleon U or DMSO only to 0.5 OD600 (about 42 h incubation). ROS production was analysed by flow 
cytometry using DHE. (A) Overlays of red fluorescence histograms obtained with yeast incubated with coleon 
U or DMSO only. M2 values correspond to the increase in the percentage of DHE positive cells obtained when 
cells were incubated with coleon U. Data represent 1 of 2 independent experiments. (B) Data are the mean ± 
s.e.m. of M2 values obtained from 2 independent experiments. Values significantly different from those 
obtained with the control yeast, *P<0.05. 
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Fig. 4.8. Effect of coleon U on ∆ψm and mitochondrial fragmentation of control yeast and yeast expressing 
PKC-α, -βΙ, -δ, -ε or -ζ and interference of human Bcl-xL with the coleon U-induced yeast cell death. 
Transformed yeast cells were diluted to 0.05 OD600 in galactose selective medium and grown with 1 µM 
coleon U or DMSO only to 0.5 OD600 (about 42 h incubation). (A, B) ∆ψm was monitored by flow cytometry 
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using DiOC6(3). (A) Overlays of green fluorescence histograms obtained with yeast incubated with coleon U 
and DMSO only. C+, positive control, control yeast treated with CCCP. M2 values correspond to the increase 
in the percentage of cells with ∆ψm loss obtained when cells were incubated with coleon U. Data represent 1 
of 2 independent experiments. (B) Data are the mean ± s.e.m. of M2 values obtained from 2 independent 
experiments. Values significantly different from those obtained with the control yeast, *P<0.05. (C) 
Mitochondrial fragmentation was analysed using yeasts expressing mt-GFP. Values correspond to the 
percentage of cells incubated with coleon U or DMSO only presenting mitochondrial fragmentation. Data are 
the mean ± s.e.m. of 3 independent experiments; means correspond to counts of at least 100 cells per sample 
analysed by fluorescence microscopy. Values significantly different from those obtained with the control yeast, 
*P<0.05. C1: Normal tubular mitochondria; C2: Mitochondrial fragmentation observed with coleon U-treated 
yeast expressing nPKC-δ or -ε. (D) The interference of Bcl-xL with the coleon U effect was analysed by c.f.u. 
counts, considering 100% survival as the number of c.f.u. obtained with DMSO. Data are the mean ± s.e.m. of 
4 independent experiments with 6 replicates each.  
 
4.4.3. Coleon U-induced apoptosis is associated with the translocation of nPKC-δ and -ε 
from the cytosol to the nucleus of yeast cells 
 In mammalian cells, it was reported that distinct subcellular translocations of a 
specific PKC isoform lead to different cellular responses (28). Since PMA and coleon U 
induced in yeast expressing nPKC-δ or -ε different cellular responses, we questioned 
whether these two PKC activators could also induce distinct subcellular translocations of 
these nPKCs in yeast cells. With this goal, immunofluorescence studies were carried out 
with yeast cells expressing nPKC-δ or -ε treated with 1 µM PMA, 1 µM coleon U or DMSO 
only. Since the results obtained with PKC-ε were not significantly different from those 
obtained with PKC-δ, the PKC-δ results were used as representative of the subcellular 
distribution obtained with the two nPKCs (Fig. 4.9A,B). The results showed that in the 
absence of activators, nPKCs were predominantly located at the cytosol of yeast cells 
(Fig. 4.9A,B; DMSO). In agreement with that reported for mammalian cells (28), PMA 
caused a marked translocation of nPKCs to the yeast plasma membrane (Fig. 4.9A,B; 
PMA). On the other hand, coleon U caused a pronounced translocation of nPKCs to the 
nucleus of yeast cells (Fig. 4.9A,B; coleon U).  
 Together, the results obtained showed that PMA and coleon U induced 
translocation of nPKCs to distinct yeast subcellular compartments. 
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Fig. 4.9. Effect of PMA and coleon U on yeast subcellular localization of PKC-δ. Analysis of PKC-δ localization 
in yeast was carried out by immunofluorescence microscopy. (A) Cytoplasmic localization of PKC-δ observed 
when yeasts were incubated with DMSO only; localization of PKC-δ at the plasma membrane observed when 
yeasts were incubated with 1 µM PMA; nuclear localization of PKC-δ observed when yeasts were incubated 
with 1 µM coleon U. (B) Quantification of subcellular distribution of PKC-δ in yeast cells incubated with PMA, 
coleon U or DMSO only; values correspond to the mean of 3 independent experiments. 
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4.5. DISCUSSION 
 
 Previous studies from our group exploited the yeast PKC expression system not 
only in searching for isoform-selective PKC modulators (18-21), but also in studying the 
role of several PKC isoforms in apoptosis regulation (17). In the present work, this yeast 
PKC assay was used to study the modulatory activity of coleon U on several PKC 
isoforms of the three PKC subfamilies, cPKCs (α and βΙ), nPKCs (δ and ε) and aPKC (ζ), 
considered as the most relevant isoforms in carcinogenesis. With this cell system, it was 
possible to analyse the effect of coleon U on each PKC isoform expressed in the same 
cellular background and without the genetic complexity of mammalian pathways and 
interference from other PKC family isoforms.  
 In agreement with that reported for human cells (1,2), we observed that 0.1 - 1 µM 
coleon U also induced yeast growth inhibition but only in cells expressing the nPKC-δ or -
ε. This isoform-selectivity was further observed for 0.3 µM coleon U using an in vitro PKC 
assay. Together, these results led us to discover that coleon U is a selective activator of 
nPKC-δ and -ε. This work also studied the molecular mechanisms of action underlying 
coleon U-induced growth inhibition in yeast expressing nPKC-δ or -ε. We demonstrated 
that this coleon U antiproliferative effect was not linked to the induction of cell cycle arrest, 
but instead to the activation of an apoptotic cell death. This is in agreement with a 
previous study performed in lymphocyte cells, where detection of PS externalisation by 
annexin V allowed the antiproliferative effect of coleon U to be associated with apoptosis 
induction (2). Herein, we have further shown that this coleon U-induced apoptosis 
involved the activation of a metacaspase- and mitochondrial-dependent pathway in yeast 
expressing nPKC-δ or -ε, as revealed by the increase in mitochondrial dysfunctions such 
as fragmentation, depolarization and ROS accumulation and by the complete abolishment 
of coleon U cytotoxic effect by the mitochondrial anti-apoptotic protein Bcl-xL.  
 Another relevant point from this work is the corroboration that a specific PKC 
isoform can induce, in the same cellular background, different cellular responses 
depending on the stimulus applied. In fact, comparing the effects of PMA and coleon U, 
we detected that these two PKC activators induced different effects in yeast due to the 
activation of the same PKC isoform. While PMA caused a G2/M cell cycle arrest, coleon U 
induced an apoptotic cell death in yeast expressing nPKC-δ or -ε. This can be explained 
by the ability of different stimuli to selectively translocate a PKC isoform to distinct 
subcellular compartments. In fact, it is believed that translocation of a specific PKC 
isoform to a cellular compartment is the major determinant of its specificity and function 
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(28). Indeed, similarly to results from mammalian cells (28,29), we found that in the 
absence of activators both nPKC-δ and -ε were localized in the cytosol of yeast cells. 
Additionally, as reported for PKC-δ (28,29) and PKC-ε (29) in mammalian cells, treatment 
of yeast cells with PMA induced translocation of these isoforms to the plasma membrane. 
On the other hand, coleon U treatment stimulated translocation of nPKC-δ and -ε to the 
nucleus of yeast cells. In accordance with the results obtained in yeast, recent studies 
performed with mammalian cells revealed that several pro-apoptotic kinases, specifically 
PKC-δ, undergo cytoplasmic-nuclear shuttling in response to DNA damage (30-32). These 
studies demonstrated that upon exposure to a genotoxic stress, such as etoposide, PKC-δ 
accumulates in the nucleus. Whereas retention of PKC-δ in the cytoplasm is compatible 
with cell survival, its nuclear retention is required for commitment to apoptosis, showing 
that cellular localization of PKC-δ regulates the survival/death pathway (30-32). Indeed, 
nuclear targeting of kinases such as PKC-δ is considered a new and essential regulatory 
mechanism that directly influences the induction of apoptosis (32). Thus, while modulation 
of nPKC-δ and -ε nuclear translocation by coleon U remains an open issue that deserves 
further studies, we corroborated previous data from mammalian cells showing that the 
correct cellular localization is critical to the function of these two kinases.  
 Though several evidences supporting the involvement of mitochondria in coleon U-
induced apoptosis are presented herein, we could not demonstrate mitochondrial 
accumulation of nPKC-δ or -ε after coleon U treatment. Interestingly, other authors 
demonstrated the involvement of mitochondria in PKC-δ-induced apoptosis in a rat 
vascular smooth muscle cell line based on the decrease of apoptosis by Bcl-2 and loss of 
∆ψm without detection of PKC-δ mitochondrial localization (33). Another work also 
showed that although induction of apoptosis via activation of PKC-δ and -ε increased 
cytochrome c release and accumulation of ROS, no PKC-δ and -ε were detected in 
mitochondria (8). Supporting these data, we showed that also in yeast, under apoptotic 
conditions, PKC-δ and -ε seem to activate a mitochondrial pathway without directly 
interfering with this organelle. As stressed by Yoshida (32), the molecular devices that 
allow various stimuli, such as coleon U, to be transmitted from the nucleus into the 
mitochondrion and which represents a point of integration for the different apoptotic 
signalling cascades are still unclear. Further studies are underway in yeast to clarify this 
issue.  
 In conclusion, this work identifies a new isoform-selective small-molecule with 
potential pharmacological applications. Indeed, as a potent and selective activator of the 
nPKC-δ and -ε, coleon U represents a promising tool to further understand the nPKC-δ 
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and -ε cellular signalling pathways in mammalian cells. Furthermore, the absence of an 
effect on cPKC-α and -β and aPKC-ζ, reported as anti-apoptotic proteins, and its 
selectivity to induce an apoptotic pathway dependent on nPKC-δ and -ε activation, 
indicate that coleon U is a promising compound for evaluation as an anti-cancer drug. 
This work also shows, for the first time, that the yeast PKC expression system allows 
reconstituting distinct subcellular translocations of a specific PKC isoform and the 
subsequent different cellular responses previously reported for mammalian systems. 
Considering these similarities and the advantages provided by the genetic tractability of 
yeast, a broader outcome of this study is the validation of this cell model to unravel the 
intra-organelle communication systems and their roles in the PKC isoform apoptotic 
signalling network, as well as to study the molecular mechanisms of action of compounds 
with potential therapeutic applications. 
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ASPARTIC VINYL SULFONES: INHIBITORS OF A CASPASE-3-
DEPENDENT PATHWAY 
 
 
5.1. ABSTRACT 
 In this article we describe an expanded structure-activity relationship study for 
vinyl sulfones as caspase-3 inhibitors, a topic virtually unexplored in the existing literature. 
Most remarkably, and to our surprise, tripeptidyl vinyl sulfones were not active for 
caspase-3, opposite to other examples described in literature for peptidyl vinyl sulfones as 
potent cysteine protease inhibitors of clan CA. Moreover, the caspase-3 inhibitory activity 
of vinyl sulfones using an in vitro assay was then confirmed using a yeast cell-based 
assay. The results show that Fmoc-protected vinyl sulfones containing only the Asp 
moiety are inhibitors of a caspase-3-dependent pathway and the IC50 values obtained in 
the yeast assay are in the same order of magnitude of that obtained with the caspase-3 
inhibitor tetrapeptidyl chloromethyl ketone, Ac-DEVD-CMK. This observation is consistent 
with appropriate cell permeability properties displayed by the vinyl sulfone inhibitors, as 
reflected by log P values ranging from 1.1 to 3.4. Overall, these results suggest that vinyl 
sulfones containing Asp at P1 should be considered for further optimization as caspase 
inhibitors and modulators of caspase-3-dependent pathways. 
Keywords: Vinyl sulfone; Caspase-3 inhibitor; Michael acceptor; Irreversible inhibitor; 
Yeast cell-based assay. 
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SO2R1NH
O
PGHN
SO2R1PGHN
CO2H
1a PG=Cbz, R1=Me
1b PG=Cbz, R1=Ph
1c PG=Fmoc, R1=Me
1d PG=Fmoc, R1=Ph
N
H
O
PGHN SO2Me
CO2H
CO2H
R2
R2
2b PG=Cbz, R2=Me, R1=Ph
2d PG=Cbz, R2=CHMe2, R1=Ph
2e PG=Cbz, R2=CHMeEt, R1=Me
2f PG=Cbz, R2=CHMeEt, R1=Ph
2g PG=Fmoc, R2=CHMe2, R1=Me
2h PG=Fmoc, R2=CHMe2, R1=Ph
2a PG=Cbz, R2=Me, R1=Me
2c PG=Cbz, R2=CHMe2, R1=Me
5.2. INTRODUCTION 
 
 Caspases are a family of cysteine endoproteases involved in cytokine maturation 
and apoptosis. They represent one of the most specific protease families yet described, 
since they have an almost absolute requirement for an aspartic acid residue in the P1 
position of their substrate (1-3). To date, only a few caspase inhibitors have entered 
preclinical studies with animal models of human diseases and their major disadvantage is 
the lack of selectivity. As a consequence, the search for effective caspase inhibitors as 
possible therapeutic agents against different diseases caused by excessive apoptosis, 
such as neurodegenerative disorders, is an important area of research (4-6). 
 One type of irreversible cysteine proteases inhibitors that has received special 
attention in the last few years are the ones based on Michael acceptor scaffolds. This 
class of inhibitors includes vinyl sulfones, which have been developed as highly potent 
inhibitors of many clan CA cysteine proteases (7). Recently, we described the first 
structure-activity relationship study of peptidyl vinyl sulfones as caspase-3 inhibitors, 
enzymes that belong to clan CD (8). Vinyl sulfones containing Asp at P1 1a-d and 2a-h 
(Fig. 5.1) were shown to be only moderate inhibitors of caspase-3, with IC50 values in the 
µM range. Dipeptidyl vinyl sulfones displayed improved activity over their counterparts 
containing Asp as the single amino acid residue, with this effect being particularly 
noticeably for the Fmoc-protected compounds. The most active compound, Fmoc-VD-
VSMe 2g, presented an IC50 value of 29 µM and was selective for caspase-3 over 
caspase-7 (8).  
 
 
 
 
 
 
 
 
Fig. 5.1. Vinyl sulfone caspase-3 inhibitors. 
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 In this study, in order to expand the structure-activity relationships (SARs) and to 
improve the inhibitory potency of vinyl sulfones, in the present study, we decided to 
extend the recognition structure by incorporating a third amino acid to derivatives 2. The in 
vitro caspase-3 inhibition for other Fmoc dipeptidyl vinyl sulfones was also studied. 
Finally, the caspase-3 inhibitory effect of the vinyl sulfones active in vitro was also 
analysed using a yeast cell-based assay.  
 In order to search for modulators of caspase-3, an independent analysis of this 
caspase is required. However, the identification of at least 14 caspase family members, 
coupled with the complex patterns of caspase gene expression, the tightly synchronized 
cascade of activation and the extensive cross-talk amongst numerous signalling pathways 
in mammalian cells, have hampered the pharmacological analysis of individual caspases 
in a cell environment (9). To address this issue, yeast expressing human caspase-3 can 
be used to analyse the caspase-3 inhibitory effect of small molecules in a simpler 
eukaryotic cell system. In fact, many researchers have used yeast expressing human 
caspase-3 to uncover the mechanisms of endogenous regulation of this caspase (10-17).  
 Indeed, the high degree of conservation of many pathways and cellular 
processes among yeast and human cells led several researchers to use yeast as a 
valuable cell model for functional studies of human proteins and as a drug screening tool 
(18-24). Additionally, though yeast has a metacaspase (Yca1p), it was shown that the 
activity of human caspase-3 in yeast is independent of Yca1p activity (17). Finally, it was 
shown that expression of an active form of caspase-3 in yeast caused a marked growth 
inhibition (10-17), which was reverted by endogenous inhibitors of caspase-3, such as 
mammalian IAPs (inhibitors of apoptosis) homologues (MIH) MIHA, MIHB and MIHC, and 
baculoviral caspase inhibitors p35 and p49 (12-16). These studies established a 
correlation between yeast cell growth and caspase-3 activity. 
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5.3. MATERIAL AND METHODS 
 
5.3.1. Chemistry 
 All reagents and solvents were obtained from commercial suppliers and were 
used without further purification. Melting points were determined using a Kofler camera 
Bock monoscope M and are uncorrected. The infrared spectra were collected on a Nicolet 
Impact 400 FTIR infrared spectrophotometer. High resolution mass spectra (HMRS) were 
performed in Unidade de Espectrometria de Masas, Santiago de Compostela. Elemental 
analyses were carried out on a C. Erba Model 1106 (Elemental Analyser for C, H and N) 
and the results are within ±0.4% of the theoretical values. Merck Silica Gel 60 F254 plates 
were used as analytical TLC; flash column chromatography was performed on Merck 
Silica Gel (200-400 mesh). 1H and 13C NMR spectra were recorded on a Bruker 400 Ultra-
Shield (400 MHz). 1H and 13C chemical shifts are expressed in δ (ppm) referenced to the 
solvent used and the proton coupling constants (J) in hertz. 
 
5.3.1.1. General procedure for the preparation of vinyl sulfones 4a-d  
 To a suspension of NaH 60% (1.8 mmol, 1.1 equiv.) in THF (5 ml), at 0 ºC, was 
added 1 equiv of the appropriate phosphonate. The resulting solution was stirred at 
temperature room for 30 minutes. A solution of 1 equiv of the appropriate aldehyde 3 in 
THF (16 ml) was added and stirred at room temperature for 2h. The solvent was removed 
under reduced pressure, and the residue was dissolved in CH2Cl2. The organic solution 
was washed with brine, dried, and concentrated. The resulting residue was flash 
chromatographed. 
 
5.3.1.2. General procedure for the preparation of vinyl sulfones 6a-d 
 A solution of the appropriate vinyl sulfone 5 (8) (1 mmol, 1 equiv.) in a 1:1 mixture 
of MeCN/Et2NH (5 ml) was stirred at room temperature for 2h. After this time, the solvent 
was removed under vacuum and the resulting residue was dissolved in DMF (3 ml). To 
this solution was added the protected dipeptide (FmocValValOSu, 1 equiv.) and the 
mixture stirred for 12h at room temperature. The reaction mixture was diluted with H2O, 
extracted with AcOEt (3×) and the organic layers combined, dried under Na2SO4 and the 
solvent removed under vacuum. The resulting residue was flash chromatographed. 
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5.3.1.3. General procedure for the preparation of vinyl sulfones 2i-m and 7a, 7b 
 The appropriate vinyl sulfone was treated with TFA at 0 ºC for 1 h. TFA was 
removed under vacuum and the final products were recrystallized from ethyl 
acetate/hexane as white solids. 
 
5.3.1.3.1. FmocAlaAspVSMe (2i) 
 Obtained in 93% yield. M.p. 97-98ºC; IR (NaCl): 3421, 3318, 3074, 2959, 1714, 
1682, 1510 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.91 (1H, d, J = 8.0 Hz), 7.77 (2H, d, J = 
8.0 Hz), 7.59 (2H, d, J = 8.0 Hz), 7.42 (2H, t, J = 8.0 Hz), 7.28 (2H, t, J = 8.0 Hz), 6.63 
(1H, dd, J = 16.0, 4.0 Hz, CH=CHSO2Me), 6.56 (1H, d, J = 16.0 Hz, CH=CHSO2Me), 5.50 
(1H, m), 5.21 (1H, sl), 4.43 (2H, m), 4.30 (1H, m), 4.16 (1H, m), 3.12 (3H, s), 2.51 (1H, m), 
2.48 (1H, m), 1.24 (3H, d, J = 8.0 Hz); 13C NMR (100 MHz, CDCl3) δ 173.86, 171.90, 
160.65, 158.68, 144.95, 141.31, 139.57, 128.78, 127.56, 124.34, 122.93, 66.68, 50.69, 
50.33, 48.17, 39.89, 38.13, 18.44; HRMS-ESI-TOF: m/z calcd C24H26N2O7SNa (M++Na) 
509.1358, found 509.1364. 
 
5.3.1.3.2. FmocAlaAspVSPh (2j) 
 Obtained in 91% yield. M.p. 99-100ºC; IR (NaCl): 3421, 3305, 3061, 2932, 1714, 
1657, 1510 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.02 (1H, d, J = 8.0 Hz), 7.74 (2H, d, J = 
8.0 Hz), 7.56-7.23 (11H, m), 6.72 (1H, dd, J = 16.0, 4.0 Hz, CH=CHSO2Ph), 6.66 (1H, d, J 
= 16.0 Hz, CH=CHSO2Ph), 5.29 (1H, m), 5.22 (1H, sl), 4.43 (2H, m), 4.30 (1H, m), 4.16 
(1H, m), 3.12 (3H, s), 2.81 (1H, m), 2.75 (1H, m), 1.25 (3H, d, J = 8 Hz); 13C NMR (100 
MHz, CDCl3) δ 173.72, 171.76, 160.51, 144.81, 140.75, 139.43, 136.77, 135.44, 133.04, 
129.08, 128.63, 128.14, 127.41, 124.20, 122.79, 66.54, 50.54, 50.18, 48.03, 39.75, 18.29; 
HRMS-ESI-TOF: m/z calc C29H28N2O7SNa (M++Na) 571.1515, found 571.1523. 
 
5.3.1.3.3. FmocIleAspVSMe (2l) 
 Obtained in 89% yield. M.p. 87-88ºC; IR (NaCl): 3305, 2971, 1727, 1657, 1523 
cm-1; 1H NMR (400 MHz, CDCl3) δ 8.01 (1H, d, J = 8.0 Hz), 7.59 (2H, d, J = 8.0 Hz), 7.45 
(2H, d, J = 8.0 Hz), 7.41 (2H, t, J = 8.0 Hz), 7.32 (2H, t, J = 8.0 Hz), 6.73 (1H, dd, J = 16.0, 
4.0 Hz, CH=CHSO2Me), 6.66 (1H, d, J = 16.0 Hz, CH=CHSO2Me), 5.50 (1H, m), 5.23 (1H, 
sl), 4.43 (2H, m), 4.30 (1H, m), 4.16 (1H, m), 3.02 (3H, s), 2.72 (1H, m), 2.60 (1H, m), 1.51 
(1H, sl), 1.23 (1H, sl), 0.97 (6H, m); 13C NMR (100 MHz, CDCl3) δ 173.20, 171.85, 160.83, 
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158.64, 144.91, 141.27, 139.53, 128.73, 127.51, 124.30, 122.89, 66.63, 60.57, 50.28, 
48.12, 39.85, 38.08, 35.66, 25.05, 16.37, 11.66; HRMS-ESI-TOF: m/z calc 
C27H32N2O7SNa (M++Na) 551.1828, found 551.1835. 
 
5.3.1.3.4. FmocIleAspVSPh (2m) 
 Obtained in 88% yield. M.p. 111-112ºC; IR (NaCl): 3429, 2974, 1705, 1523 cm-1; 
1H NMR (400 MHz, CDCl3) δ 8.00 (1H, d, J = 8.0 Hz), 7.75 (2H, d, J = 8.0 Hz), 7.61-7.23 
(11H, m), 6.73 (1H, dd, J = 16.0, 4.0 Hz, CH=CHSO2Ph), 6.63 (1H, d, J = 16.0 Hz, 
CH=CHSO2Ph), 5.46 (1H, m), 5.24 (1H, sl), 4.49 (2H, m), 4.23 (1H, m), 4.15 (1H, m), 2.73 
(1H, m), 2.58 (1H, m), 1.51 (1H, sl), 1.27 (1H, sl), 0.68 (6H, m); 13C NMR (100 MHz, 
CDCl3) δ 173.11, 171.76, 160.73, 144.81, 140.75, 139.43, 136.77, 135.44, 133.04, 129.08, 
128.63, 128.14, 127.41, 124.20, 122.79, 66.54, 60.47, 50.18, 48.03, 39.75, 35.56, 24.95, 
16.27, 11.56; HRMS-ESI-TOF: m/z calc C32H34N2O7SNa (M++Na) 613.1984, found 
613.1993. 
 
5.3.1.3.5. FmocValValAspVSMe (7a) 
 Obtained in 69% yield. M.p. 96-97ºC; IR (NaCl): 3283, 2949, 1741, 1700, 1655, 
1522 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.23 (1H, sl), 8,12 (1H, sl), 7.76 (2H, d, J = 8.0 
Hz), 7.41-7.33 (6H, m), 6.74 (1H, dd, J = 16.0, 4.0 Hz, CH=CHSO2Me), 6.47 (1H, d, J = 
16.0 Hz, CH=CHSO2Me), 4.70 (2H, d, J = 8.0 Hz), 4.60 (1H, sl), 4.54 (1H, sl), 4.47 (2H, 
m), 3.28 (1H, sl), 2.93 (3H, s), 2.78 (1H, dd, J = 8.0, 4.0 Hz), 2.57 (1H, dd, J = 8.0, 4.0 
Hz), 2.03 (1H, m), 1.85 (1H, m), 1.07 (6H, d, J = 8.0 Hz), 1.00 (6H, d, J = 8.0 Hz); 13C 
NMR (100 MHz, CDCl3) δ 172.39, 172.21, 171.81, 160.79, 158.60, 144.87, 144.87, 
141.23, 139.49, 128.69, 127.47, 124.26, 122.85, 66.54, 59.11, 58.33, 50.19, 48.03, 39.76, 
37.99, 30.48, 19.04; HRMS-ESI-TOF: m/z calc C31H39N3O8SNa (M++Na) 636.2356, found 
636.2363. 
 
5.3.1.3.6. FmocValValAspVSPh (7b) 
 Obtained in 73% yield. M.p. 86-87ºC; IR (NaCl): 3314, 2992, 1740, 1702, 1666, 
1516 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.50 (1H, sl), 7.88 (2H, d, J = 8.0 Hz), 7.79 (2H, 
d, J = 8.0 Hz), 7.71 (1H, m), 7.58 (2H, m), 7.43 (4H, m), 7.33 (2H, m), 7.16 (1H, sl), 6.50 
(1H, dd, J = 16.0, 4.0 Hz, CH=CHSO2Ph), 6.25 (1H, d, J = 16.0 Hz, CH=CHSO2Ph), 4.70 
(2H, d, J = 8.0 Hz), 4.60 (1H, sl), 4.46 (1H, m), 4.39 (2H, sl), 4.15 (1H, sl), 2.83 (1H, dd, J 
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= 8.0, 4.0 Hz), 2.62 (2H, m), 2.27 (1H, m), 1.11 (6H, d, J = 8.0 Hz), 0.91 (6H, d, J = 8.0 
Hz); 13C NMR (100 MHz, CDCl3) δ 172.34, 172.16, 171.76, 160.73, 144.81, 140.75, 
139.43, 136.77, 135.44, 133.03, 129.09, 128.64, 128.64, 127.42, 124.21, 122.79, 66.56, 
59.13, 58.35, 50.22, 48.05, 39.78, 30.50, 19.06; HRMS-ESI-TOF: m/z calc 
C36H41N3O8SNa (M++Na) 698.2512, found 698.2516. 
 
5.3.2. Caspase-3 in vitro assays 
 Caspase-3 fluorimetric assay was used, which is based on the hydrolysis of the 
peptide substrate acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) by 
caspase-3, resulting in the release of the fluorescent 7-amido-4-methylcoumarin (AMC) 
moiety. Briefly, 5 µl of stock solution in assay buffer (10 U/ µl) of caspase-3 (caspase-3, 
human, recombinant, Calbiochem) were added to 5 µl of the tested inhibitors at various 
concentrations. The reaction was initiated by the addition of 190 µl of substrate to a final 
concentration of 200 µM in assay buffer (20 mM HEPES, 2mM EDTA, 0.1% CHAPS, and 
5 mM DTT, pH 7.4). Liberation of AMC was monitored continuously at 37ºC using a Tecan 
infinite M200 (Tecan, Switzerland) 96-well plate reader (white plates from Greiner bio-one, 
Germany) using an excitation wavelength of 360 nm and an emission wavelength of 460 
nm. Inhibitors stock solutions were prepared in DMSO, and serial dilutions were made in 
DMSO. Controls were performed using enzyme alone, substrate alone, enzyme with 
DMSO and a positive control (Ac-DEVD-CMK, Calbiochem). 
 
5.3.3. Plasmids, yeast strain, transformation and growth conditions 
 Constructed yeast expression plasmid pGALL-LEU2 encoding human reverse 
caspase-3, an active form of human caspase-3, and the respective empty vector were 
kindly provided by Dr. C. J. Hawkins (Children’s Cancer Centre, Royal Children’s Hospital, 
Parkville, Australia). Plasmids have a galactose-inducible GAL1/10 promoter.  
 Saccharomyces cerevisiae CG379 (α ade5 his7-2 leu2-112 trp1-289 ura3-52 [Kil-
O]; Yeast Genetic Stock Center) strain was transformed by the lithium acetate method as 
described (24). Transformed cells were routinely grown in a minimal selective medium 
with 2% (w/v) glucose, 0.67% (w/v) yeast nitrogen base without amino acids (Difco) and 
all the amino acids required for yeast growth (50 µg/ml) except leucine, at 30ºC, with 
mechanical shaking (200 r.p.m.) to approximately 1 optical density (OD600; Jenway 6310 
Spectrophotometer). To induce expression of human caspase-3, yeast cells were diluted 
to 0.05 OD600 in a minimal selective medium with 2% (w/v) galactose and raffinose, 
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instead of glucose, and 3% (v/v) glycerol, and grown at 30ºC with mechanical shaking 
(200 r.p.m.) to 0.3 OD600. 
 
5.3.3.1. Western blot analysis 
 Preparation of yeast extracts and Western blot analysis were performed basically 
as described (24). Expression of human caspase-3 in yeast was detected using the anti-
caspase-3 rabbit polyclonal antibody (1:200; Santa Cruz Biotechnology), followed by the 
anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (1:5000; Santa 
Cruz Biotechnology). For loading control, membranes were stripped and reprobed with the 
anti-Pgk1p mouse monoclonal antibody (1:5000; Molecular probes) followed by the anti-
mouse HRP-conjugated secondary antibody (1:5000; Santa Cruz Biotechnology). 
Immunoblots were developed by enhanced chemiluminescence.  
 
5.3.3.2. Yeast caspase-3 assay 
 To analyse the effect of compounds on the growth of yeast expressing human 
caspase-3 and control yeast (transformed with the vector without the cDNA encoding 
human caspase-3; pGALL), transformed cells were incubated in galactose selective 
medium with 5 – 100 µM vinyl sulfones, 5 – 50 µM Ac-DEVD-CMK (positive control; 
Caspase-3 inhibitor III; Calbiochem) or 0.1% DMSO only to 0.3 OD600. Cell growth was 
analysed by counting the number of colony-forming units (CFU) per ml obtained after 2 
days incubation, at 30 ºC, on Sabouraud Dextrose Agar plates. The percentage of growth 
stimulation of yeast expressing caspase-3 (proportional to the degree of caspase-3 
inhibition) caused by compounds was calculated considering the number of CFU obtained 
with yeast expressing caspase-3 incubated only with DMSO as 100% growth. 
Concentration-response curves for 5 – 100 µM vinyl sulfones and 5 - 50 µM Ac-DEVD-
CMK were obtained, considering the maximal growth stimulation achieved with 25 µM Ac-
DEVD-CMK as 100% caspase-3 inhibition, and the lowest concentration that caused 50% 
caspase-3 inhibition (IC50) calculated.  
 
5.3.3.3. Statistical analysis 
 Data were analysed statistically using the SigmaStat 3.5 software. Differences 
between means were tested for significance using the unpaired Student´s t test (P < 0.05). 
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5.4. RESULTS AND DISCUSSION 
 
5.4.1. Chemistry 
 Dipeptidyl aldehydes 3a and 3b were synthesized as reported before from the 
correspondent dipeptide acids using Weinreb chemistry and used without further 
purification. After Horner-Wadsworth-Emmons reaction between the dipeptidyl aldehydes 
3a and b with the correspondent phosphonate, vinyl sulfones 4a-d were obtained with 
yields of 36-53%. Deprotection of vinyl sulfones 4a-d with TFA, afforded vinyl sulfones 2i-
m with yields of 88-93% (Scheme 1). 
 
Scheme 1. Synthesis of Fmoc-dipeptidyl vinyl sulfones 2i-m. 
 
 To improve the potency of the inhibitors, we decided to extend the molecular 
recognition by incorporating a third amino acid, Valine, since it has been shown 
experimentally to be favourable at the P3 position (25). We had tried before, without 
success, to obtain the dipeptidyl vinyl sulfones 2 by Fmoc deprotection of the nitrogen 
atom of the vinyl sulfones 5a and b, using several different basic conditions (piperidine, 
triethylamine, DBU) (8). However, recently this Fmoc deprotection was accomplished in 
the presence of Et2NH (26). Using the same methodology, vinyl sulfones 6a and b were 
obtained in a one pot reaction, by N-deprotection of vinyl sulfones 5a and b using Et2NH 
in acetonitrile, followed by coupling with the dipeptide FmocValValOSu in DMF with yields 
of 54-57%. Deprotection of vinyl sulfones 6a and b with TFA, afforded vinyl sulfones 7a 
and b with yields of 69-73% (Scheme 2). 
 
Scheme 2. Synthesis of Fmoc-tripeptidyl vinyl sulfones 7a and b. 
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 All of the proposed structures were established by NMR (1H, 13C, COSY and 
HMQC), IR, and MS. The stereochemistry around the double bond was established using 
the corresponding 1H NMR coupling constant, where a double doublet (J = 16.0 Hz and 4 
Hz) and a doublet (J = 16.0 Hz) are observed for the β and α proton relative to the sulfone 
group, respectively, confirming the presence of the E isomer on vinyl sulfones 2i-m and 
7a, 7b. 
 
5.4.2. Biological activity 
 The vinyl sulfones synthesized were examined for their ability to inhibit the 
activity of recombinant human effector caspase-3. The IC50 values were determined using 
a fluorometric assay and the tetrapeptidyl chloromethyl ketone Ac-DEVD-CMK was used 
as positive control. Fmoc dipeptidyl vinyl sulfones with Ala at position P2 2i and 2j were 
inactive against caspase-3 for the tested concentrations (<200 µM), as we had observed 
previously for the Cbz-Ala-Asp vinyl sulfones 2a and 2b counterparts. 
 Surprisingly, the presence of Ile on vinyl sulfones 2l and 2m did not improve the 
activity related to the Fmoc-Val-Asp vinyl sulfones 2g and 2h, as was observed before for 
the Cbz dipeptidyl series. Most remarkably, and to our surprise, tripeptidyl vinyl sulfones 
were not active for caspase-3, opposite to other examples described in literature for 
peptidyl vinyl sulfones as potent cysteine protease inhibitors of clan CA (7). In fact, the 
presence of a third amino acid on vinyl sulfones 2g and 2h also resulted in lost of activity 
against caspase-3, as observed for the Fmoc-tripeptidyl vinyl sulfones 7a and b. 
 The vinyl sulfones that were active in vitro were then studied using a yeast cell-
based assay (Table 5.1). In this assay, inhibitors of caspase-3 are those compounds that 
stimulate the growth of yeast expressing human caspase-3 without interfering with the 
growth of control yeast (transformed with the vector without the cDNA encoding human 
caspase-3). 
 To implement this assay, we firstly confirmed that, as previously reported by 
other authors (10-17), yeast expression of human reverse caspase-3, an active form of 
human caspase-3 (Fig. 5.2) caused a marked growth inhibition, when compared to control 
yeast (pGALL) (Fig. 5.3). Additionally, the reduction of this caspase-3-induced yeast 
growth inhibition by the commercial caspase-3 inhibitor, Ac-DEVD-CMK, (Fig. 5.3) 
corroborated the correlation, between stimulation of growth of yeast expressing caspase-3 
and caspase-3 inhibition, and validated this assay to search for small molecule inhibitors 
of caspase-3. 
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Table 5.1. Inhibition of human caspase-3 using a yeast cell system by vinyl sulfones (PG-N-X-CH=CHSO2R) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2. Expression of human reverse caspase-3 in yeast was confirmed by Western blot analysis. Control 
yeast (pGALL) and yeast expressing caspase-3 were incubated in galactose selective medium to 0.3 OD600. 
Full length procaspase (32 kDa) and the respective cleaved fragments (processed caspase-3) were detected 
using an anti-caspase-3 polyclonal antibody. Detection of Pgk1p was used as loading control. Immunoblots 
were developed by chemiluminescence. 
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Compound PG X R IC50 (µM)a Growth Stimulation 
(%)b 
    Cell System (Control Yeast) 
1c Fmoc Asp Me 23.7±4.5 1.7 ± 3.2 
1d Fmoc Asp Ph 16.2±2.0 2.8 ± 2.3 
2c Cbz Val-Asp Me 35.3±3.3* -1.0 ± 0.4 
2e Cbz Ile-Asp Me 30.5±3.5* -3.3 ± 2.1 
2f Cbz Ile-Asp Ph 28.3±8.9 1.9 ± 2.2 
2g Fmoc Val-Asp Me 34.0±4.3* -7.0 ± 0.1 
2h Fmoc Val-Asp Ph 29.9±3.4* 1.3 ± 3.9 
Ac-DEVD-CMK ― ― ― 13.4±2.8 1.7 ± 3.2 
The percentage of growth stimulation was calculated considering 100% growth the number of CFU 
obtained with transformed yeast incubated with DMSO only.  
a
 IC50 values, were obtained from concentration-response curves of 5-100 µM vinyl sulfones and 5-50 µM 
Ac-DEVD-CMK, which were obtained considering the maximal growth stimulation obtained with 25 µM Ac-
DEVD-CMK as 100% caspase-3 inhibition. Data are means ± s.e.m. of IC50 values obtained from 4-5 
independent experiments with 6 replicates each. IC50 value significantly higher than that obtained with Ac-
DEVD-CMK, *P< 0.05.  
b
 Each compound was tested in control yeast at the concentration that caused the maximal effect on yeast 
expressing caspase-3. Positive values indicate stimulation of yeast growth. Data are means ± s.e.m. of 4 
independent experiments with 6 replicates each. 
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Fig. 5.3. Expression of human caspase-3 caused a marked yeast growth inhibition that was significantly 
reduced by the commercial caspase-3 inhibitor Ac-DEVD-CMK. Transformed yeast cells were incubated in 
galactose selective medium with 25 µM Ac-DEVD-CMK or DMSO only to 0.3 OD600. Yeast growth was 
evaluated by CFU counts, considering the number of CFU obtained with control yeast (pGALL) incubated only 
with DMSO as 100% growth. Data are means ± s.e.m. of 4 independent experiments with 6 replicates each. 
Value of yeast expressing caspase-3 incubated with Ac-DEVD-CMK significantly higher than that obtained 
with DMSO only, *P < 0.05. 
 
 Subsequently, the effect of vinyl sulfones 1c, 1d, 2c, 2e-f and 2g-h on caspase-3 
activity was also analysed using the yeast caspase-3 assay. For that, concentration-
response curves for 5 - 100 µM vinyl sulfones and 5 - 50 µM Ac-DEVD-CMK (positive 
control) were obtained, considering the maximal growth stimulation achieved with 25 µM 
Ac-DEVD-CMK as 100% caspase-3 inhibition (Fig. 5.4A), and the IC50 value (lowest 
concentration of compound that caused 50% caspase-3 inhibition) was determined for 
each compound. The results obtained showed that all vinyl sulfones active in vitro 
behaved as inhibitors of a caspase-3 pathway in the cell-based assay (Table 5.1). In fact, 
vinyl sulfones 1c, 1d, 2c, 2e-f and 2g-h, did not interfere with the growth of control yeast. 
This indicates that these vinyl sulfones had no effect on endogenous yeast proteins, such 
as yeast caspase-like. However, they inhibited human caspase-3-induced yeast growth 
inhibition. This reveals that they inhibited caspase-3 directly or indirectly by inhibition of a 
caspase-3-dependent pathway. 
 Based on Table 5.1, it was observed that the IC50 values for vinyl sulfones 1c, 1d, 
2c, 2e-h determined in the yeast assay ranged from 16 to 35 µM and were within the 
same order of magnitude of that determined for Ac-DEVD-CMK (13 µM - Table 5.1). A 
remarkable increase in the activity of some vinyl sulfones, identified as weak inhibitors of 
caspase-3 in the in vitro assay, was observed in the yeast-cell based assay. In particular, 
vinyl sulfone 1d, exhibited a proliferative effect (reduction of caspase-3-induced growth 
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inhibition) in the same order of magnitude of the commercial caspase-3 inhibitor, Ac-
DEVD-CMK (Fig. 5.4A,B and Table 5.1). These results indicate that, in spite of their poor 
activity as inhibitors of caspase-3 (8), vinyl sulfones 1c, 1d, 2c, 2e-f and 2h are inhibitors 
of a caspase-3-dependent pathway. In fact, since these compounds have a lower potency 
in vitro than in the yeast-cell based assay, we hypothesize that although they inhibit 
caspase-3 their main effect can be ascribed to the inhibition of a caspase-3-dependent 
pathway by modulation of other proteins of its pathway that indirectly inhibit caspase-3. In 
fact, in the case of Fmoc-Asp vinyl sulfones 1c and 1d the lower selectivity for caspase-3, 
can be explained because the recognition structure is less extended than the one of the 
dipeptide counterparts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.4. Concentration-response curves for (A) Ac-DEVD-CMK and (B) vinyl sulfone 1d. The percentage of 
growth stimulation caused by compounds was calculated considering the number of CFU obtained with yeast 
expressing caspase-3 incubated with DMSO only as 100% growth. Concentration-response curves were 
obtained considering the maximal growth stimulation obtained with 25 µM Ac-DEVD-CMK as 100% caspase-3 
inhibition. Data are mean ± s.e.m. 4 to 5 independent experiments. 
 
 Overall, the results obtained from the yeast cell-based assay strongly suggest 
that the vinyl sulfones reported in the present study are inhibitors of a caspase-3-
dependent pathway. Importantly, the calc log P values (27) for vinyl sulfones range from 
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1.1 to 3.4 (Table 5.2), i.e. significantly higher than that of Ac-DEVD-CMK (calc log P = -
0.6), suggesting that they present appropriate cell permeability properties. 
 
Table 5.2. Relevant parameters for preliminary permeation properties of vinyl sulfones 1c, 1d, 2c and 2e-h 
(data for Ac-DEVD-CMK are also included for comparison). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound PG X R logPa 
1c Fmoc Asp Me 2.22 
1d Fmoc Asp Ph 2.34 
2c Cbz Val-Asp Me 1.16 
2e Cbz Ile-Asp Me 1.53 
2f Cbz Ile-Asp Ph 2.38 
2g Fmoc Val-Asp Me 2.33 
2h Fmoc Val-Asp Ph 3.43 
Ac-DEVD-CMK ― ― ― -0.63 
a
 Estimated by the ALOGPS 2.1 algorithm (27). 
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5.5. CONCLUSION 
 
 The comprehensive SAR study of vinyl sulfones as caspase-3 inhibitors, 
incorporating one, two and three amino acid residues, reveals that introduction of a third 
amino acid in dipeptidyl vinyl sulfones (i.e. converting 2g and 2h into 7a and 7b, 
respectively), did not improve the inhibitory activity determined using the biochemical 
assay. For all the series of vinyl sulfones synthesized, the compounds active against 
caspase-3 were then tested in a yeast cell system expressing this enzyme. This yeast 
assay revealed that Fmoc vinyl sulfones containing Asp at P1 1c and 1d were inhibitors of 
a caspase-3-dependent pathway in a cell system, with IC50 values similar to that obtained 
with the positive control (Ac-DEVD-CMK). In spite of their lack of selectivity to caspase-3, 
they can be considered potent modulators of a caspase-3-dependent pathway and 
therefore interesting compounds to be explored in vivo. Additionally, they can be used as 
lead compounds for the development of more potent and selective caspase-3 inhibitors. 
Further work must be carried out in order to identify the molecules of the caspase-3 
pathway also modulated by these compounds. 
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SELECTIVE ACTIVATION OF HUMAN CASPASE-7 BY PRENYLATED 
FLAVONOIDS, REVEALED BY YEAST ASSAYS 
 
 
6.1. ABSTRACT 
 Several works showed that prenylated flavonoids have potent antiproliferative 
activities in distinct human tumour cells. In order to identify the molecular targets involved 
in the antiproliferative effects of these compounds, their modulatory activities on three key 
regulators of cell proliferation and death, caspase-3, caspase-7 and p53, were analysed. 
For this purpose, yeast assays based on the heterologous expression of these human 
target proteins were used. As previously reported for caspase-3 and wild-type p53, the 
expression in yeast of an active form of human caspase-7, caused a marked growth 
inhibition which was stimulated or reverted by activators or inhibitors, respectively. Using 
these yeast phenotypic assays for human caspase-3, caspase-7 and p53, we identified 
three prenylated flavonoids, 5,6-dihydroxy-7-prenyloxyflavone, 3-hydroxy-7-
geranyloxyflavone and artelastin, that activated caspase-7 with a higher potency than the 
standard activator of caspase-3 and -7, procaspase activating compound-1 (PAC-1). We 
also showed that the yeast growth inhibition induced by expression of caspase-7 was 
associated to cell cycle arrest in G2/M and S phases and apoptosis. Moreover the 
stimulation of this inhibitory effect by PAC-1 and the three prenylated flavonoids was 
associated with an increase in the percentage of cells in S phase. These flavonoids, in 
contrast to PAC-1, did not interfere with the activity of caspase-3 and had no effect on p53 
activity. Altogether, in this work, three potent activators of caspase-7, 5,6-dihydroxy-7-
prenyloxyflavone, 3-hydroxy-7-geranyloxyflavone and artelastin, are identified. Promising 
pharmacological applications can be therefore envisaged for these prenylated flavonoids, 
particularly as anticancer agents in tumours without caspase-3 or a functional p53 
pathway, or with elevated levels of caspase-7. 
 
Keywords: Caspase-3; Caspase-7; p53; Prenylated flavonoids; Yeast 
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6.2. INTRODUCTION 
 
 Flavonoids are widely known for their potent antitumor activity. In fact, these 
compounds have been described as potent apoptotic inducers in human tumour cells (1, 
2). In conformity with this, baicalein and 3,7-dihydroxyflavone exhibited antiproliferative 
effects in several human tumour cell lines (3-5). Moreover, it was recently shown that the 
suitable addition of prenyl side chains to baicalein and 3,7-dihydroxyflavone, increased the 
growth inhibitory effect of these flavonoids (6). These data indicate that prenylated 
flavonoids may represent a promising group of compounds to search for anticancer agents. 
In fact, the natural prenylated flavonoid artelastin, isolated from Artocarpus elasticus (7), 
integrated the “In vitro Anticancer Drug Discovery Screen” (NSC 710340) from the National 
Cancer Institute (NCI), potently inhibiting the growth of distinct human tumour cells (8). 
However, though the antiproliferative effect of some of these prenylated flavonoids have 
been attributed to the induction of apoptosis and/or cell cycle arrest (6, 8), the molecular 
mechanism of action behind these activities remains to be uncovered.  
Previous reports showed the induction of a caspase-dependent apoptosis in 
several human tumour cells by baicalein (3, 4) and 3,7-dihydroxyflavone (5). The caspase 
family of cysteine proteases is composed by 15 members that are grouped into the 
inflammatory and apoptotic sub-families. Apoptotic caspases can be further divided into 
two functional groups based on their position in the apoptotic cascade, the apical or 
initiator caspases (caspase-2, -8, -9 and -10) and the executioner or downstream 
caspases (caspase-3, -6 and -7) [reviewed in (9)]. It is widely established that cleaved 
apoptotic caspase substrates exert major roles in the apoptotic pathway [reviewed in (9, 
10)]. However, low or transient levels of caspase activation may also lead to non-apoptotic 
responses, such as cell proliferation and differentiation (11-13). Due to their crucial roles 
in cell proliferation and death, caspases, particularly the executioners, are major 
therapeutic targets in pathologies where these cellular processes are dysregulated, such 
as cancer and neurodegeneration [reviewed in (14, 15)]. In this context, small molecule 
activators and inhibitors of caspases represent promising therapeutic agents to stimulate 
and prevent apoptosis in cancer and neurodegenerative disorders, respectively. Among 
the three apoptotic executioner caspases, caspase-3 and -7 had been considered 
functionally redundant proteases. However, several data sustain that these caspases 
have also distinct roles in apoptosis [reviewed in (10, 16)]. In fact, mice deficient in either 
caspases exhibit distinct phenotypes (17). Moreover, caspase-3 and -7 exhibit distinct 
activities towards multiple substrates. In fact, while caspase-3 is responsible for the 
cleavage of the majority of substrates during the demolition phase of apoptosis, caspase-
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7 is more selective (18). This emphasizes the therapeutic value of selective caspase-7 
small molecule modulators. 
The activation of a p53-dependent apoptosis by baicalein has been also reported 
(3, 4). The p53 tumour suppressor protein acts as a major defence against cancer, and 
altered p53 activity is often observed in human cancers. In fact, about 50% of all reported 
cancers have a mutation in the TP53 gene. Among the remaining cancers that retain a 
wild-type (wt) p53, the p53 pathway is often inactivated due to multiple defects in p53 
responses. Hence, restoring p53 function has been considered a promising strategy in 
anticancer therapy (19, 20). Thus, small molecule activators of p53 are also considered 
promising anticancer agents.  
 Yeast expressing a given human disease-related protein has widely contributed to 
the discovery of promising therapeutic agents (21-23). Though mammalian cells provide a 
more adequate physiological model system, yeast allows a clean read-out in a null- or 
almost null-background environment for the expression of the human target protein. Even 
when yeast possesses an orthologue of the human protein expressed most often it 
displays structural but not functional homology, and therefore does not respond to the 
same compounds that act as modulators in human cells. Moreover, the analysis of drug 
targets in a eukaryotic environment with a considerable lower redundancy level, such as in 
yeast, allows most often the unambiguous measurement of a specific effect on a given 
target (21-23). Several examples illustrating the advantages of yeast as a drug screening 
tool can be referred. For instance, a potent and selective activator of novel protein kinase 
C (PKC) δ and ε was identified by our group using yeast cells expressing individual 
members of mammalian PKC family (24). In another recent work, we also identified 
selective inhibitors of human caspase-3 by testing a library of vinyl sulfones (25).  
 Similarly to human wt p53 (26), the expression of active forms of human caspase-3 
and -7 in yeast causes a marked growth inhibition that is proportional to the degree of 
human caspase activation (27-29). This inhibitory effect of recombinant human proteins 
expressed in yeast has been used in the establishment of drug screening assays based on 
the direct assessment of the yeast cell growth. Though no orthologues of human p53 have 
been found in yeast, in the case of caspases, a possible interference of the yeast 
metacaspase (Yca1p) has been considered. However, the activity of human caspases in 
yeast was shown to be independent of Yca1p (29). 
In this work, several prenylated derivatives of baicalein and 3,7-dihydroxyflavone, 
and the natural prenylated flavonoid artelastin, with antiproliferative activities in several 
human tumour cells (6, 8), were studied in order to identify the molecular targets involved 
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in their growth inhibitory effects. With this goal, the modulatory activity of these 
compounds on the three major regulators of cell proliferation and death, caspase-3, 
caspase-7 and p53, was tested. To this end, yeast assays based on the heterologous 
expression of these human target proteins were used. It was found that 5,6-dihydroxy-7-
prenyloxyflavone, 3-hydroxy-7-geranyloxyflavone and artelastin are potent activators of 
caspase-7. 
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6.3. MATERIAL AND METHODS 
 
6.3.1. Plasmids 
 Constructed yeast expression plasmid pGALL-(LEU2) encoding auto-activating 
forms of human caspase-3 (reverse (rev)-caspase-3; procaspase-3 with the small subunit 
preceding the prodomain and large subunit) or caspase-7 (caspase-753; procaspase-7 
lacking the N-terminal 1-53 amino acid prodomain) and the empty vector were kindly 
provided by Dr. Christine J. Hawkins (Department of Haematology and Oncology, Royal 
Children’s Hospital, Australia); pLS89-(TRP1) encoding human wt p53 and the empty 
vector were kindly provided by Dr. Richard Iggo (Swiss Institute for Experimental Cancer 
Research, Switzerland). Plasmids used have a galactose-inducible GAL1-10 promoter. 
Construction of these yeast plasmids was previously described (30-32).  
 
6.3.2. Yeast strain, transformation and growth conditions 
 Saccharomyces cerevisiae CG379 was transformed as reported (33). To ensure 
selection of transformed yeast, cells were routinely grown in glucose minimal selective 
medium. To induce expression of human caspase-3, caspase-7 or wt p53, yeast cultures 
were diluted to 0.05 optical density at 600 nm (OD600) in 2% (w/v) galactose and raffinose 
selective medium and grown at 30 ºC under continuous shaking (33). Effects of 
expression of caspase-3 (25) and wt p53 (26) on yeast growth were analysed as 
previously described. Yeast expressing caspase-7 and control yeast (transformed with the 
empty vector, pGALL) were grown for up to 50 hours for growth curves experiments. For 
the analysis of the effect of caspase-7 on yeast growth, cells were incubated for 36 hours 
(time required by yeast expressing caspase-7 to achieve approximately 0.40 OD600). 
Yeast growth was analysed by counting the number of colony-forming units per ml 
(CFU/ml) after 2 days incubation at 30 ºC on Sabouraud Dextrose Agar plates. 
 
6.3.3. Western blot analysis 
 Western blot analysis to confirm expression of human caspase-3 (25) and human 
wt p53 (26) in yeast were previously reported. Western blot analysis to confirm the 
expression in yeast of human caspase-7 was performed basically as described (33). To 
analyse the expression of human caspase-7, a mouse monoclonal anti-caspase-7 
antibody, which detects caspase-7 full length precursor and the large subunit (LS) of 
cleaved caspase-7 (Santa Cruz Biotechnology), followed by an anti-mouse horseradish-
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peroxidase (HRP)-conjugated secondary antibody (Southern Biotechnology), were used. 
For loading control, membranes were stripped and reprobed with a mouse monoclonal 
anti-yeast phosphoglycerate kinase (Pgk1p) antibody (Molecular probes). Immunoblots 
were developed by chemiluminescence.  
 
6.3.4. Cell death markers 
 Propidium iodide (PI) staining and terminal deoxynucleotidyltransferase-mediated 
dUTP nick-end labelling (TUNEL) staining, to monitor plasma membrane integrity and 
DNA fragmentation, respectively, were performed basically as described (33). For PI 
staining, cells were incubated with 5 µg/ml PI (Molecular Probes) for 10 min at room 
temperature; fluorescence was monitored by flow cytometry. TUNEL assay was 
performed using the In Situ Cell Death Detection Kit, Fluorescein (Roche Applied 
Science); samples were observed under a fluorescence microscope. 
 
6.3.5. Reactive oxygen species (ROS) accumulation 
 Analysis of mitochondrial ROS accumulation was performed basically as described 
(24). Briefly, cells were incubated with 5 µg/ml dihydroethidium (DHE; Sigma-Aldrich) for 
30 min at 30 °C, and fluorescence was monitored by flow cytometry.  
 
6.3.6. Cell cycle 
 DNA content was monitored by flow cytometry, as described (24). Briefly, about 
107 cells were fixed in 70% (v/v) ethanol, digested with 250 µg/ml RNase A (DNase-free; 
Sigma–Aldrich) and 1 mg/ml Proteinase K (Sigma–Aldrich), and afterwards incubated with 
10 µM Sytox Green Nucleic Acid (Alfagene). Yeast cell cycle phases were identified and 
quantified using ModFit LT software (VeritySoftware House Inc.). 
 
6.3.7. Effects of PAC-1 and flavonoids on yeast growth 
 All compounds were prepared in dimethyl sulfoxide (DMSO; Sigma). Details 
concerning synthesis of baicalein (1) and 3,7-dihydroxyflavone (2) prenylated derivatives, 
namely 5,6-dihydroxy-7-prenyloxyflavone (1a) and 3-hydroxy-7-geranyloxyflavone (2a) 
(Fig. 6.1), have been previously reported (6). Isolation of artelastin (3) (Fig. 6.1) have 
been previously described (7). In yeast caspase-3/-7 assays, procaspase activating 
compound 1 (PAC-1; Calbiochem), a standard activator of caspase-3 and -7, was used as 
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positive control. To analyse the effect of compounds on yeast cell growth, transformed 
cells were incubated in galactose selective medium with 0.1 - 25 µM PAC-1, 0.1 - 10 µM 
flavonoids or 0.1% DMSO only, at 30 ºC under continuous shaking to approximately 0.4 
OD600. Cell growth was analysed as described above. For each transformant, the 
percentage of drug-induced growth inhibition was estimated considering 100% growth the 
number of CFU obtained with yeast incubated with DMSO only. EC50 values were 
obtained from concentration-response curves of 0.1 – 25 µM PAC-1 and 0.1 – 10 µM 
flavonoids, and correspond to the concentration that caused 50% of the maximal 
stimulation of growth inhibition obtained with 25 µM PAC-1 on yeast expressing caspase-
7.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Chemical structures of baicalein (1), 3,7-dihydroxyflavone (2), 5,6-dihydroxy-7-prenyloxyflavone 
(1a), 3-hydroxy-7-geranyloxyflavone (2a) and artelastin (3). 
 
6.3.8. Fluorescence microscopy and flow cytometric data acquisition and analysis 
 For fluorescent microscopic examination, samples were observed under an 
Eclipse E400 fluorescence microscope (Nikon) equipped with a 100 W mercury lamp and 
appropriate filter setting. Cells were observed with an oil immersion lens (Plan Fluor 
100/1.30). Flow cytometric analysis was performed using a FACSCalibur flow cytometer 
(BD Biosciences) and the CellQuest software (BD Biosciences).  
 
(2) (1) 
(1a) (2a) 
(3) 
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6.3.9. Statistical analysis 
 Data were analysed statistically using the SigmaStat 3.5 software. Differences 
between means were tested for significance using the unpaired Student´s t-test (P<0.05). 
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6.4. RESULTS 
 
6.4.1 Expression of human caspase-753 in yeast induces growth inhibition associated with 
cell cycle arrest in G2/M and S phases and apoptosis 
Human caspase-753 is an auto-activated form of caspase-7 both in yeast (27, 28) 
and mammalian cells (34). In this work, expression of human caspase-753 in yeast was 
confirmed by Western blot analysis. Using an antibody that recognizes the 34 kDa 
caspase-7 full-length precursor (procaspase) and the 19 kDa large subunit (LS) of cleaved 
caspase-7, we also detected the absence of the 34 kDa band (Fig. 6.2A). This indicated 
that human caspase-753 was successfully processed into an active form in our yeast strain 
and under our growth conditions. Moreover, similarly to human rev-caspase-3 (25) and wt 
p53 (26), the previously reported growth inhibition induced by expression of an active 
caspase-7 in yeast (27, 28) was confirmed (Fig. 6.2B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. Expression of human caspase-7 in yeast induces growth inhibition associated with apoptosis and 
cell cycle arrest. Yeast expressing human caspase-7 and control yeast (pGALL) were grown in galactose 
selective medium for up to 50 hours for growth curves experiments or for 36 hours (time required by yeast 
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expressing caspase-7 to achieve ~0.40 OD600) in all other experiments. (A) Expression of human caspase-7 in 
yeast was confirmed by Western blot analysis. Full length procaspase-7 (34 kDa) and the large subunit (LS) of 
cleaved caspase-7 (19 kDa) were detected using an anti-caspase-7 monoclonal antibody. Pgk1p was used as 
a loading control. Immunoblots were developed by chemiluminescence and represent 1 of 2 experiments. (B) 
Growth curves obtained by CFU counts. Data are means ± s.e.m. of 6 independent experiments with 6 
replicates each. (C) Percentage of growth obtained for 36 h incubation and considering the number of CFU 
obtained with control yeast as 100% growth. Data are means ± s.e.m. of 6 independent experiments with 6 
replicates each. (D) DNA fragmentation (TUNEL + cells) and loss of plasma membrane integrity (PI + cells). 
Data are means ± s.e.m. of 3 independent experiments. (E) Mitochondrial ROS accumulation. Values 
correspond to the increase in the percentage of DHE + cells obtained with yeast expressing caspase-7 when 
compared to control yeast. Data are means ± s.e.m. of 3 independent experiments. In B - E, values 
significantly different from control yeast: *P< 0.05. (F) Analysis of DNA content using Sytox Green. Values 
correspond to the quantification of yeast cell cycle phases and are means of 3 independent experiments.  
 
This inhibitory effect was maximal after approximately 36 h incubation (Fig. 
6.2B,C). For this incubation time, the caspase-7-induced growth inhibition was 
accompanied by a significant increase in DNA fragmentation with no loss of plasma 
membrane integrity (Fig. 6.2D), and by a pronounced increase in mitochondrial ROS 
accumulation (Fig. 6.2E). These data indicated the activation in yeast of an apoptotic cell 
death involving mitochondrial ROS accumulation by human caspase-7. Moreover, it was 
detected the interference of human caspase-7 with the yeast cell cycle progression. In 
fact, the expression of human caspase-7 in yeast increased the percentage of cells in 
G2/M and S phases (Fig. 6.2F). Altogether, these results indicated that this active form of 
human caspase-7 induced yeast growth inhibition which is associated with cell cycle 
arrest in G2/M and S phases and apoptosis. 
 
6.4.2. Development of a yeast assay to search for small molecule modulators of human 
caspase-7 
 In our previous works, it was shown that expression of human wt p53 in yeast 
induced growth inhibition, which was markedly increased by the known natural p53 
activator PKCδ and inhibited by the selective p53 inhibitor pifithrin-α (26, 35). In another 
work, we confirmed that expression of human rev-caspase-3 in yeast also induced growth 
inhibition, which was reverted by the standard caspase-3 inhibitor, Ac-DEVD-CMK (25). In 
these studies, a correlation between yeast cell growth and degree of activity of the 
expressed human protein was confirmed. These works therefore established yeast 
phenotypic assays to search for modulators of human caspase-3 and p53, which are 
based on the direct assessment of the yeast cell growth. In these assays, activators and 
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inhibitors of the human target protein will increase and reduce, respectively, the yeast 
growth inhibition induced by the expressed human protein, without affecting the growth of 
control yeast (transformed with the empty vector). In fact, using this strategy, promising 
inhibitors of human caspase-3 were already identified by our group by testing a library of 
vinyl sulfones (25).  
 In the present work, the heterologous expression of the activated form of human 
caspase -7 described above was exploited and validated as a yeast phenotypic assay for 
the screening of small molecule modulators of human caspase-7. For that, the effect of 
the standard activator of caspase-3 and -7, PAC-1 (36) was tested on yeast cells 
expressing human caspase-7. As expected, for 0.1 – 25 µM, PAC-1 stimulated caspase-
7-induced growth inhibition in a dose-dependent manner, without affecting the growth of 
control yeast (Fig. 6.3). A correlation between stimulation of growth inhibition and 
caspase-7 activation was therefore established. The suitability of the previously 
established yeast caspase-3 assay (25) to search for activators of human caspase-3 was 
further corroborated in this study by testing PAC-1. As expected, PAC-1 also stimulated 
caspase-3-induced growth inhibition, without interfering with the growth of control yeast. 
Though PAC-1 has been reported as a more potent activator of caspase-3 than caspase-
7 in mammalian cells (36), in our yeast assays the maximal effect obtained with PAC-1 
was similar on both caspases (Table 6.1).  
 
Table 6.1. Increase of human caspase-3-, caspase-7- and p53-induced yeast growth inhibition by PAC-1, 5,6-
dihydroxy-7-prenyloxyflavone (1a), 3-hydroxy-7-geranyloxyflavone (2a) and artelastin (3). 
 
 
 
 
 
 
Values correspond to the maximal increase on human caspase-3-, caspase-7- and p53-
induced growth inhibition achieved with 25 µM PAC-1 and 1 µM 5,6-dihydroxy-7-
prenyloxyflavone (1a), 3-hydroxy-7-geranyloxyflavone (2a) and artelastin (3). The 
percentage of drug-induced growth inhibition was estimated considering 100% growth the 
number of CFU obtained with yeast incubated with DMSO only. Values are mean ± s.e.m. of 
6 independent experiments with six replicates each; values significantly higher than control 
yeast, *P< 0.05. NT: effect of compound was not tested. 
   
 Drug-induced growth inhibition (%) 
 Caspase-3 Caspase-7 p53 
PAC-1 24.8 ± 2.6* 25.1 ±3.2* NT 
1a 3.7 ± 7.0 23.0 ±1.9* 6.9 ± 3.6 
2a 6.9 ± 0.9 22.9 ± 4.9* 6.8 ± 2.6 
3 5.0 ± 4.4 28.1 ± 4.5* -0.7 ± 5.4 
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Figure 6.3. Concentration-response curves for the effects of PAC-1, baicalein (1), 3,7-dihydroxyflavone (2), 
5,6-dihydroxy-7-prenyloxyflavone (1a), 3-hydroxy-7-geranyloxyflavone (2a) and artelastin (3) on the growth of 
yeast expressing human caspase-7 and control yeast (pGALL). Transformed yeasts were incubated in 
galactose selective medium with 0.1 - 25 µMPAC-1, 0.1 - 10 µM flavonoids or 0.1% DMSO only, to ~0.4 
OD600. For each transformant, the percentage of drug-induced growth inhibition was estimated considering 
100% growth the number of CFU obtained with yeast incubated with DMSO only. Data are means ± s.e.m. of 
6 independent experiments with 6 replicates each; values significantly different from control yeast: *P< 0.05. 
 
6.4.3. 5,6-Dihydroxy-7-prenyloxyflavone (1a), 3-hydroxy-7-geranyloxyflavone (2a) and 
artelastin (3) increased human caspase-7 activity, with no effects on the activity of human 
caspase-3 and p53 
 
 The modulatory activity of baicalein (1) and 3,7-dihydroxyflavone (2) prenyl-
derivatives (1a and 2a) and artelastin (3) on human caspase-3, caspase-7 and wt p53 
was analysed using the yeast phenotypic assays developed for each human protein.  
 When 5,6-dihydroxy-7-prenyloxyflavone (1a), a monoprenylated derivative of 
baicalein (1) (Fig. 6.1), was tested, a remarkable increase of caspase-7-induced growth 
inhibition was obtained for 1 – 10 µM (Fig. 6.3). Since this compound did not interfere with 
the control yeast, this result indicated that flavonoid 1a was an activator of caspase-7. 
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Though the maximal effects obtained with PAC-1 and flavonoid 1a on caspase-7 were 
similar (Table 6.1), the estimated EC50 values indicated that flavonoid 1a was a more 
potent activator of caspase-7 than PAC-1 (Table 6.2). However, contrarily to that obtained 
with caspase-7, flavonoid 1a did not interfere with caspase-3- and p53-induced growth 
inhibition. In fact, the maximal effects obtained with this compound on these human 
proteins were not significant (Table 6.1). These results indicated that flavonoid 1a potently 
and selectively activated caspase-7. Interestingly, when the effect of the non-prenylated 
analogue of flavonoid 1a, baicalein (1), was tested in yeast cells expressing caspase-7, a 
non-specific effect of this compound was observed. In fact, baicalein (1) inhibited the 
growth of yeast expressing caspase-7 as well as of control yeast (pGALL) (Fig. 6.3). 
 Monogeranylated derivative of 3,7-dihydroxyflavone (2), 3-hydroxy-7-
geranyloxyflavone (2a), and artelastin (3) (Fig. 6.1), behaved similarly to flavonoid 1a. In 
fact, 0.1 – 10 µM flavonoid 2a and 0.1 – 1 µM flavonoid 3 markedly increased caspase-7-
induced growth inhibition without affecting the growth of control yeast (Fig. 6.3). It is also 
interesting to note the absence of effect of 3,7-dihydroxyflavone (2), the non-prenylated 
analogue of flavonoid 2a, on yeast expressing caspase-7 (Fig. 6.3). Additionally, as 
obtained with flavonoid 1a, flavonoids 2a and 3 also did not interfere with caspase-3- and 
p53-induced yeast growth inhibition (Table 6.1), and presented lower EC50 values than 
PAC-1 on caspase-7 (Table 6.2).  
 
Table 6.2. EC50 values obtained for PAC-1, 5,6-dihydroxy-7-prenyloxyflavone (1a), 3-hydroxy-7-
geranyloxyflavone (2a) and artelastin (3) on human caspase-7.  
 
 
 
 
 
EC50 values were obtained from concentration-response curves of 0.1 – 25 µM PAC-1 
and 0.1 – 10 µM 5,6-dihydroxy-7-prenyloxyflavone (1a), 3-hydroxy-7-geranyloxyflavone 
(2a) and artelastin (3), and correspond to the concentration that caused 50% of the 
maximal stimulation of growth inhibition obtained with 25 µM PAC-1 on caspase-7. The 
percentage of drug-induced growth inhibition was estimated considering 100% growth 
the number of CFU obtained with yeast incubated with DMSO only. Values are mean ± 
s.e.m. of EC50 values obtained from 6 independent experiments; EC50 value significantly 
lower than PAC-1, *P< 0.05.  
 EC50 (µM) 
PAC-1 0.65 ± 0.18 
1a 0.26 ± 0.03* 
2a 0.14 ± 0.03* 
3 0.1 ± 0.01* 
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 Moreover, in this work, it was observed that, similarly to PAC-1, the stimulation of 
caspase-7-induced yeast growth inhibition by flavonoids 1a, 2a and 3 was not associated 
with an increase in the percentage of apoptotic cells, as assessed by TUNEL and PI 
staining (not shown), but instead to effects on the yeast cell cycle. In fact, when compared 
to yeast cells expressing caspase-7 incubated with DMSO only, it was observed that 
PAC-1 and flavonoids 1a, 2a and 3 increased the percentage of cells in S phase (Fig. 6. 
4). 
 
 
 
 
 
 
Figure 6.4. Effects of PAC-1, 5,6-dihydroxy-7-prenyloxyflavone (1a), 3-hydroxy-7-geranyloxyflavone (2a) and 
artelastin (3) on the cell cycle progression of yeast cells expressing human caspase-7. Yeast expressing 
caspase-7 was incubated with 25 µM PAC-1, 1 µM flavonoids or 0.1% DMSO only for ~0.4 OD600. Analysis of 
DNA content was monitored using Sytox Green. Values correspond to the quantification of cell cycle phases 
and represent means of 3 independent experiments; with PAC-1, flavonoids 2a and 3, S and G2/M values are 
significantly different from DMSO only: P< 0.05. 
 
 Together, these results indicated that 5,6-dihydroxy-7-prenyloxyflavone (1a), 3-
hydroxy-7-geranyloxyflavone (2a) and artelastin (3) are activators of caspase-7. 
Additionally, in comparison with the positive control PAC-1, the higher potency obtained 
with flavonoids 1a, 2a and 3 on caspase-7 also indicated that they are potent activators of 
caspase-7.  
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6.5. DISCUSSION 
 
 A recent work showed that prenylated derivatives of baicalein (1) and 3,7-
dihydroxyflavone (2) had potent antiproliferative activities in several human tumour cell 
lines (6). Supporting the promising anticancer activity of prenylated flavonoids, an earlier 
study showed that the natural prenylated flavonoid artelastin (3) potently inhibited the 
growth of distinct tumour cells (8, 37). In spite of this finding, the molecular mechanisms 
mediating the antiproliferative effects of these compounds are still uncovered. The main 
goal of the present work was therefore to identify the molecular targets involved in the 
growth inhibitory effects of prenylated flavonoids. Since previous works have reported the 
involvement of caspases and/or p53 in the apoptotic cell death induced by baicalein (1) 
and 3,7-dihydroxyflavone (2) in human tumour cells (3-5), the modulatory activity of these 
prenylated flavonoids on the three major regulators of cell proliferation and death, 
caspase-3, caspase-7 and p53, was therefore analysed. 
To achieve this goal, yeast cells expressing human caspase-3, caspase-7 or wt 
p53 were used. Previous works performed by our group established yeast phenotypic 
assays, based on the direct assessment of the yeast cell growth, to search for inhibitors of 
human caspase-3 (25) and for activators and inhibitors of p53 (26, 35). In the present 
work, a yeast phenotypic assay to search for activators of human caspase-7 is developed. 
We started to confirm that the expression of an active form of human caspase-7 induced 
inhibition of yeast growth as previously reported (27, 28). Moreover, we showed that this 
growth inhibitory effect of human caspase-7 in yeast was associated with an apoptotic cell 
death and a G2/M and S cell cycle arrest. Though it is well-established that caspase-7 is a 
major executioner of apoptosis, its involvement in non-apoptotic responses, namely in cell 
cycle progression, has also been reported in mammalian cells (12). This work represents 
the first report for a regulatory effect of human caspase-7 on yeast cell cycle progression. 
Since the role of caspase-7 in the regulation of cell cycle progression is still largely 
unclear, this work opens the way to the use of the yeast model system in the elucidation 
of this issue. Additionally, by testing the standard activator of caspase-3 and -7, PAC-1, 
we validated the yeast caspase-7 assay and the previously reported yeast caspase-3 
assay (25) to the search for small molecule activators of human caspase-3 and -7. 
Moreover, the capability of PAC-1 to potently activate both caspases, reported in 
mammalian cells (36), was further confirmed in yeast.  
Subsequently, by using the established yeast screening assays, we identified three 
prenylated flavonoids, 5,6-dihydroxy-7-prenyloxyflavone (1a), 3-hydroxy-7-
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geranyloxyflavone (2a) and artelastin (3) that activated caspase-7 with a higher potency 
than PAC-1. It was also shown that the stimulation of caspase-7-induced yeast growth 
inhibition by PAC-1 and flavonoids 1a, 2a and 3 was associated with an increase in the 
percentage of cells in S phase. Interestingly, the antiproliferative effects of flavonoids 1a 
and 3 in human tumour cells were also attributed respectively to a G1 (6) and S (8) cell 
cycle arrest. Additionally, in opposition to PAC-1, these flavonoids did not interfere with 
the activity of human caspase-3. This absence of effect of flavonoids 1a, 2a and 3 on 
human caspase-3 is in accordance with previous results obtained in human tumour cells 
(6, 8). In fact, similar antiproliferative activities of flavonoids 1a, 2a and 3 were obtained in 
NCI-H460 (non-small cell lung cancer) and A375-C5 (melanoma) with caspase-3 and 
MCF-7 (breast adenocarcinoma) without caspase-3. Besides, none of these prenylated 
flavonoids interfered with the activity of human p53 in yeast.  
It is also interesting to note that, in opposition to flavonoid 1a, its non-prenylated 
analogue, baicalein (1), markedly inhibited the growth of control yeast. This indicated the 
conservation in yeast of the molecular targets of baicalein (1). The identification of these 
molecular targets, and respective orthologues in mammals, could therefore advance our 
knowledge about the antiproliferative effect of this flavonoid in human tumour cells. These 
results also indicate that the monoprenylation is a structural requirement for the selectivity 
of flavonoid 1a to caspase-7, since when absent in baicalein (1) non-specific effects in 
yeast were observed. Moreover, it was verified that, contrarily to flavonoid 2a, its non-
prenylated analogue 3,7-dihydroxyflavone (2) had no effect on caspase-7. This can 
therefore indicate that the monogeranylation is a structural requirement for caspase-7 
activation by flavonoid 2a. Important data are therefore provided by this work concerning 
structural requirements for the activity and selectivity of these prenylated flavonoids 
towards caspase-7. 
As a whole, the present work identify three potent activators of caspase-7, 5,6-
dihydroxy-7-prenyloxyflavone (1a), 3-hydroxy-7-geranyloxyflavone (2a) and artelastin (3). 
Promising pharmacological applications can be therefore envisaged for these compounds 
not only as probes in the study of caspases pathway, but also as anticancer agents. In 
fact, flavonoids 1a, 2a and 3 may represent an alternative strategy for personalized 
cancer treatment, namely against tumours without caspase-3 (e.g. breast 
adenocarcinoma) or a functional p53 pathway (e.g. chronic myelocytic leukemia), or with 
elevated levels of caspase-7 (e.g. prostate cancer).  
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PKC isoforms, p53 tumour suppression protein, caspase-3 and -7 have crucial 
roles in different cellular processes namely, cell proliferation and death. Therefore, these 
cellular players represent key therapeutic targets in human diseases where these 
processes are dysregulated, such as cancer and neurodegeneration. The present thesis 
focused on the use of yeast to study functional, molecular and pharmacological aspects of 
these mammalian proteins. 
 
 
7.1. REGULATION OF P53 ACTIVITY IN CELL PROLIFERATION AND DEATH BY 
PKC ISOFORMS: TRANSCRIPTION-DEPENDENT AND -INDEPENDENT P53 
MECHANISMS IN YEAST 
 
Though several works had already reported the p53 phosphorylation and the 
activation of the p53 transcriptional activity by PKCδ (1, 2), the role of other PKC isoforms 
in the regulation of p53 activity was still largely unknown. Hence, with the present thesis, 
we aimed to clarify this relevant issue. For this purpose, we first attempted to reconstitute 
in yeast a mammalian PKC isoform-p53 network which could allow the direct assessment 
of the function of specific PKCα, δ, ε and ζ (reported as major PKC isoforms in 
carcinogenesis) in the regulation of p53 activity in cell proliferation and death. 
Before setting up in yeast the co-expression of p53 and individual PKC isoforms, 
we confirmed that expression of the human wt p53 in yeast induced growth inhibition as 
previously reported by Amor and colleagues (3). However, in our case this effect was not 
associated with cell death but instead with the induction of a cell cycle arrest. Moreover, 
the regulation of yeast cell growth by p53 through a transcription-dependent mechanism 
was also pointed by us. Together, these observations supported the establishment of a 
yeast p53 phenotypic assay to perform functional and pharmacological studies of p53. 
Subsequently, we further exploited this yeast p53 assay to elucidate the regulation of p53 
activity in cell proliferation by PKC isoforms. 
The results obtained, in unstressed cells, show a differential regulation of p53-
induced growth inhibition by PKC isoforms with the identification of positive and negative 
regulators among the tested PKC isoforms. In fact, whereas PKCα reduced the p53-
induced yeast growth inhibition, PKCδ and ε phosphorylated p53 and markedly increased 
its effect. Moreover, PKCζ had no effect on p53 activity. Interestingly, similar results were 
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obtained for PKCδ, ε  and ζ under stress conditions. In fact, while PKCα and ζ had no 
effect on p53 activity, PKCδ and ε stimulated p53-mediated apoptosis. Together, this work 
provides a new pharmacological strategy of p53 regulation through modulation of PKCδ 
and ε, with the identification of these kinases as key therapeutic targets in tumours with a 
wt p53.  
Moreover, as described in mammalian cells (4-6), this work also reveals in yeast 
the cooperation between transcription-dependent and -independent p53 mechanisms to 
ultimately cause an apoptotic cell death. In fact, it provides the first evidence for the 
conservation in yeast of a transcription-independent p53-mediated apoptosis 
characterized by the p53 translocation to mitochondria. Moreover, relevant insights about 
this p53 transcription-independent mechanism are revealed. Since mitochondrial 
localization of p53 was only detected under an apoptotic scenario, this study corroborates 
the hypothesis raised by others in mammalian cells (5, 6) that the p53 mitochondrial 
localization determines whether cells die or arrest growth. Additionally, it shows that, 
besides the reported activation of a p53 transcriptional activity, PKCδ also triggers the p53 
translocation to mitochondria. It also identifies PKCε as an additional activator of this 
transcription-independent p53 apoptotic mechanism. The identification of activators of p53 
translocation to mitochondria, achieved with this work, advances our knowledge about an 
unknown issue concerning the regulation of p53 transcription-independent mechanisms. 
Finally, it has been proposed that physical and functional interactions of p53 with various 
members of the Bcl-2 family are involved in the transcription-independent route of p53-
mediated cell death. However, the underlying mechanisms are not completely clarified. 
The extensive and successful exploitation of yeast to study the structural and functional 
properties of members of Bcl-2 family (7) allied to the observation of p53 translocation to 
yeast mitochondria open new perspectives to the understanding of how interactions 
between p53 and Bcl-2 family members promote MOMP. Though yeast was early 
considered devoid of members of the Bcl-2 family, a Bcl-xL interacting protein harbouring 
a Bcl-2 homology (BH3) domain, the Ybh3p, which translocates to mitochondria in 
response to a lethal stimulus mediating the disruption of mitochondrial membrane 
potential, was recently identified in S. cerevisiae (8). In this context the yeast model 
system emerges as a valuable tool that may provide relevant clues to the design of 
promising alternative strategies for p53-based cancer therapy. 
A schematic illustration of the regulation of transcription-dependent and -
independent p53 mechanisms by nPKCδ and ε in yeast is presented in Fig. 7.1. 
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Fig. 7.1. Regulation of transcription-dependent and -independent p53 mechanisms by nPKCδ and ε in yeast. 
(A) Human wt p53 expressed in yeast has nuclear localization and induces growth inhibition associated with a 
S-phase cell cycle arrest, which is abolished by the selective inhibitor of p53 transcriptional activity, PFT-α, 
and markedly increased by nPKCδ and ε. (B) Under stress conditions induced by H2O2 (represented with a 
yellow flash), nPKCδ and ε stimulate the p53 translocation to mitochondria and a mitochondrial-dependent 
apoptotic pathway characterized by an increase on mitochondrial ROS production, ∆Ψm loss and 
mitochondrial network fragmentation. Mitochondrial p53 translocation in yeast is inhibited by the selective 
inhibitor of mitochondrial p53 translocation, PFT-µ . 
 
 
7.2. ROLE OF PKC ISOFORMS IN APOPTOSIS: PHYSIOLOGICALLY RELEVANT 
SUBSTRATES 
 
In the last years, yeast has emerged as an important cell model to study the role of 
PKC isoforms in apoptosis. In fact, using this cell system, important data have been 
provided in this area with the identification of relevant apoptotic substrates of individual 
PKC isoforms. An additional contribution to advance our knowledge in this area is 
provided by this thesis.  
Concerning PKCα, several reports indicate an anti-apoptotic activity for this 
isoform (9-11). Additionally, some contradictory results suggesting a pro-apoptotic role for 
PKCα have also been reported (12-14). This pro-apoptotic function of PKCα was 
corroborated in previous works performed in yeast. In fact, this isoform stimulated acetic 
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acid-induced apoptosis (15), abolished the Bcl-xL anti-apoptotic effect (15), and 
stimulated the pro-apoptotic activity of Bax (16). However, in the scope of the studies 
developed in this thesis, we found that PKCα does not stimulate H2O2-induced yeast 
apoptosis. Similarly to that reported in mammalian cells (17, 18), this result corroborates 
that the apoptotic function of a specific PKC isoform, namely PKCα, is highly dependent 
on the stimulus applied. In fact, it was shown that distinct stimuli can induce the 
translocation of a specific PKC isoform to distinct subcellular compartments. 
Subsequently, this is associated to the phosphorylation of distinct substrates, and 
therefore to distinct cellular responses. In the case of H2O2, the PKCα substrates do not 
seem to be conserved in yeast. Moreover, we also found that PKCα does not modulate 
p53 apoptotic activity. This may therefore suggest that p53 is not a substrate of PKCα. 
Concerning PKCδ, the well-known pro-apoptotic function of this isoform in 
mammalian cells (19) was widely confirmed in yeast. In fact, a previous study showed the 
stimulation of acetic acid-induced apoptosis by PKCδ (15). This study also revealed that 
PKCδ  does not regulate the anti-apoptotic protein Bcl-xL. During this thesis, we found that 
PKCδ also stimulates coleon U-induced apoptosis. Additionally, similarly to that reported 
in mammalian cells (2, 20-22), we confirmed that PKCδ regulates the p53 apoptotic 
activity. Interestingly, stimulation of H2O2-induced apoptosis by PKCδ in yeast was only 
achieved in the presence of p53. This corroborates similar studies performed in 
mammalian cells, in which the stimulation of H2O2-induced apoptosis was practically 
abolished in the presence of rottlerin (a selective inhibitor of PKCδ) and in null-p53 cells 
(21). This may suggest that, for this stimulus, the pro-apoptotic activity of PKCδ is highly 
dependent on a specific substrate that seems to be p53.  
Concerning PKCε, this isoform is frequently regarded as having anti-apoptotic 
properties in mammalian cells (19, 23). Although the mechanisms responsible for its anti-
apoptotic function are still not well clarified, it seems to involve the regulation of Bcl-2 
family proteins, namely Bax and Bad (23). In fact, the yeast cell model revealed that PKCε 
also regulates Bcl-xL, markedly increasing its activity (15). Although several studies 
suggest that PKCε favours life over death, others exist reporting the involvement of this 
isoform in apoptosis promotion (24). In fact, a previous study in yeast showed the 
stimulation of acetic acid-induced apoptosis by PKCε (15). In the present thesis, it is also 
shown the stimulation of coleon U- and H2O2-induced yeast apoptosis by this isoform. 
Curiously, for H2O2, the pro-apoptotic function of PKCε seems to be conserved in yeast, 
contrarily to that observed with the other isoforms tested. This work also shows that PKCε 
phosphorylates p53 and stimulates the p53 apoptotic activity. This may suggest that p53 
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is a substrate of PKCε. Together, these results obtained in yeast suggest that the 
apoptotic function of PKCε seems to be highly dependent on its accessibility to key 
apoptotic proteins, such as Bcl-xL and p53. The translocation of PKCε to distinct 
subcellular compartments, for instance due to distinct stimuli applied, may expose the 
PKC isoform to distinct substrates and this can be responsible for the distinct responses 
elicited by PKCε.  
Concerning PKCζ, it is also well-accepted the anti-apoptotic role of this isoform in 
mammalian cells (19). However, it was previously shown in yeast the stimulation of acetic 
acid-induced apoptosis by PKCζ (15). In spite of this, when PKCζ was co-expressed with 
Bcl-xL in yeast, it markedly enhanced the Bcl-xL anti-apoptotic activity with a complete 
abolishment of acetic acid-induced apoptosis (15). PKCζ was therefore identified in yeast 
as a regulator of the anti-apoptotic protein Bcl-xL. The present work also corroborates an 
anti-apoptotic activity for PKCζ. In fact, it shows that PKCζ did not stimulate H2O2-induced 
yeast apoptosis. Additionally, it reveals that in yeast PKCζ does not regulate p53 
apoptotic activity. This may therefore suggest that p53 is not a substrate of PKCζ. 
 
 
7.3. IDENTIFICATION OF A SELECTIVE SMALL MOLECULE ACTIVATOR OF 
NPKCδ AND ε 
 
The high complexity of the PKC-signalling pathway in mammalian cells has 
hampered the identification of isoform-selective PKC modulators. In fact, the development 
of new therapeutic strategies involving the modulation of PKC activity by many identified 
PKC modulators has being discarded in early phases of clinical trials due to their lack of 
selectivity (25, 26). Potent and selective modulators of individual PKC isoforms are 
therefore highly required in the PKC research field. 
In this thesis, we used yeast cells individually expressing PKCα, βI, δ, ε or ζ to 
elucidate the molecular mechanism of action of coleon U, a diterpene compound isolated 
from Plectranthus grandidentatus reported to induce apoptosis in human cells (27), 
although the molecular mechanism of action associated with this coleon U-induced 
apoptosis have was not elucidated. Since several diterpene compounds, such as phorbol 
esters, had been recognised as potent PKC activators, the yeast PKC expression system 
was exploited to study the modulatory activity of coleon U on individual PKC isoforms. As 
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reported for human cells, coleon U also induced an apoptotic cell death in yeast, involving 
the mitochondrial pathway and metacaspase activation, but only in yeast cells expressing 
PKCδ or ε. The results obtained led to the discovery of a potent and selective activator of 
PKCδ and ε, which activity was thereafter confirmed in human cells (28). This compound 
therefore represents a promising pharmacological probe to study PKC-signalling 
pathways involving these isoforms in mammalian cells, as performed by Maghzal and 
colleagues (28). Furthermore, the stimulation of an apoptotic pathway independent of 
PKCα, βI and ζ, commonly reported as anti-apoptotic proteins, confers to coleon U 
promising applications in anticancer therapy.  
Interestingly, in this work, we also showed that while PMA induced PKCδ/ε 
translocation from the cytosol to the plasma membrane and a G2/M cell cycle arrest, 
coleon U induced PKCδ/ε translocation from the cytosol to the nucleus and an apoptotic 
cell death. These results confirm in yeast cells previous evidences from mammalian cells 
(17, 18, 29) and reveal that different stimuli can induce the translocation of a same PKC 
isoform to distinct cellular compartements, which may be subsequently associated with 
different cellular responses. Moreover, they support the notion that the nuclear retention of 
PKC isoforms, particularly of PKCδ/ε, may be a required factor for commitment to 
apoptosis (30, 31).  
A schematic illustration of the molecular mechanism of action of PMA and coleon 
U in yeast cells expressing PKCδ/ε is presented in Fig. 7.2. 
 
 
 
 
 
 
 
 
 
 
Fig. 7.2. Molecular mechanism of action of PMA and coleon U in yeast cells expressing nPKCδ/ε. nPKCδ and 
ε expressed in yeast have cytoplasmic localization. PMA induces the translocation of nPKCδ/ε to the plasma 
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membrane and a G2/M cell cycle arrest. On the contrary, coleon U induces the translocation of nPKCδ/ε to the 
nucleus and a metacaspase (Yca1p)- and mitochondrial-dependent apoptosis, which is abolished by the co-
expression in yeast of the human anti-apoptotic protein Bcl-xL. DNA fragmentation, Yca1p activation and 
mitochondrial alterations (increase on mitochondrial ROS production, ∆Ψm loss and network fragmentation) 
induced by coleon U are represented with yellow flashes. 
 
 
7.4. IDENTIFICATION OF SELECTIVE SMALL MOLECULE MODULATORS OF 
CASPASE-3 AND -7 
 
As major regulators of cell proliferation and death, caspase-3, caspase-7 and p53 
are therefore considered key therapeutic targets in human diseases where these cellular 
processes are dysregulated, such as cancer and neurodegeneration. In this context, small 
molecule activators and inhibitors of these proteins may be used to stimulate and prevent 
apoptosis in cancer and neurodegenerative disorders, respectively (32-37). However, 
similarly to PKC family, the high complexity of p53 and caspase-signalling pathways in 
mammalian cells has hampered the identification of selective modulators of these 
proteins. 
With this thesis, we aimed to develop yeast assays for the screening of small 
molecule modulators of human caspase-3 and caspase-7. With this goal, we firstly 
confirmed the previously reported growth arrest induced by expression of active forms of 
human caspase-3 or -7 in yeast. In the case of caspase-7, this growth inhibitory effect was 
further associated with apoptosis and cell cycle arrest in G2/M and S phases. A 
correlation between yeast cell growth and human caspase activity was thereafter 
established using standard caspase activators and inhibitors. Using the yeast caspase-3 
assay, new promising caspase-3 inhibitors were subsequently identified by testing a 
chemical library of vinyl sulfones (from the iMed.UL group), which are described as 
inhibitors of many cysteine proteases from clan CA (papain superfamily) (38).  
The yeast assays developed in this thesis to search for modulators of human wt 
p53, caspase-3 and caspase-7 were also used to identify the molecular targets involved in 
the antiproliferative effect of several prenylated flavonoid derivatives of baicalein and 3,7-
dihydroxyflavone and of the natural prenylated flavonoid artelastin (from the CEQUIMED-
UP group) on distinct human tumour cell lines. (39, 40). With this study, three potent 
activators of caspase-7, 6-dihydroxy-7-prenyloxyflavone, 3-hydroxy-7-geranyloxyflavone 
and artelastin, were identified. These prenylated flavonoids have promising 
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pharmacological applications not only as probes in the study of caspase-signalling 
pathways, but also as anticancer agents. In fact, these flavonoids may represent an 
alternative therapeutic strategy against tumours without caspase-3 (e.g. breast 
adenocarcinoma) and/or a functional p53 pathway (e.g. chronic myelocytic leukemia), or 
with elevated levels of caspase-7 (e.g. prostate cancer).  
Besides the promising therapeutic applications in cancer (caspase-7 activators) 
and neurodegeneration (caspase-3 inhibitors), the small molecule modulators of caspase-
3 and -7 identified in this thesis have been used by the Medicinal Chemistry groups 
involved in the referred studies as lead compounds in the synthesis of new modulators of 
caspase-3 and -7 with improved potency and selectivity.  
 
 
7.5. CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
 
In the present thesis, valuable data about the biology and pharmacology of major 
protein regulators of cell proliferation and death are provided using the yeast model 
system. Additionally, new targets and therapeutic opportunities are also revealed. In fact, 
the yeast assays herein developed and exploited in the screening of activators and 
inhibitors of the disease-related proteins also led to the discovery of promising 
pharmacological tools and therapeutic agents against devastating diseases, such as 
cancer and neurodegeneration. 
The yeast research performed in this thesis confirmed the tremendous potential of 
this model system towards the study of PKC isoforms, p53 and caspase family members. 
We anticipate therefore that new promising discoveries can be done in these areas using 
this model organism. In fact, new ways were opened and several relevant questions were 
raised with this work that would be interesting to cover in future works, namely: 
a) The identification of endogenous yeast pro-apoptotic substrates and respective 
orthologues in mammalian cells would certainly help in the identification of PKC isoform-
specific substrates; 
b) Since the p53 phosphorylation pattern observed under an apoptotic scenario 
was similar to that observed in unstressed cells, it would be important to determine 
whether p53 phosphorylation by PKCδ and ε is in fact a relevant factor for the stimulation 
of p53-mediated apoptosis by these PKC isoforms; 
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c) Further studies could be performed to ascertain if p53 interacts with the already 
identified yeast orthologues involved in MOMP. Future studies addressing the 
identification of these proteins and their human orthologues would certainly provide new 
insights about the transcription-independent p53 apoptotic activity; 
d) The evidence herein provided about the regulation of p53 activities by PKCδ 
and ε indicate that coleon U could be used as a valuable pharmacological agent also in 
p53-related human diseases. The effect of this small molecule in human tumour cell lines 
with wt p53 could be therefore evaluated; 
e) As a first-line screening tool, the activity of the small molecules identified as 
modulators of caspase-3 and -7 has to be validated in human cells. Additionally, the data 
provided by this study support the use of the developed yeast assays to evaluate the 
activity of new synthesized compounds on caspase-3 and -7; 
f) Contrarily to p53, the regulation of other members of the p53 family, namely p63 
and p73, by PKC isoforms is largely unknown. The use of the yeast cell system to study 
this issue would certainly provide new insights about the regulation of p63 and p73 by 
PKC isoforms. This would certainly provide new pharmacological strategies for the 
regulation of the activity of p63 and p73 by targeting these kinases.  
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